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Abstract  
Mitogen-activated protein kinase (MAPK) signalling pathways are important 
signalling pathways involved in mediating various cellular processes including 
both cell survival and cell death. The c-Jun N-terminal kinase (JNK) pathway, 
the p38 pathway and the extracellular signal-regulated kinase (ERK1/2) 
pathway are three well-studied conventional MAPK signalling pathways. 
Previous research has shown these MAPK signalling pathways play an 
important role in the development and progression of leukaemia and in the 
response of leukemic cells to therapy. Whilst it appears to be well established 
that the constitutive activation of ERK mediates leukemic cell survival, the roles 
of the JNK and p38 signalling pathways in leukemogenesis, in particular the 
role in acute myeloid leukaemia (AML), are less well understood. 
 This thesis investigates the role of the JNK, p38 and ERK signalling 
pathways in leukemic death. MAPK signalling pathways were targeted in the 
U937 monocytic cell line using small molecule MAPK inhibitors in combination 
with various cell stressors: UV light, chemotherapeutic agents (doxorubicin 
and vincristine) and heat treatment. The effects on cell death were examined 
using plate-based assays, flow cytometry and fluorescence microscopy. 
Preliminary investigations were also performed in peripheral blood 
mononuclear cells (PBMCs) from healthy individuals to allow a comparison to 
non-leukemic cells.  
 Results show inhibition of ERK signalling in U937 cells induced cell death 
and ERK signalling had little effect on UV-induced and heat treatment-induced 
cell death. JNK signalling and p38 signalling provided protection against UV-
induced cell death in both U937 cells and in PBMCs from healthy individuals. 
JNK and p38 signalling mediated cell survival in response to heat treatment to 
a certain extent. JNK signalling was required for the induction of cell death 
induced by doxorubicin whereas p38 signalling provided a level of protection 
against doxorubicin-induced cell death. U937 cells were found to be more 
sensitive to vincristine treatment than PBMCs from healthy individuals and the 
activation of JNK and p38 signalling was essential for vincristine-induced cell 
death in U937 cells.  
 Taken together, the results presented in this thesis demonstrate that the 
roles of the JNK, p38 and ERK signalling pathways in leukemic cell death are 
stimuli-specific. This highlights the importance of understanding the 
involvement of particular pathways in the response to specific 
chemotherapeutic agents, in order to provide effective leukaemia therapy. 
Therapeutic inhibition of MAPK signalling pathways to increase the sensitivity 
of leukemic cells to chemotherapy could be beneficial when MAPKs are 
involved in providing protection against chemotherapy-induced cell death. For 
chemotherapies which require MAPK activation for cell death, failure to 
activate MAPKs may provide a mechanism for chemoresistance. Therapeutic 
methods to enhance activation of the pathways provide a possible approach 
to increase the susceptibility of leukemic cells to death.  
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Chapter 1: Introduction 
1.1 Rationale for the study 
Cell signalling is a critical process involved in co-ordinating a range of cellular 
processes including: cell growth, cell differentiation, inflammation, metabolism 
and cell death (Uings & Farrow, 2000). Deregulation of complex signalling 
networks underpins the molecular basis of many diseases, including cancer. 
Driven by genetic changes, abnormalities in signalling pathways allow cancer 
cells to rapidly proliferate, survive and often invade other tissues (Giancotti, 
2014; Kolch, Halasz, Granovskaya, & Kholodenko, 2015; Sever & Brugge, 
2015). Understanding which signalling pathways are deregulated, and the 
ways in which these pathways are changed, will provide a greater insight into 
the mechanisms involved in carcinogenesis. It is also important to gain 
knowledge of how signalling pathways are altered in response to 
chemotherapy. Targeting signalling pathways in cancer cells is of great 
therapeutic value. Although there are general principles underlying all cancers, 
signalling pathways are altered in a tissue and cell-type specific manner 
(Giancotti, 2014). Therefore, in order to provide effective cancer therapy, it is 
necessary to understand how signalling pathways are deregulated specifically 
in each type of cancer.  
The work presented in this thesis will focus on leukaemia, a class of 
haematological cancers which originate in the bone marrow and result in the 
production of immature or abnormal leucocytes (Figure 1.1 and Table 1.1). Of 
the 357,000 new cases of cancer reported in the United Kingdom (UK) in 2014, 
around 9,500 of these were cases of leukaemia (Cancer Research UK, 2017). 
In 2014, there were around 4,500 deaths in the UK because of leukaemia. 
These figures highlight the important requirements for improved treatments for 
leukaemia, with the ultimate aim of increasing survival rates. Gaining a greater 
understanding of how signalling pathways function in the development of 
leukaemia and in the response to treatment will aid future leukaemia therapy. 
This thesis will investigate the role of a particular class of signalling pathways, 
the mitogen-activated protein kinase (MAPK) signalling pathways, and the role 
these signalling pathways play in leukemic cell death. 
Chapter 1: Introduction  
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Figure 1.1: Haematopoiesis and the development of leukaemia 
During haematopoiesis, haematopoietic cells are generated from stem cells in the bone marrow via the myeloid or lymphoid lineage. Defects in haematopoiesis 
result in diseases such as leukaemia. Acute leukaemia is characterised by a rapid increase in immature blasts whereas chronic leukaemia is characterised by 
the build-up of mature, abnormal leucocytes.   
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Table 1.1: Classification of leukaemia  
(Information taken from Cancer Research UK, 2017) 
Type of leukaemia Incidence Subtypes 
  Acute myeloid leukaemia 
(AML) 
Most common type of leukaemia  
 
Highest incidence in older adults – incidence rates increase 
rapidly from around 40 years old 
 
More common in males (57%) than females (43%)  
Myeloblastic leukaemia (M0, M1, M2) 
 
Acute promyelocytic leukaemia (M3) 
 
 Acute myelomonocytic leukaemia (M4) 
 
 Acute monocytic leukaemia (M5) 
 
 Acute erythroid leukaemia (M6) 
 
 Acute megakaryoblastic (M7) 
Acute lymphocytic leukaemia  
(ALL) 
Most common in children, teenagers and young adults-
highest incidence in children less than 4 years old 
 
More common in males (59%) than females (41%)  
Acute precursor B-cell leukaemia 
 
Acute B-lymphoblastic leukaemia 
 
Acute T-lymphoblastic leukaemia  
Chronic myeloid leukaemia 
(CML) 
Highest incidence in older adults – incidence rates increase 
rapidly from around 55 years old 
 
More common in males (59%) than females (41%) 
Chronic granulocytic leukaemia (CGL) 
 
Juvenile CML 
 
Chronic neutrophilic leukaemia (CNL) 
 
Chronic myelomonocytic leukaemia (CMML) 
 
Atypical CML 
 
Chronic lymphocytic leukaemia 
(CLL) 
Very rare in children and young adults. Highest incidence in 
older adults- incidence rates increase rapidly from 45 years 
old 
 
More common in males (63%) than females (37%) 
B-cell chronic lymphocytic leukaemia (B-CLL) 
 
T-cell chronic lymphocytic leukaemia (T-CLL) 
 
Hairy cell leukaemia 
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1.2 Cancer Development 
The development and progression of cancer is a multi-step process driven by 
genetic changes within a cell. The transformation of a ‘normal’ non-cancer cell, 
into a rapidly proliferating, abnormal cancer cell is an extremely complex 
process, which results in a small number of important underlying properties. 
These general properties are described as the ‘hallmarks of cancer’ (Figure 
1.2) (Hanahan & Weinberg, 2011; Hanahan & Weinberg, 2000). 
 
 
 
 
 
 
Figure 1.2: Hallmarks of cancer  
Six hallmarks of cancer were initially identified: self-sufficiency in growth signals, insensitivity 
to anti-growth signals, evasion of apoptosis, enabling limitless replicative potential, sustaining 
angiogenesis, and tissue invasion and metastasis. A further four hallmarks were later 
proposed: evasion of the immune system, deregulation of metabolism, genome instability and 
tumour-promoting inflammation. (Adapted from Hanahan & Weinberg, 2011; Hanahan & 
Weinberg,  2000). 
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Deregulation of cell signalling pathways underlies each of the hallmarks of 
cancer (Giancotti, 2014; Sever & Brugge, 2015) and examples of signalling 
pathways affecting these properties will briefly be considered:  
• Genome instability - accumulation of genetic alterations during cell 
division is one of the underlying principles for the development of cancer 
(Pikor, Thu, Vucic, & Lam, 2013). Genomic instability in cancer cells occurs 
mainly as a result of failure in DNA repair mechanisms and cell cycle 
checkpoint signalling (Shen, 2011). The ATM-Chk2-p53 and ATR-Chk1-
p53 signalling pathways involved in DNA damage signalling, are often 
deregulated in cancer cells (Smith, Tho, Xu, & Gillespie, 2010). Inactivation 
of the p53 tumour suppressor, which is involved in an extensive number of 
signalling pathways, contributes to genome instability (Negrini, Gorgoulis, 
& Halazonetis, 2010). 
 
• Deregulation of metabolism - metabolism in cancer cells is 
reprogrammed towards aerobic glycolysis (Warburg effect) in order to meet 
the anabolic demands required for growth and proliferation (Phan, Yeung, 
& Lee, 2014). Metabolic reprogramming in cancer cells is the result of 
mutations in oncogenes and tumour suppressors which alter signalling 
pathways involved in metabolism, for example the frequently 
hyperactivated PI3K-AKT-mTOR signalling pathway (Khan, Yap, Yan, & 
Cunningham, 2013; Lien, Lyssiotis, & Cantley, 2016). 
 
• Enabling limitless replicative potential - cancer cells develop 
mechanisms which allows the cells to divide indefinitely. The main 
mechanism utilised by cancer cells is the reactivation of telomerase, which 
occurs in greater than 85% of cases of cancer (Akincilar, Unal, & 
Tergaonkar, 2016). Reactivation of telomerase is achieved by the 
transcriptional activation of telomerase reverse transcriptase (TERT) which 
is controlled by signalling pathways involving the transcription factors Myc, 
β-catenin and nuclear factor κB (NF-κB) (Li & Tergaonkar, 2016).  
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• Evasion of the immune system - cancer cells evade the immune system 
by three main mechanism: loss of antigenicity, loss of immunogenicity and 
by creation of an immunosuppressive cancer microenvironment (Beatty & 
Gladney, 2015). Loss of antigenicity is mainly due to defective antigen 
processing and presentation, such as the downregulation of pathways in 
cancer cells which affect the major histocompatibility complex (MHC) I 
pathway (Vinay et al., 2015). Loss of immunogenicity can occur by the 
secretion of suppressive cytokines such as interleukin-10 (IL-10) and 
transforming growth factor (TGF-β) and the downstream pathways affected 
by these cytokines.  
 
• Tissue invasion and metastasis - in order for metastasis to occur, cancer 
cells must break away from the primary tumour, invade connective tissues 
and spread to distant sites in the body (Jiang et al., 2015). Loss of cell-cell 
adhesion, for examples through the loss of E-cadherin, allows dissociation 
of cancer cells from the primary site and in addition changes in cell-matrix 
interactions enable cells to invade connective tissue. Signalling pathways 
involved in maintaining cell-cell adhesion and cell-matrix interactions, such 
as PI3/AKT and FAK/integrin signalling pathways are altered in cancer 
cells (Zhao & Guan, 2011).  
 
• Sustaining angiogenesis - cancer cells require a constant supply of 
oxygen and nutrients to survive which is facilitated by the establishment of 
a vascular network, termed angiogenesis. The most commonly 
deregulated signalling pathway which mediates cancer angiogenesis is 
vascular endothelial growth factor (VEGF)-receptor signalling (Nishida, 
Yano, Nishida, Kamura, & Kojiro, 2006; Ziyad & Iruela-Arispe, 2011).  
 
• Tumour promoting inflammation - inflammation plays a critical role in the 
development of cancer; cancer microenvironments are often infiltrated with 
inflammatory cells (Coussens & Werb, 2002). NF-κB signalling is an 
important pathway involved in inflammation and deregulation of NF-κB  
signalling has been reported in many cancers (Colotta, Allavena, Sica, 
Garlanda, & Mantovani, 2009). NF-κB signalling in inflammatory cells can 
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stimulate NF-κB signalling in cancer cells, causing the recruitment of 
further immune cells, such as tumour-associated macrophages (TAMs) to 
the cancer site. TAMs support cancer development by aiding cell 
proliferation, invasion and metastasis, stimulating angiogenesis and 
inhibiting the anti-cancer immune response (Liu & Cao, 2015). 
Although each of these hallmarks of cancer explains the general principles 
underlying the development and progression of cancer, there is variability in 
the extent to which they apply to specific cancers. For example, in leukaemia, 
sustained angiogenesis and tissue invasion and metastasis are less important 
due to the location of the leukemic cells in the bone marrow and blood stream. 
The most important ‘hallmarks of cancer’ in terms of the research presented 
in the thesis are: self-sufficiency in growth signals, insensitivity to anti-growth 
signals and evasion of apoptosis:  
 
• Self-sufficiency in growth signals - constitutive activation of signalling 
pathways involved in growth is a feature of cancer cells; it enables cells to 
progress through the cell cycle independently of external signals. Self-
sufficiency in growth signals can be achieved by multiple mechanisms. One 
such mechanism is the self-production of growth factors such as platelet-
derived growth factor (PDGF) or transforming growth factor-α (TGF-α). An 
alternative mechanism is increased levels of growth factor receptors, for 
example the upregulation of epidermal growth factor receptors (EGFR) 
(Gutschner & Diederichs, 2012; Hanahan & Weinberg 2000). Self-
sufficiency in growth signals can also occur as a result of constitutive 
activation of signalling components downstream of growth factor-receptor 
binding. Components of the Ras-Raf-MEK-ERK signalling pathway are 
frequently deregulated in many cancers (Santarpia, Lippman, & El-Naggar, 
2012). Disruption of negative-feedback mechanisms can also account for 
self-sufficiency in growth signals (Gutschner & Diederichs, 2012). 
 
• Insensitivity to anti-growth signals - in non-cancer cells, cell proliferation 
is tightly regulated by negative regulators which control cell division. 
Cancer cells can become insensitive to anti-growth signals via several 
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mechanisms. One mechanism is the downregulation of anti-growth factor 
receptors, such as the transforming growth factor-β (TGF-β) receptor. 
Insensitivity to anti-growth signals also occurs due to inactivation of the 
tumour suppressors, p53 and the retinoblastoma protein (Sherr & 
McCormick, 2002). 
 
• Evasion of apoptosis - cancer cells acquire the ability to evade apoptosis, 
a form of programmed cell death. Evasion of apoptosis typically occurs due 
to deregulation of apoptotic machinery. This can result in either the 
upregulation of anti-apoptotic proteins (Bcl-2) and inhibitors of apoptosis 
(IAPs) or the down-regulation of pro-apoptotic proteins (Bim, Bax, Bad) 
(Fernald & Kurokawa, 2013). Various upstream signalling pathways which 
regulate apoptosis are deregulated in cancer and include the PI3-
kinase/Akt signalling pathway, c-Jun N-terminal kinase pathway and p38 
signalling pathway. Loss of p53 also provides cancer cells with a 
mechanism for apoptosis evasion (Fridman & Lowe, 2003). 
 
1.3 Mitogen-activated protein kinase signalling  
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine 
protein kinases which are highly conserved amongst eukaryotes (Cargnello & 
Roux, 2011). MAPKs, are responsible for relaying, amplifying and integrating 
signals from an extracellular stimuli into an intracellular response (Zhang & 
Liu, 2002). MAPK signalling pathways regulate a diverse range of cellular 
processes. These include: differentiation, proliferation, growth and apoptosis, 
in addition to the involvement of MAPKs in both the stress and immune 
responses (Plotnikov, Zehorai, Procaccia, & Seger, 2011; Wada & Penninger, 
2004; Zhang, Liu, & Liu, 2002; Zhang & Dong, 2005). This section will discuss 
the current knowledge regarding MAPK signalling pathways, their role in 
leukemogenesis and in response to leukaemia therapy, and in addition, how 
these pathways can be targeted.  
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1.3.1 MAPK signalling cascade 
MAPK signalling pathways are activated in response to a range of external 
stimuli including growth factors, cytokines, and cell stresses such as ultraviolet 
(UV) light, temperature, osmolarity, hypoxia and drugs (Cuevas, Abell, & 
Johnson, 2007; Kyriakis & Avruch, 2001). Each MAPK signalling pathway is 
organised into a three-tiered protein kinase cascade consisting of three protein 
kinases: mitogen-activated protein kinase kinase kinases (MAPKKKs), 
mitogen-activated protein kinase kinases (MAPKKs) and mitogen-activated 
protein kinases (MAPKs), which are activated sequentially (Figure 1.3). At 
least twenty MAPKKKS, seven MAPKKs and at least eleven MAPKs have 
been identified (Dhanasekaran & Johnson, 2007). 
MAPKKKs, alternatively named MAP3K or MEKKK, are the first kinases 
in the cascade to be activated. MAPKKKs are activated in response to stimuli, 
via receptor-dependent and receptor-independent mechanisms, typically 
involving interactions with signalling proteins such as GTP-binding proteins 
(Munshi & Ramesh, 2013). MAPKKKs dually phosphorylate serine or 
threonine residues at conserved positions in the activation loop of the 
downstream substrate, a MAPKK, alternatively termed MAP2K or MEK. 
Complexity and diversity of MAPK signalling is achieved by the ability of a 
single MAPKK to be activated by multiple MAPKKKs (Johnson, Dohlman, & 
Graves, 2005).  
MAPKKs are responsible for phosphorylating and activating MAPKs. All 
MAPKs contain a Tyr-X-Thr motif within an activation loop, located in a kinase 
domain between the N-terminal and C-terminal domain (Cargnello & Roux, 
2011). ‘X’ is either a glutamate, proline or glycine and is dependent on the 
individual MAPK protein. Dual phosphorylation, by the appropriate MAPKK, of 
both the tyrosine and threonine residue within the motif, is required for the 
activation of the MAPK. MAPKs activate a range of MAPK-activated protein 
kinases (MAPKAPKs), which are located in various subcellular locations. In 
the cytoplasm, MAPKs control phosphorylation of other kinases and 
cytoskeletal proteins. Alternatively, MAPKs can translocate into the nucleus 
and phosphorylate transcription factors involved in gene expression. 
Collectively, these control the appropriate cellular process in response to the 
given stimuli.  
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Figure 1.3: General structure of a mitogen-activated protein kinase signalling 
pathway  
Each mitogen-activated protein kinase signalling pathway is composed of three kinases, 
mitogen-activated protein kinase kinase kinase (MAPKKK), mitogen-activated protein kinase 
kinase (MAPKK) and mitogen-activated protein kinase (MAPK) which act sequentially. 
Activation of the cascade, by various stimuli, results in the activation of targets in the nucleus 
or cytoplasm which ultimately brings about changes in cellular responses. (Adapted from 
Morrison, 2012).  
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1.3.2 Classification of MAPKs  
Fourteen mammalian MAPKs have been characterised into seven different 
MAPK groups, based on sequence homology and substrate specificity 
(Cargnello & Roux, 2011; Dickinson & Keyse, 2006). MAPKs can be further 
classified into conventional or atypical MAPKs. c-Jun N-terminal kinases 
(JNK1/2/3), p38 kinases (p38α/β/γ/δ) and extracellular signal-regulated 
kinases (ERK1/2 and ERK5) are conventional MAPKs. Atypical MAPKs 
include: ERK3/4, ERK7/8 and nemo-like kinases (NLK). Classification into 
conventional and atypical MAPKs is based on the mechanism of activation by 
upstream signalling molecules (Coulombe & Meloche, 2007). Conventional 
MAPKs (JNK1/2/3, p38α/β/γ/δ, ERK1/2 and ERK5) contain the conserved Thr-
X-Tyr motif in the activation loop of the kinase domain (Cargnello & Roux, 
2011). For atypical MAPKs, ERK3/4 and NLK, a glycine or glutamic acid 
residue is present instead of a tyrosine residue (Coulombe & Meloche, 2007). 
The atypical kinase, ERK7, contains the conserved motif, Thr-Glu-Tyr in the 
activation loop, but there is a lack of evidence that ERK7 is phosphorylated by 
upstream molecules, rather ERK7 is activated by autophosphorylation (Abe et 
al., 2001). There is a greater understanding regarding the regulation, 
specificity and function of conventional MAPKs, compared to atypical MAPKs. 
Hence the conventional MAPKs, JNK1/2, p38 and ERK1/2 remain the focus in 
this thesis.  
  
Chapter 1: Introduction  
13 
 
1.4 Extracellular signal-regulated kinase-1/2 (ERK1/2) signalling 
1.4.1 Overview of ERK1/2 signalling pathway 
The extracellular signal-regulated kinase-1/2 (ERK1/2) signalling pathway, 
also known as the MAPK/ERK pathway or Ras-Raf-MEK-ERK pathway, is the 
most characterised MAPK signalling pathway (Figure 1.4). ERK signalling 
plays a prominent role in cell survival and is involved in regulating 
differentiation, proliferation, growth, metabolism, cell migration and cell 
morphology (Shaul & Seger, 2007; Yoon & Seger, 2006).   
 The ERK signalling pathway is predominantly activated by a range of 
mitogenic stimuli including cytokines, phorbol esters and growth factors such 
as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
nerve growth factor (NGF) and insulin-like growth factor 1 (IGF-1) (Cargnello 
& Roux, 2011). In addition, ERK signalling can be activated by cell stresses 
such as osmotic stress and microtubule depolymerisation (Raman, Chen, & 
Cobb, 2007). The mitogenic stimuli typically initiate ERK signalling by binding 
to, and activating cell surface receptors, for example growth factors typically 
activate receptor tyrosine kinases (RTKs) (Perona, 2006). Binding of the 
growth factor causes dimerisation of the receptor and subsequent 
autophosphorylation of the tyrosine residues in the cytoplasmic domain. The 
phosphorylated tyrosine residues bind a series of cytoplasmic adaptor 
proteins. Growth factor receptor-bound protein 2 (Grb2) binds to the 
phosphorylated tyrosine residues through a Src homology 2 SH2 domain and 
Grb2 also contains two SH3 domains which allows exchange factors such as 
son of sevenless (SOS) to bind to Grb2 (Margolis, Skolnik, Margolis, & Skolnik, 
1994). This enables the recruitment of Ras proteins (H-Ras, K-Ras and N-
Ras) to the membrane. Ras proteins are GTPases which are inactive when 
GDP-bound but conversion of GDP to GTP, catalysed by guanine exchange 
nucleotide factors (GEFs), results in active GTP-bound Ras (Omerovic, 
Laude, & Prior, 2007). Active Ras is able to recruit the MAPKKKs involved in 
ERK signalling to the membrane for activation.   
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Figure 1.4: Generic structure of the ERK pathway 
The ERK signalling pathway is activated by the binding of mitogenic stimuli to cell surface 
receptors Activation of cell surface receptors allows binding of adaptor proteins and exchange 
factors which facilitates the recruitment of Ras and subsequent Raf proteins. Activated Raf 
proteins phosphorylate and activate MEK1/2 which in turn phosphorylate ERK1/2. Activated 
ERK1/2 can activate over 200 cytoplasmic and nuclear targets. 
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 The main MAPKKKs involved in ERK1/2 signalling are members of the 
Raf kinase family: A-Raf, B-Raf and C-Raf (Raf-1), with Raf-1 being the best 
characterised isoform (Wellbrock, Karasarides, & Marais, 2004). In addition to 
Raf kinases, other MAPKKKs involved in ERK signalling are Mos, tumour 
progression locus 2 (Tpl2) kinase and MAPK/ERK kinase kinase 1 (MEKK1) 
but the involvement of these MAPKKKs is restricted to certain cell types and 
stimuli (Raman et al., 2007; Wortzel & Seger, 2011). Mos functions in the 
reproductive system (Gotoh & Nishida, 1995), whereas Tpl2 functions mainly 
in transformed cells (Salmeron et al., 1996) and MEKK1 is involved in the 
response to stress stimuli (Lange-Carter, Pleiman, Gardener, Blumer, & 
Johnson, 1993).  
The MAPKKs involved in ERK signalling are MEK1 (45 kDa) and MEK2 
(46 kDa). MEK1 and MEK2 are structurally similar to other MEK proteins 
consisting of a catalytic kinase domain surrounded by a regulatory N-terminus 
region and a C-terminus region (Roskoski, 2012). MEK1 and MEK2 are 86% 
identical in sequence in the catalytic domain (Frémin & Meloche, 2010). Unlike 
other MEKs, MEK1 and MEK2 also contain a leucine-rich nuclear export 
sequence (NES) in the N-terminus region (Fukuda, Gotoh, Gotoh, & Nishida, 
1996) and a proline-rich sequence in the kinase domain which is important for 
MEK regulation (Catling, Schaeffer, Reuter, Rukmini Reddy, & Weber, 1995). 
MEK1 and MEK2 are activated by the dual phosphorylation of serine residues 
within the conserved Ser-Xaa-Ala-Xaa-Ser/Thr motif within the activation loop 
of MEK1 and MEK2 (Raman et al., 2007; Shaul & Seger, 2007). Human MEK1 
is phosphorylated at Ser218 and Ser222 whereas MEK2 is phosphorylated at 
Ser222 and Ser226 (Lavoie & Therrien, 2015).  
ERK1 (44kDa) and ERK2 (42kDa), encoded for by the genes, MAPK3 
and MAPK1 respectively, are the only known substrates of MEK1 and MEK2 
(Shaul & Seger, 2007). ERK1 was the first mammalian MAPK to be 
characterised (Boulton et al., 1990) and later ERK1 and ERK2 were identified 
as kinases activated in response to insulin and nerve growth factor (NGF) 
(Boulton et al., 1991). MEK1 and MEK2 activate ERK1 and ERK2 through the 
dual phosphorylation of threonine and tyrosine residues within the Thr-X-Tyr 
motif in the activation loop of the ERK kinases (Payne et al., 1991; Shaul & 
Chapter 1: Introduction  
16 
 
Seger, 2007). Human ERK1 is phosphorylated at Thr202 and Tyr204 whereas 
ERK2 is phosphorylated at Thr185 and Tyr187 (Lavoie & Therrien, 2015). 
ERK1 and ERK2 are ubiquitously expressed in all tissues but ERK2 is 
generally expressed at higher levels than ERK1 (Buscà, Pouysségur, & 
Lenormand, 2016). ERK1 and ERK2 are 83% identical in sequence (Cargnello 
& Roux, 2011).   
Around 200 substrates of phosphorylated ERK1/2 have been identified, 
including both cytoplasmic and nuclear targets (Yoon & Seger, 2006). 
Cytoplasmic targets include proteins involved in regulating cell 
adhesion/migration (myosin light chain kinase-MLCK, paxillin and focal 
adhesion kinase-FAK), cell-cell communication (connexin 43-Cx43), cell death 
(death associated protein kinase-DAPK) and proteins involved in maintaining 
cytoskeletal structure (Ramos, 2008). Alternative cytoplasmic targets of ERK 
signalling are mitogen-activated protein kinase-activated protein kinases 
(MAPKAPKs). The main MAPKAPK activated by ERK signalling is ribosomal 
S6 kinase (RSK) (Sturgill, Ray, Erikson, & Maller, 2002). MAPK-interacting 
protein kinase (MNK) and mitogen- and stress-activated protein kinases 
(MSK) are additional MAPKAPKs activated by ERK1/2 (Deak, Clifton, Lucocq, 
& Alessi, 1998; Fukunaga & Hunter, 1997; Wortzel & Seger, 2011). Nuclear 
targets of phosphorylated ERK1/2 include transcription factors such as c-Jun, 
c-Fos, Elk-1 (Wortzel & Seger, 2011).  
 
1.4.2 Role of ERK signalling in leukemogenesis 
ERK signalling is involved in regulating the proliferation, differentiation and 
apoptosis of haematopoietic cells, allowing cells to respond to stimuli in the 
microenvironment of the bone marrow and blood. Early evidence showing the 
constitutive activation of ERK signalling in leukaemia cells highlighted the 
potential involvement of ERK signalling in leukemogenesis. Deregulation of 
ERK signalling allows immature or abnormal leukemic cells to proliferate, 
survive and avoid apoptosis.  
 Constitutive activation of ERK signalling has been reported in 
numerous studies, in both leukemic cell lines and primary leukemic cells. Out 
of 14 AML cell lines and 5 CML cell lines (from blast crisis) studied, significant 
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activation of MEK1/2 was observed in 8 and 2, of the AML and CML cell lines, 
respectively (Morgan, Dolp, & Reuter, 2001). ERK1/2 activation correlated 
with MEK1/2 activation; ERK1/2 activation was measured in 9 of the AML cells 
lines and 2 of the CML cell lines. Constitutive phosphorylation of ERK1/2 in 
the AML cell lines, NB4 and OCI-AML3, were confirmed in two alternative 
studies (Milella et al., 2001; Ricciardi et al., 2005). Constitutive activation of 
ERK1/2 has been reported in the majority (greater than 50%) of blasts from 
newly diagnosed AML patients (Kim et al., 1999; Milella et al., 2001; Ricciardi 
et al., 2005; Towatri et al., 1997). In addition to newly diagnosed AML patients, 
high levels of phosphorylated ERK1/2 have also been reported in samples 
from patients with relapsed or refractory AML (Ricciardi et al., 2005). Levels of 
phosphorylated ERK may have great prognostic value; high levels of 
phosphorylated ERK2 in AML cells is associated with a poor prognosis 
(Kornblau et al., 2006).  
Constitutive activation of ERK signalling in leukemic cells is a result of 
either mutations in components of the ERK pathway, changes in the activity of 
phosphatases involved in regulating ERK signalling or changes in external 
stimuli, such as chemotherapy drugs. Mutations in MEK1/2 and ERK1/2 are 
rare and the constitutive activation of ERK signalling is primarily due to 
mutations in Ras proteins and to a lesser extent Raf proteins. Activating point 
mutations in Ras proteins, at codons 12, 13 and 61 are one of the most 
common genetic alterations in leukaemia, with varying frequencies among 
different leukaemia subtypes (Table 1.2). In leukaemia, mutations in N-RAS 
are more frequent than in K-RAS; H-RAS mutations are rare. Mutations in Ras 
proteins favour GTP-binding, producing a constitutively active GTP-bound 
form of Ras, promoting proliferative and survival signals (Prior, Lewis, & 
Mattos, 2012). In AML, mutations are common in the FMS-like tyrosine kinase 
3 (FLT3) gene, which encodes for a receptor tyrosine kinase upstream of Ras 
(Table 1.2). FLT3 mutations can be categorised into two main types: internal 
tandem duplication (FLT3/ITD) mutations in the juxtamembrane domain of the 
receptor and point mutations in the activation loop of the tyrosine kinase 
domain (FLT3/TKD) (Levis, 2013; Levis & Small, 2003). Both mutations result 
in the constitutive activation of FLT3 and subsequent hyperactivation of Ras 
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and downstream kinases involved in ERK signalling which promotes 
leukemogenesis (Masson & Rönnstrand, 2009). Mutations directly in Ras 
proteins are extremely rare in CML. However in Philadelphia chromosome-
positive CML, formation of the fusion BCR-ABL gene and consequent 
constitutive tyrosine kinase activity, results in increased levels of active GTP 
(Table 1.2) (Kurzrock, Jordan, Gutterman, & Talpaz, 1988; Zou & Calame, 
1999).  
Initially Raf proteins were only considered to have an important role in 
cancer development due to their effects downstream of Ras proteins. It later 
became apparent that Raf proteins can themselves be directly mutated, 
resulting in constitutively activate ERK signalling, independent of upstream 
Ras proteins. Although mutations in Raf proteins are very common in cancer, 
with B-Raf being mutated in around 8% of all cancers (Holderfield, Deuker, 
Mccormick, & Mcmahon, 2014), Raf mutations in leukaemia are rare and 
appear to be restricted to certain types of leukaemia.  For example, the most 
common BRAF mutation, V600E, is found in almost all (>97%) cases of hairy 
cell leukaemia, a rare type of leukaemia (Ahmadzadeh et al., 2014; Blombery 
et al., 2012; Falini, Martelli, & Tiacci, 2016; Tiacci et al., 2011). In contrast, it 
is apparent that B-Raf is not commonly mutated in AML. B-Raf mutations were 
reported in only 4% of AML cases (Lee et al., 2004), and other studies 
examining a larger number of cases did not report any Raf mutations in AML 
cases  (Smith et al., 2003; Trifa et al., 2012).  
Although it has been well established that genetic mutations, such as 
those discussed in the Ras and Raf proteins contribute to leukemogenesis, 
there is an emerging role of phosphatases in the development of leukaemia. 
Altered phosphatase activity can deregulate ERK signalling, allowing 
constitutively active ERK signalling. Phosphatase of activated cells 1 (PAC1) 
was one of the first phosphatases to be implicated in leukemogenesis. The 
PAC1 gene is downregulated in acute leukemic cells compared to normal bone 
marrow cells and is associated with the constitutive activation of ERK in 
leukemic cells (Kim et al., 1999). The protein phosphatase 2A (PP2A) family 
of serine/threonine phosphatases involved in downregulating ERK signalling 
(Millwards, Zolnierowicz, & Hemmings, 1999), has also been identified as one 
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of the main families of phosphatases dysregulated in leukaemia. Inhibition of 
PP2A activity, and the consequent hyperactivation of ERK signalling and 
leukemic cell survival has been reported in various types of leukaemia 
(Arrizau, Pippa, & Oder, 2016; Cristóbal, Garcia-Orti, Cirauqui, Alonso, & 
Calasanz, 2011; Neviani et al., 2005). Inhibition of PP2A activity can be 
caused by either post-translational modifications to the enzymatic  C subunit 
or through the activity of regulatory proteins which interact with the regulatory 
A and B subunits of PP2A (Ramaswamy, Spitzer, Kentsis, Ruvolo, & 
Gutierrez, 2015; Yang, Huang, Lu, Li, & Huang, 2012). Reactivation of PP2A 
activity in leukemic cells induces apoptosis (Gutierrez et al., 2014; 
Ramaswamy et al., 2015; Smith et al., 2016; Yang et al., 2012).  
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Table 1.2: Genetic alterations causing the constitutive activation of Ras in leukaemia  
(Adapted from Reuter, Morgan, & Bergmann, 2000). 
 
[1] Bos, 1989, [2] Bryne & Marshall, 1998, [3] Farr, Saikit, Erlicht, Mccormickf, & Marshall, 1988, [4] Janssen et al., 1987, [5] Gilliland & Griffin, 2002, [6] Levis, 2013, [7] Löwenberg 
et al., 2005, [8] Liang et al., 2006, [9] Vogelstein et al., 1990, [10] Browett & Norton, 1989, [11] Neri, Knowlest, Greco, Mccormickt, & Dalla-Favera, 1988, [12] Irving et al., 2014, 
[13] Bennour et al., 2012, [14] Onida et al., 2002, [15] Zou & Calame, 1999, [16] Doménech et al., 2012, [17] Kanagal-Shamanna et al., 2015.
Leukaemia subtype Mutation Frequency (%) References 
Acute myeloid leukaemia (AML) Point mutation of N-RAS, K-RAS 20-30 [1-4] 
FLT3/ITD or FLT3/TKD 
 
20-30 [5-7]  
Childhood AML 
 
Point mutation of N-RAS, K-RAS 20-30 [3,8,9] 
Acute lymphocytic leukaemia (ALL) 
 
Point mutation of N-RAS, K-RAS 20 [10,11] 
Childhood ALL Point mutation of N-RAS, K-RAS 
 
10-35 [8,12] 
Chronic myeloid leukaemia (CML) BCR-ABL t(9;22), Ras-GTP 
 
90-95 [13-15] 
Chronic lymphocytic leukaemia (CLL) Point mutation of N-RAS, K-RAS 5-10 
 
[16,17] 
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1.4.3 Targeting ERK signalling in leukaemia  
The constitutive activation of ERK signalling in leukemic cells, which occurs 
via a range of mechanisms, is essential for the survival of leukemic cells. The 
important role of ERK signalling in mediating leukemic cell survival has been 
highlighted by studies in which targeting ERK signalling, in particular inhibition 
of the pathway, has been shown to reduce the survival of leukemic cells. 
Inhibition of ERK signalling, by targeting MEK1 using PD98059 or PD184352, 
inhibited the growth of OCI-AML3, HL-60 and NB4 cells, AML cell lines with 
high levels of active ERK (Milella et al., 2001). An alternative MEK inhibitor, 
U0126, induced apoptosis in alternative AML cell lines (KG1a, THP-1, M07e, 
HEL and TF-1) (Kerr et al., 2003). Investigations of the effect of a range of 
ERK signalling inhibitors on the growth of a variety myeloid leukemic cell lines 
showed Ras inhibitors (FT-277 and FPT-3) and MEK inhibitors (U0126 and 
PD98059) resulted in growth inhibition of the majority of AML cell lines (HL-
60, NB-4, THP-1, MUTZ-2/3 and OCI-AML2/5) and CML cell lines (K562, EM-
2, JK-1, LAMA-84) tested (Morgan et al., 2001). The pro-apoptotic effects of 
ERK inhibitors were confirmed in NB-4 cells, the AML cell line which showed 
the highest sensitivity towards the inhibitors. It has also been shown that 
inhibition of MEK, using PD98059, inhibits the growth and induces apoptosis 
in primary AML cells with constitutively active ERK, but not in normal 
haematopoietic progenitor cells (Lunghi et al., 2003; Milella et al., 2001). 
 Collectively the studies discussed suggest the ERK signalling pathways 
are a promising therapeutic target for leukaemia. In particular, these studies 
have focused mainly on targeting ERK in AML cells. This is not surprising, as 
targeting components of the ERK signalling pathway downstream of Ras might 
be beneficial in AML therapy, where the exact mutations causing constitutive 
activation of ERK1/2, are not always known. This is in contrast to therapy for 
CML, where the majority of patients have the BCR-ABL fusion gene and 
constitutive tyrosine kinase activity, making tyrosine kinase inhibitors a more 
effective therapeutic approach for CML.  
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1.4.4 Role of ERK signalling in response to leukaemia therapy 
Targeting ERK signalling alone is not the only potential therapy for AML. 
Targeting ERK signalling in combination with pro-apoptotic small molecules or 
conventional chemotherapeutic agents might provide a more effective 
treatment strategy. This approach has been taken in a limited number of 
studies. PD98059 sensitised AML cell lines (OCI-AML3, NB4 and HL60) to all-
trans retinoic acid, a chemotherapeutic agent used in the treatment of AML. 
Treatment of  HL-60 cells with PD98059 prior to cytarabine (Ara-C), a 
treatment for AML and ALL, increased the sensitivity of HL60 cells to Ara-C-
induced apoptosis (Milella et al., 2001). ABT-737 is a Bcl-2 inhibitor which 
inhibits cell growth and induces apoptosis in AML cells; pre-treatment of OCI-
AML3 cells with PD98059 increased the apoptotic effects of ABT-737 
(Konopleva et al., 2006). 
 
1.4.5 Inhibitors of ERK signalling 
As there is promising evidence for the potential therapeutic targeting of ERK 
signalling, numerous ERK signalling inhibitors have, and continue to be 
developed. These include ERK inhibitors for use in in vitro studies to gain a 
greater understanding of ERK signalling in various processes and inhibitors 
which can be used therapeutically in humans. General strategies to target ERK 
signalling include: preventing Ras membrane localisation using 
farnesyltransferase inhibitors (FTIs), directly targeting the GTP-binding pocket 
of Ras, interfering with RAS-SOS or RAS-Raf interactions, inhibiting Raf, MEK 
or ERK (Samatar & Poulikakos, 2014). Targeting ERK signalling upstream of 
Raf has been a challenge and more extensive testing of such inhibitors is 
required. The focus has therefore been on the development of small molecule 
inhibitors to target Raf, MEK1/2 and ERK1/2 (Table 1.3) 
Several Raf inhibitors, such as vemurafenib, dabrafenib and encorafenib 
have been developed (Table 1.3) Raf inhibitors appear to be particularly 
effective in patients with BRAF(V600E) and have therefore mainly been used 
to target ERK in melanoma skin cancer, where the frequency of BRAF(V600E) 
mutation rate is higher, and also in hairy cell leukaemia (Dietrich et al., 2016; 
Tiacci et al., 2015). In cells with wild-type BRAF, rather than inhibiting Raf, Raf 
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inhibitors cause the activation of Raf and downstream ERK signalling 
components (Halaban et al., 2010; Hatzivassilou et al., 2010; Poulikakos, 
Zhang, Bollag, Shokat, & Rosen, 2010). This makes Raf inhibitors unsuitable 
in types of leukaemia, such as AML in which the BRAF(V600E) is rare. 
MEK1/2 and ERK1/2 inhibitors are therefore more attractive targets for 
inhibition of ERK signalling in leukaemia.  
The focus has been on the development of MEK1/2 inhibitors as MEK1/2 
are attractive targets for ERK signalling inhibitors for two main reasons: 
MEK1/2 function downstream of Ras and Raf where the majority of mutations 
occur and ERK1/2 are the only known substrates of MEK1/2 and therefore 
MEK1/2 inhibitors are highly selective for ERK1/2 signalling. The first small 
molecule MEK1/2 inhibitor to be developed was PD98059, and then U0126 
was later developed (Table 1.3). PD184352 was the first MEK inhibitor to enter 
clinical trials but was unsuccessful. PD184352 however, in addition to U0126 
have been extensively used in in vitro studies, including studies on leukemic 
cells. More recently developed MEK inhibitors include: PD0325901, 
Trametinib, selumetinib, binimetinib and cobimetinib (Table 1.3), but have 
mainly been tested in melanoma cells.  
 Whilst the focus has been on the development of Raf and MEK 
inhibitors, there has been less progress on the development of ERK1/2 
inhibitors. Initially it was believed that there would be no benefit of targeting 
ERK1/2 compared to MEK1/2 as ERK1/2 are the only substrates of MEK1/2 
(Samatar & Poulikakos, 2014). However, emerging evidence suggests that 
Raf and MEK inhibitors can cause negative feedback and increased levels of 
active ERK, which indicates the potential for directly targeting ERK1/2. ERK 
inhibitors might also be beneficial in cells resistant to Raf or MEK inhibitors. 
Recently developed ERK inhibitors include: SCH772984, FR180204, VTX11e 
and GDC-0994 (Table 1.3). ERK inhibitors are still in the relatively early stages 
of development but could provide a more effective method of targeting ERK 
signalling in leukaemia in the future.  
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In this thesis, U0126 and PD184352 will be used to target ERK 
signalling as these inhibitors have been widely used and shown to be effective 
at inhibiting ERK signalling in leukemic cells.  
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Inhibitor Mechanism of action Additional information References 
Raf inhibitors     
Vemurafenib 
(PLX4032) 
 
Inhibitor of all RAF isoforms in vitro. Potent inhibitor of 
mutated B-Raf in vivo.   
First B-Raf inhibitor to enter clinical trials. Approved for 
BRAF(V600E) melanoma 
[1,2] 
Dabrafenib 
(GSK2118436) 
 
Potent ATP-competitive inhibitor of mutated B-Raf Second BRAF inhibitor developed.  Approved for 
BRAF(V600E) melanoma 
[3,4] 
Encorafenib 
(LGX818)  
Potent inhibitor of mutated B-Raf Currently in phase 3 trials in patients with BRAF(V600E) 
melanoma and colorectal cancer  
[5.6] 
MEK inhibitors    
PD98059 Non-ATP-competitive inhibitor which prevents the activation 
of MEK but does not inhibit MEK activity 
 
Not suitable for clinical trials due to weak inhibitory effect 
in vitro, poor solubility and inadequate bioavailability 
[7,8] 
U0126 
 
Inhibits MEK1/2 activation by binding to the inactive form of 
MEK1/2 and therefore prevents the recruitment of Raf-1 
 
Not suitable for clinical trials but widely used in in vitro 
studies 
[9,10] 
PD184352  
(CI-1040) 
Selective non-ATP-competitive inhibitor of MEK1/2 
 
Greater potency than PD98059 and U0126. First MEK 
inhibitor to enter clinical trials and demonstrate in vivo 
activity but trials terminated due to poor solubility and 
rapid clearance. Widely used in in vitro studies 
 
[11-13]  
PD0325901 
 
Highly potent and specific non-ATP-competitive inhibitor of 
MEK1/2 
A structural analogue of PD184352 with greater potency, 
improved solubility and increased bioavailability. 
Development stopped at phase 1 study due to retinal 
vein occlusion toxicities 
 
[14,15] 
Selumetinib 
(AZD6244, 
ARRY-142886) 
Potent, highly selective non-ATP-competitive inhibitor of 
MEK1/2. Locks MEK1/2 into an inactive conformation 
allowing ATP to bind but prevents interactions required for 
catalysis and access to ERK activation loop 
Well tolerated in phase I trial. Antitumor activity shown in 
phase II trial of patients with advanced melanoma 
[16-19]  
Trametinib 
(GSK1120212) 
Reversible, highly selective allosteric inhibitor of MEK1/2 
activation and kinase activity  
Approved for BRAF(V600E) melanoma [20-22] 
Table 1.3: Inhibitors of ERK signalling 
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[1] Flaherty et al., 2010,  [2] Yang et al., 2010, [3] Falchook et al., 2012, [4] Hauschild et al., 2012, [5] Li et al., 2016, [6] Stuart et al., 2012, [7] Alessi, Cuenda, Cohen, Dudley, 
& Saltielʈ, 1995, [8] Dudley, Pang, Decker, Bridgest, & Saltiel, 1995, [9] Duncia et al., 1998, [10] Favata et al., 1998, [11] Allen et al., 2003, [12]  LoRusso et al., 2005, [13] 
Sebolt-Leopold et al., 1999, [14] Brown, Carlson, Loi, & Graziano, 2007, [15]  LoRusso et al., 2010, [16] Davies et al., 2007, [17] Kirkwood et al., 2012, [18] Leijen et al., 2011, 
[19] Yeh et al., 2007, [20]  Abe et al., 2011, [21] Gilmartin et al., 2011, [22] Leonowens et al., 2014, [23] Ascierto et al., 2013, [24] Choo et al., 2012, [25] Rice et al., 2012, [26] 
Chaikuad et al., 2014, [27] Morris et al., 2013, [28] Ohori et al., 2005, [29] Aronov et al., 2009, [30] Robarge et al., 2014. 
 
 
Inhibitor Mechanism of action Additional information References 
Binimetinib 
(MEK162) 
 
Potent ATP non-competitive allosteric inhibitor of MEK1/2 Tested in phase 2 study and showed a response in 
melanoma cells harbouring NRAS or BRAF(V600E) 
[23] 
Cobimetinib 
(GDC-0973) 
 
Binds to and inhibits the catalytic activity of MEK1 Used in combination with Vemurafenib in the treatment of 
melanoma  
[24,25] 
ERK inhibitors     
SCH772984 ATP-competitive inhibitor of ERK1/2. Inhibits ERK 
enzymatic activity and subsequent phosphorylation of S6 
kinase. Also stabilises a conformational state of ERK which 
prevents activation by MEK1/2 
 
Effective in RAS and B-Raf mutant cancer cells 
 
 
[26,27] 
FR180204 Potent, cell permeable ATP-competitive inhibitor of ERK1/2 
 
Not yet extensively profiled and relatively limited usage [28] 
VTX11e ATP-competitive inhibitor of ERK2. Binds to ERK2 and 
prevents phosphorylation of downstream substrates 
 
Orally bioavailable.  [29] 
GDC-0994 Highly selective inhibitor of ERK1/2 In early phase 1 clinical development  
 
[30] 
Table 1.3: Inhibitors of ERK signalling 
Continued 
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1.5 c-Jun N-terminal kinase (JNK) signalling 
1.5.1 Overview of JNK signalling pathway 
JNK signalling, an alternative MAPK signalling pathway, is involved in a variety 
of cellular processes including, inflammation, cell proliferation, differentiation, 
metabolism and cell death (Figure 1.5) (Bubici & Papa, 2014). In contrast to 
ERK signalling, which is predominantly involved in regulating cell survival, JNK 
signalling plays a more prominent role in the induction of apoptosis in response 
to stress.  
JNK signalling is mainly activated by stress stimuli such as environmental 
cell stressors (UV, hypoxia, heat shock and osmotic shock), pathogens 
(lipopolysaccharide, peptidoglycan) and chemotherapy drugs (Figure 1.5) 
(Bogoyevitch & Kobe, 2006; Derijard et al., 1994; Matsuda, Kawasaki, 
Moriguchi, Gotoh, & Nishida, 1995; Seki, Brenner, & Karin, 2012). Other 
stimuli which activate JNK signalling are cytokines (tumour necrosis factor, 
interleukin-1) and growth factors (transforming growth factor β, epidermal 
growth factor, platelet-derived growth factor) (Bubici & Papa, 2014; Seki et al., 
2012; Westwick, Weitzel, Minden, Karin, & Brenner, 1994).  
In response to stimuli, MAPKKKs involved in JNK signalling are activated 
by GTPases such as Ras protein family members (Raf MKKKs) or Rho family 
of GTPases (Cdc42, RhoA) (Chen & Cobb, 2006; Gallagher, Gutowski, 
Sternweis, & Cobb, 2004; Russell, Lange-Carter, & Johnson, 1995). Out of 
twenty MAPKKKs identified, fourteen are involved in the activation of JNK 
signalling (Johnson & Nakamura, 2007). MEKK1 was the first MAPKKK 
identified to have a role in JNK signalling (Widmann, Gerwins, Johnson, Jarpe, 
& Johnson, 1998). Other MAPKKKs involved in JNK signalling include: 
members of the mixed lineage kinase family (MLK1-3), MEK kinases (MEKK1-
4), apoptosis signal-regulating kinases (ASK1/2), tumour progression locus 2 
kinase (TPL2), dual leucine zipper kinase (DLK), serine/threonine-protein 
kinase TAO1/2 and transforming growth factor activated kinase 1 (TAK1) 
(Cargnello & Roux, 2011; Fanger, Gerwins, Widmann, Jarpe, & Johnson, 
1997; Gallo & Johnson, 2002; Kyriakis & Avruch, 2001). 
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Figure 1.5: Generic structure of the JNK pathway  
The JNK signalling pathway is activated by cell stressors, cytokines and growth factors which 
activate MEK kinases (MEKK), mixed lineage kinases (MLKs) and alternative MAPKKKs. 
Activated MAPKKKs phosphorylate and activate MKK4/7 which in turn phosphorylate 
JNK1/2/3. Activated JNK1/2/3 can activate over 50 nuclear and cytoplasmic targets. 
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In the JNK signalling cascade, MAPKKKs cause the phosphorylation of 
two main MAPKKs: MKK4 and MKK7 (Cargnello & Roux, 2011). MKK4 and 
MKK7 dually phosphorylate downstream JNK proteins at threonine 183 
(Thr183) and tyrosine 185 (Tyr185) residues in the conserved Thr-Pro-Tyr 
residues in the activation loop of JNK. MKK4 shows preference for the 
phosphorylation of tyrosine whereas MKK7 shows preference for the 
phosphorylation of threonine and therefore MKK4 and MKK7 appear to 
function synergistically in the activation of JNK proteins (Lawler, Fleming, 
Goedert, & Cohen, 1998; Zou et al., 2007). Whilst MKK4 is specific for JNK 
signalling, MKK7 is involved in both JNK and p38 signalling (Haeusgen, 
Herdegen, & Waetzig, 2011).  
In humans, there are three main JNK proteins, JNK1, JNK2 and JNK3, 
which are encoded for by MAPK8, MAPK9 and MAPK10, respectively (Bubici 
& Papa, 2014). The JNK proteins are greater than 85% identical in sequence 
to each other (Cargnello & Roux, 2011). The diversity of JNK proteins arises 
from alternative splicing, which gives rise to at least ten different JNK isoforms 
(JNK1α1, JNK1α2, JNK1β1, JNK1β2, JNK2α1, JNK2α2, JNK2β1, JNK2β2, 
JNK3α1, JNK3α2) with molecular weights between 46 and 55 kDa (Bubici & 
Papa, 2014). JNK1 and JNK2 are ubiquitously expressed in most types of 
tissues whereas JNK3 expression is restricted to neuronal tissues in the brain 
and to a lesser extent in cardiac tissue, smooth muscle tissues and testes 
(Bode & Dong, 2007; Bogoyevitch & Kobe, 2006). Due to the restricted 
expression of JNK3, it is believed JNK3 may have a different function to JNK1 
and JNK2; JNK1 and JNK2 however appear to have overlapping functions 
(Bode & Dong, 2007).  
At least 50 different substrates of phosphorylated JNK are known, 
including both nuclear and non-nuclear proteins (Seki et al., 2012). c-Jun and 
other members of the Jun family of transcription factors are the main nuclear 
targets of activated JNK (Bogoyevitch & Kobe, 2006; Derijard et al., 1994). A 
Jun protein (c-Jun, JunB, JunD) dimerises with a Fos protein (c-Fos, FosB, 
Fra-1, Fra-2) to form the activator protein-1 (AP-1) transcription factor (Bubici 
& Papa, 2014). Activating transcription factor-2 (ATF-2) and ETS domain-
containing protein (Elk-1) are alternative transcription factors activated by JNK 
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signalling (Cavigelli, Dolfi, Claret, & Karin, 1995; Van Dam et al., 1995). Other 
nuclear targets include nuclear factor of activated T cells (NFAT), c-Myc and 
p53 and nuclear hormone receptors such as the glucocorticoid receptor and 
retinoic acid receptor (Alarcon-Vargas & Ronai, 2004; Bogoyevitch & Kobe, 
2006, 2006; Buschmann et al., 2001; Gupta, Campbell, Derijard, & Davis, 
1995; Ortega-Pérez et al., 2005; Rogatsky, Logan, Garabedian, & Yamamoto, 
1998; Yang, Whitmarsh, Davis, & Sharrocks, 1998). Non-nuclear targets 
include cytoplasmic cytoskeletal proteins (DCX, Tau) and apoptotic regulatory 
proteins (Bcl-2, Bad, Bax and Bim) (Bogoyevitch, 2006).  
 
1.5.2 Role of JNK signalling in leukemogenesis  
JNK signalling has different and opposing functions in cancer; there is 
evidence JNK can act as a tumour promoter and as a tumour suppressor 
(Bubici & Papa, 2014; Tournier, 2013). This is not surprising given the dual 
role of JNK signalling in regulating both cell survival and cell death. The JNK 
isoforms, JNK1 and JNK2 also have different and opposing functions in 
different types of cancer. The physiological and pathological function of JNK 
signalling depends on the stimuli, the cellular context, the JNK isoform 
involved, the strength and duration of JNK activation and hence the balance 
between JNK-mediated survival and JNK-mediated apoptosis (Gururajan et 
al., 2005; Platanias, 2003; Wagner & Nebreda, 2009).  Whilst the role of JNK 
signalling in carcinogenesis appears to be well established in solid tumours, 
the role of JNK signalling in the development of haematological malignancies, 
such as leukaemia, is poorly understood.  
 There is limited evidence suggesting the role of JNK signalling in the 
development and progression of chronic leukaemias. High levels of activated 
JNK, in particular JNK1 have been reported in BCR/ABL-expressing CML cell 
lines (Burgess et al., 1998; Cripe et al., 2002). Constitutive BCR/ABL kinase 
activity results in activated JNK signalling in CML cells; inhibition of JNK 
signalling through the use of a dominant negative mutant of c-Jun, prevents 
the transforming ability of BCR/ABL (Raitano, Halpern, Hambuch, & Sawyers, 
1995). Inhibition of JNK signalling, using a cytoplasmic JNK inhibitor, JIP-1, 
reduced cell proliferation and prevented the transforming activity of BCR/ABL 
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(Dickens et al., 1997). In particular constitutive BCR/ABL kinase activity results 
in the activation of JNK1 and inhibition of the JNK1 isoform prevents 
BCR/ABL-mediated transformation and survival of pre-B cells (Hess, Pihan, 
Sawyers, Favell, & Davis, 2002). JNK signalling is important for survival in 
BCR/ABL-expressing cells due to its ability to control Bcl-2 expression. The 
inability of BCR/ABL-expressing cells to survive in cells in which JNK signalling 
is inhibited, is due to decreased expression of Bcl-2; transgenic expression of 
Bcl-2 reverses the effects observed in JNK-inhibited cells. Collectively these 
studies suggest high levels of activated JNK play an important role in 
BCR/ABL-mediated transformation of haematopoietic cells.  
There is also evidence that the constitutive activation of JNK signalling 
pathway plays an important role in the development of adult T-cell leukaemia 
(ATL) (Xu et al., 1996). Constitutive activation of JNK was observed in 
lymphocytes transformed in vitro by the human T cell leukaemia virus type 1 
(HTLV-1) and in leucocytes from ATL patients. An alternative study  has also  
reported the involvement of JNK signalling in HTLV-1-mediated ATL (Arnulf et 
al., 2002). Transforming growth factor-β1 (TGF- β1) signalling, a signalling 
pathway involved in the inhibition of T cell proliferation, is repressed by the 
Tax oncoprotein of HTLV-1 through a pathway involving the hyperactivation of 
JNK signalling; this implicates JNK signalling in ATL leukemogenesis.   
In T-cell acute lymphocytic leukaemia (T-ALL) cell lines, low levels of 
activated JNK were measured, yet the low levels were required for survival of 
the T-ALL cells (Cui et al., 2009). Inhibition of JNK signalling in T-ALL cells, 
using the JNK inhibitors SP600125 and AS601245, induced cell cycle arrest 
and apoptosis in T-ALL cells. This study suggests that mechanisms, other than 
the hyperactivation of JNK may exist for the role of JNK signalling in 
leukemogenesis.  
The studies discussed suggest JNK signalling is involved in the 
development and progression of different types of leukaemias. However the 
current understanding of the involvement of JNK signalling in 
leukaemogenesis appears to be restricted to these limited numbers of studies. 
Further investigations are needed to gain a more thorough understanding of 
the role of JNK signalling in leukemogenesis. Identifying the specific functions 
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of JNK signalling in certain types of leukaemia, will provide valuable 
information regarding how the JNK pathway can be targeted therapeutically to 
reduce survival and induce cell death in leukemic cells. 
  
1.5.3 Role of JNK signalling in the response to leukaemia therapy  
Activation of JNK signalling is a common event following chemotherapy 
treatment, and is often required for induction of apoptosis (Fan & Chambers, 
2001). JNK signalling is activated in leukemic cells in response to a range of 
chemotherapeutic agents such as arsenic trioxide, paclitaxel and vincristine; 
the importance of JNK activation in mediating cell death induced by these 
chemotherapeutic agents however was not investigated (Bates, Lewis, 
Eastman, & Danilov, 2015; Davison, Mann, Waxman, & Miller, 2004; Peng et 
al., 2016; Shiah, Chuang, & Kuo, 2001). Activation of JNK signalling is 
essential for ceramide-induced apoptosis in K562 cells, a CML cell line (Nica 
et al., 2008). It has also been reported in K562 cells that PBOX-6, an anti-
leukemic agent, causes the activation of JNK1 and JNK2 which is required for 
apoptosis induced by PBOX-1 (Mc Gee et al., 2002). Inhibition of JNK 
signalling prevents PBOX-1-induced apoptosis in K562 cells.  
Failure to activate JNK signalling may therefore be a possible 
mechanism to explain the resistance of leukemic cells to chemotherapy. This 
has previously been shown to be the case in AML cells; failure to activate JNK 
signalling, conferred resistance to anthracycline chemotherapeutic agents 
(Lagadinou et al., 2008). The anthracyclines, daunorubicin and doxorubicin 
activate JNK signalling in U937 cells, in particular the activation of JNK1; JNK1 
however is not activated in anthracycline-resistant derived U937 cells (U937R 
cells) in response to anthracycline treatment. Further work in primary blasts 
from AML patients demonstrated that for patients who showed 
chemoresistance to daunorubicin, JNK was not activated by daunorubicin in 
the primary AML blasts in vitro. These results are consistent with studies in 
solid cancers, which show failure to activate JNK signalling is associated with 
chemoresistance (Brozovic et al., 2004;  Li et al., 2005, 2006).  
In contrast, there is evidence high levels of activated JNK can contribute 
to chemoresistance in leukemic cells. Constitutive activation of JNK signalling 
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has been reported in HL60/ADR cells, an anthracycline resistant AML cell line 
(Cripe et al., 2002). Inhibition of JNK signalling, using JNP (a non-
phosphorylatable form of c-Jun) reduced the resistance of the HL60/ADR cells 
to daunorubicin. In primary AML cells, there was a strong association between 
constitutive activation of JNK signalling and failure to respond to treatment. 
The constitutive activation of JNK also correlated with high levels of multi-drug 
resistance protein (MRP)-efflux in the primary blasts. JNK signalling inhibition 
reduced MRP-efflux in the HL60/ADR cells. JNK activation has also been 
implicated in mediating resistance of T-cell ALL cells to tetrandrine, an anti-
leukemic drug (Liou et al., 2017). Constitutive activation of JNK signalling was 
reported in tetrandrine-resistant Jurkat cells compared to tetrandrine-sensitive 
Jurkat cells and there was no difference in the expression of P-glycoprotein 
(P-gp) between tetrandrine-resistant and tetrandrine-sensitive cells. Inhibition 
of JNK signalling reduced tetrandrine resistance in the tetrandrine-resistant 
Jurkat cells; this suggests JNK signalling mediates resistance of Jurkat cells 
to tetrandrine but not through P-gp expression. An alternative mechanism of 
JNK-mediated chemoresistance has been proposed in T-cell acute 
lymphocytic leukaemia (T-ALL) cells. JNK1/2 was constitutively activated in 
Sup-T1 cells, a T-cell ALL cell line resistant to etoposide (Leung et al., 2008). 
Activated JNK1/2 caused an increase in the degradation of BimEL, a 
proapoptotic protein (Leung et al., 2008). Inhibition of JNK signalling, using 
SP600125 increased levels of BimEL and increased etoposide-induced 
apoptosis. JNK-mediated degradation of BimEL is therefore a possible 
mechanism of chemoresistance in leukemic cells.  
It appears that there is therefore conflicting evidence for the role of JNK 
signalling in the response of leukemic cells to chemotherapeutic agents. Whilst 
it has been demonstrated failure to activate JNK signalling is associated with 
chemoresistance (Lagadinou et al., 2008), others have argued that 
constitutive activation of JNK signalling contributes to chemoresistance (Cripe 
et al., 2002; Leung et al., 2008; Liou et al., 2017).  However the mechanism 
by which constitutive activation of JNK might mediate chemoresistance is not 
fully understood. The opposing effects observed in different types of leukemic 
cells and in response to different chemotherapeutic agents, suggest the role 
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of JNK signalling in mediating chemoresistance in leukemic cells is cell- and 
agent-specific. Gaining a greater understanding of the role of JNK-mediated 
cell death in response to specific chemotherapeutic agents in specific cell lines 
will provide an insight into how the JNK pathway can be targeted 
therapeutically to increase the susceptibility of leukemic cells to 
chemotherapy-induced cell death.  
 
1.5.4 Inhibitors of JNK signalling 
Given the important role of JNK signalling in disease development, 
progression and response to chemotherapeutic agents, inhibitors have been 
developed to target JNK signalling. The focus was initially of the development 
of small molecule ATP-competitive inhibitors, but has more recently been on 
the design of peptide inhibitors and ATP-site directed covalent inhibitors 
(Table 1.4). (Cui, Zhang, Zhang, & Xu, 2007). JNK signalling inhibitors mainly 
target JNK kinases.  
The majority of small molecule JNK inhibitors are ATP-competitive 
inhibitors which function by competing with ATP for the binding site of the 
kinase and thereby preventing the phosphorylation of downstream substrates 
(Bogoyevitch & Arthur, 2008; Siddiqui & Reddy, 2010). Around 40 different 
small molecule ATP-competitive JNK inhibitors have been identified (Cui et 
al., 2007). The most commonly used ATP-competitive JNK inhibitors are 
CEP1347, SP600125, AS601245, CC-401 and AS602801 (Table 1.4). These 
inhibitors have been successful in therapeutically targeting JNK signalling in 
diseases, in particular neurodegenerative diseases (Yarza, Vela, Solas, & 
Ramirez, 2015). SP600125 however is the most extensively used JNK inhibitor 
in in vitro studies, including those utilising leukemic cell lines such as U937 
cells (Moon et al., 2008; Moon, Choi, & Kim, 2011; Park et al., 2008). The use 
of ATP-competitive inhibitors is limited by two main factors: lack of efficacy 
and poor selectivity. The efficacy of ATP-competitive inhibitors is reduced by 
high levels of intracellular ATP and therefore high concentrations of the 
inhibitor are needed in order to compete with ATP (Bogoyevitch, 2005; Bubici 
& Papa, 2014). In addition, ATP-competitive inhibitors display poor selectively 
as these inhibitors target the ATP-binding site which is highly conserved in 
protein kinases, making it difficult for the inhibitors to differentiate between the 
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different JNK isoforms and to distinguish between JNK kinases and other 
protein kinases (Bogoyevitch & Arthur, 2008; Bubici & Papa, 2014). 
 Targeting JNK, at a site other than the ATP-binding site of JNK, such 
as the substrate binding site or regulatory site of the kinase, provides a more 
specific mechanism of inhibition than ATP-competitive inhibitors  
(Bogoyevitch, 2005). Much attention has been given to the development of 
peptide inhibitors which act in substrate-competitive manner, binding directly 
to the substrate-binding site of JNK. The first examples of JNK peptide 
inhibitors were JIP-derived peptides. JNK activation is facilitated by a 
scaffolding protein, JNK-interacting protein-1 (JIP1), which simultaneously 
binds JNK and upstream signalling components (Willoughby, Perkins, Collins, 
& Whitmarsh, 2003). JIP-derived JNK peptide inhibitors include: TI-JIP, TAT-
TI-JIP and D-JNKI-1 (Bogoyevitch, 2005). The first JIP-derived JNK peptide 
inhibitor designed was a truncated inhibitor based on JIP1 (TI-JIP), a short 10 
residue peptide, the minimum residues of JIP required for binding to JNK (Barr, 
Kendrick, & Bogoyevitch, 2002; Bonny, Oberson, Negri, Sauser, & Schorderet, 
2001). The non-permeable TI-JIP peptide was enhanced by attaching an N-
terminal TAT protein transduction domain sequence from the human 
immunodeficiency virus to produce a permeable TAT-TI-JIP peptide (Bonny et 
al., 2001). Poor stability of this peptide led to further development and the 
production of a stable peptide, D-JNKI-1. More recently PYC71N, a peptide 
not derived from JIP, has been developed (Ngoei et al., 2011). PYC71N is a 
potentially useful inhibitor for investigating JNK-mediated substrate 
interactions. Peptide inhibitors are often reversible, but the design of novel, 
irreversible cysteine-directed covalent inhibitors, such as JNK-IN-8, has 
addressed this problem (Zhang et al., 2012). Low concentrations of peptide 
inhibitors are required to effectively inhibit JNK signalling, but the peptides are 
often subject to proteolytic degradation in vivo, which limits their use 
(Bogoyevitch, 2005).  
  The ATP-competitive inhibitor SP600125 and the novel covalent JNK 
inhibitor, JNK-IN-8 will be used to target JNK signalling in this thesis. Whilst 
SP600125 has extensively been used in previous in vitro studies, JNK-IN-8 
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has been used in a limited number of studies and there are no previous reports 
of its use in leukemic cells. 
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Inhibitor Mechanism of action Additional Information References 
 
ATP-competitive JNK 
inhibitors 
   
CEP-1347 (KT7515) 
 
ATP-competitive inhibitor of mixed lineage kinase 
family members including MLK3  
JNK inhibitor widely used mainly in the treatment of 
neurodegenerative disorders  
[1-4] 
 
SP600125 Reversible ATP-competitive inhibitor of JNK1/2/3  Extensively used in in vitro studies and in animal models. 
Usage limited due to poor specificity towards JNK and 
clinical safety profile unknown 
 
[5,6] 
AS601245 
(JNK inhibitor V) 
Potent ATP competitive inhibitor of JNK1/2/3 Selective for JNK3 at low doses. Only inhibits c-Jun 
phosphorylation at high concentrations due to limited cell 
penetration. AS6001245 has neuroprotective properties 
 
 
[7-9] 
CC-401 Potent ATP-competitive inhibitor of JNK1/2/3 Second generation inhibitor based on the structure of 
SP600125 which shows greater selectivity than SP600125 
for JNK. Phase 1 clinical trial of CC-401 in AML terminated. 
Mainly been used in renal injury models  
 
[10,11] 
AS602801 
(Bentamapimod) 
ATP-competitive inhibitor of JNK1/2/3 Orally bioavailable. Potential anti-cancer agent but requires 
further testing  
 
[11,12] 
Peptide JNK inhibitors    
TI-JIP  
(JIP-1) 
Peptide inhibitor of JNK which competes for JIP1 
binding site on JNK, inhibiting JIP1-JNK binding 
and preventing JNK substrate phosphorylation. 
Peptide binding also induces conformational 
changes which distorts the ATP-binding site of 
JNK, lowering the ATP binding affinity 
 
Peptide based on residues 153-163 of JIP-1 scaffold 
protein. Poor cell permeability 
[13-16] 
Table 1.4: Inhibitors of JNK signalling 
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[1] Kaneko et al., 1997, [2] Maroney et al., 1998, [3] Maroney et al., 2001, [4] Saporito, Hudkins, & Maroney, 2002, [5] Bennett et al., 2001, [6] Bain, McLauchlan, Elliott, & Cohen, 
2003, [7] Carboni et al., 2004, [8] Gaillard et al., 2005,  [9] Carboni et al., 2008,  [10] Ma et al., 2007,  [11] Messoussi et al., 2014, [12]  Okada et al., 2016, [13] Bonny, Oberson, 
Negri, Sauser, & Schorderet, 2001, [14] Barr, Kendrick, & Bogoyevitch, 2002, [15] Bogoyevitch, Boehm, Oakley, Ketterman, & Barr, 2004, [16] Heo et al., 2004, [17] Kato et al., 
2008, [18] Bubici & Papa, 2014, [19] Holzberg et al., 2003,  [20] Ngoei et al., 2011, [21] Zhang et al., 2012, [22] Ebelt & van Den Berg, 2013, [23] Li, Song, Ji, & Xu, 2013, [24] 
Xie et al., 2014. 
Inhibitor Mechanism of action Additional information References 
TAT-TI-JIP 
(JNK Inhibitor VII) 
Cell permeable peptide inhibitor of JNK which 
competes for JIP1 binding site on JNK, inhibiting 
JIP-JNK binding and preventing JNK substrate 
phosphorylation 
TI-JIP coupled to 10 residues derived from human 
immunodeficiency virus TAT protein sequence 
 
 
 
 
[13,17] 
D-JNKI-1  
(XG-102) 
 
Peptide inhibitor of JNK which competes for JIP1 
binding site on JNK, inhibiting JIP-JNK binding 
and preventing JNK substrate phosphorylation 
JIP-1 peptide synthesis in the reverse sequence from D-
amino acids rather than L-amino acids. Improved 
intracellular stability of the peptide but decreased efficacy. 
Inhibition of JNK activity decreased 15-20-fold compared to 
JIP-1 
 
[13,18] 
TAT-c-Jun peptide 
 
Cell permeable peptide inhibitor which competes 
directly with c-Jun for c-Jun-binding site on JNK, 
inhibiting JNK-cJun interaction 
 
Peptide derived from the δ-domain of c-Jun  [19] 
PYC71N Cell permeable peptide inhibitor which inhibits the 
interaction of c-Jun with JNK1  
Peptide interacts with inactive JNK1 and c-Jun but does not 
interact with active, phosphorylated JNK1   
 
[20] 
ATP-site directed 
covalent inhibitors 
   
JNK-IN-8 
(JNK Inhibitor XVI) 
Cell-permeable, irreversible inhibitor of JNK1/2/3. 
Forms a covalent bond with a conserved cysteine 
residue in JNK and prevents the phosphorylation 
of c-Jun 
Used in a limited number of studies targeting JNK in head 
and neck squamous cell carcinoma and breast cancer 
[21-24] 
Table 1.4: Inhibitors of JNK signalling 
Continued 
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1.6 p38 signalling pathway 
1.6.1 Overview of p38 signalling 
p38 signalling, an alternative stress-activated MAPK signalling pathway 
(Figure 1.6) was identified independently by three research groups (Freshney 
et al., 1994; Han, Lee, Bibbs, & Ulevitch, 1994; John Rouse et al., 1994). p38 
signalling is involved in regulating a range of cellular processes, similar to 
those that are regulated by JNK signalling and include: cell differentiation, 
proliferation, inflammation and cell death (Ono & Han, 2000).  
p38 signalling is therefore activated by similar stimuli as for JNK 
signalling: cytokines, cell stressors and growth factors (Figure 1.6). The 
cytokines involved in the activation of p38 signalling are typically 
proinflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and 
interleukin-1 (IL-1) (Cargnello & Roux, 2011; Freshney et al., 1994; Pietersma 
et al., 1997). Environmental stressors which stimulate p38 signalling are UV 
light, heat shock, osmotic shock, ischaemia and DNA-damaging drugs 
(Bogoyevitch et al., 1996; Clerk, Fuller, Michael, & Sugden, 1998; Hazzalin et 
al., 1996; Moriguchi et al., 1996; Zou & Blank, 2017). p38 signalling is also 
activated, but to a lesser extent, by growth factors (Escós, Risco, Alsina-
Beauchamp, & Cuenda, 2016).   
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Figure 1.6: Generic structure of the p38 pathway 
The p38 signalling pathway is activated by cell stressors, cytokines and growth factors which 
activate MEK kinases (MEKK), mixed lineage kinases (MLKs) and alternative MAPKKKs. 
Activated MAPKKKs phosphorylate and activate MKK3/6 which in turn phosphorylates 
p38α/β/γ/δ. Activated p38α/β/γ/δ can activate cytoplasmic targets and nuclear transcription 
factors.  
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In response to the stimuli, small GTP-binding proteins, such as Rac1 and 
Cdc42, are involved in the activation of the MAPKKKs involved in p38 
signalling (Bagrodia, Dé, Davis, & Cerione, 1995; Zhang et al., 1995). 
MAPKKKS activated include: MLK2/3, MEKK3/4, ASK1, TAK1, DLK1, TPL2 
and TAO1/2 (Cuadrado & Nebreda, 2010; Ichijo et al., 1997; Moriguchi et al., 
1996; Zarubin & Han, 2005).  
MKK3 and MKK6 are the MAPKKs responsible for the phosphorylation 
and activation of the p38 and are highly specific for p38 activation (Enslen, 
Raingeaud, & Davis, 1998). MKK4, a MAPKK mainly involved in the JNK 
signalling pathway, is also capable of activating p38α (Derijard et al., 1995). 
The p38 isoforms are differentially activated by MKK6 and MKK3; all four p38 
isoforms are activated by MKK6 whereas MKK3 activates p38α, p38γ and 
p38σ but not p38β (Enslen et al., 1998). The activation of p38 MAPKKs is 
stimuli-specific. For example, MKK3 and MKK6 activates p38γ and p38β in 
response to environmental stressors (Remy et al., 2010). MKK6 is responsible 
for the activation of p38γ in response to tumour necrosis factor-α (TNF-α), 
whereas MKK3 activates p38σ in response to UV, hyperosmotic shock and 
anisomycin.  
 MKK3/6 are responsible for the activation of the p38 proteins by dually 
phosphorylating tyrosine and threonine residues within the conserved Thr-Gly-
Tyr motif in the activation loop of the p38 protein (Cuadrado & Nebreda, 2010). 
In humans, there are four main p38 proteins: p38α, p38β, p38γ and p38σ 
which are encoded by the genes MAPK14, MAPK11, MAPK12 and MAPK13, 
respectively (Zou & Blank, 2017). p38 proteins are divided into two subgroups, 
p38α/p38β and p38γ/p38σ; p38α and p38β are around 74% identical in 
sequence whereas p38γ and p38σ are 70% identical in sequence to each 
other (Cuenda & Rousseau, 2007; Escós et al., 2016; Jiang et al., 1996). The 
different p38 isoforms are widely expressed but display differential tissue 
expression. p38α is the best characterised protein and is ubiquitously 
expressed in the majority of cell types (Escós et al., 2016). p38β is 
predominantly expressed in brain tissue and also at high levels in thymus and 
spleen but is not expressed in skeletal muscle (Beardmore et al., 2005). p38ƴ 
expression is restricted to skeletal and heart muscle (Cuenda & Rousseau, 
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2007; Li, Jiang, Ulevitch, & Han, 1996). p38σ is expressed at high levels in 
endocrine glands such as those located in the pancreas, testes, kidney and 
small intestine (Escós et al., 2016; Kumar et al., 1997). The specific function 
of each p38 protein is not well established but it is known that each p38 has 
overlapping substrate specificity.  
More than 100 downstream targets of p38 have been identified, which 
are mainly either kinases in the cytoplasm or transcription factors in the 
nucleus (Zou & Blank, 2017). MAP kinase-activated protein kinase 2 
(MAPKAPK-2) was the first p38α substrate to be identified (John Rouse et al., 
1994). Other protein kinases phosphorylated by p38 include: MK3, MAP 
Kinase Interaction Protein Kinase (MNK1), p38 regulated activated kinase 
(PRAK) and mitogen- and stress-activated kinase (MSK1/2) (Deak, Clifton, 
Lucocq, & Alessi, 1998; Fukunaga & Hunter, 1997; New et al., 1998; Ono & 
Han, 2000). Transcription factors activated by p38 include: activating 
transcription factor (ATF-1/2/6), tumour protein p53 and CCAAT-enhancer-
binding homologous protein (CHOP) (Cuenda & Rousseau, 2007; Zou & 
Blank, 2017). Hsp27 and cycle proteins (cyclin D1, Cdc25) are alternative 
substrates of p38 (Cuadrado & Nebreda, 2010; Cuenda & Rousseau, 2007).  
 
1.6.2 Role of p38 signalling in leukemogenesis  
p38 signalling, plays an important role in the maintenance of haematopoiesis 
homeostasis, by tightly controlling the balance between proliferation and 
growth inhibition signals (Feng, Wen, & Chang, 2009; Porras & Guerrero, 
2011). Deregulation of p38 signalling, can disrupt the balance and promote the 
development of haematopoietic malignancies, such as leukaemia. Similarly as 
for JNK signalling, the role of p38 signalling in leukemogenesis is less well 
understood than for ERK signalling.  
 p38 signalling is required for leukemic cell survival, in particular it is 
critical for the motility of leukemic cells which is essential for cell survival. 
Survival of leukemic cells is highly dependent on bone marrow stromal support 
(Manabe, Coustan-Smith, Behm, Raimondi, & Campana, 1992; Nishii et al., 
1999; Panayiotidis, Jones, Ganeshaguru, Foroni, & Hoffbrand, 1996). The 
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interaction between the bone marrow stroma-secreted chemokine, stromal-
derived factor-1α (SDF-1α/CXCL12) and the chemokine receptor type 4 
(CXCR4) expressed on haematopoietic cells is important for leukemic cell 
migration (Bradstock & Gottlieb, 1995; Juarez et al., 2009; Perim et al., 2015). 
CXCR4 is highly expressed on progenitor ALL cells, making ALL cells more 
sensitive to CXCL12 than normal haematopoietic progenitors (Spiegel et al., 
2004). p38 signalling is required for the CXCL12/CXCR4–mediated homing of 
B-cell ALL cells to the bone marrow; p38 signalling however is not involved in 
the CXCL12/CXCR4–mediated chemotaxis of normal haematopoietic 
progenitors (Juarez et al., 2009). Whilst p38 signalling is essential for 
chemotaxis of B-cell ALL cells, it was believed to not be required for the 
proliferation of primary B-cell ALL cells (Bendall, Baraz, Juarez, Shen, & 
Bradstock, 2005). However contradicting evidence suggests p38 signalling is 
in fact necessary for proliferation of ALL cells. Inhibition of p38 signalling, using 
the inhibitor SB203580, reduced the cytokine production of bone marrow 
stromal cells and reduced the stroma-mediated proliferation of ALL cells 
(Gaundar, Bradstock, & Bendall, 2009).  
The constitutive activation of p38, as a result of the hyperactivation of 
MKK3/6 has been reported in B-CLL cells (Ringshausen et al., 2004). In 
agreement with the studies in B-cell ALL cells (Bendall et al., 2005; Juarez et 
al., 2009), p38 signalling is also important for the survival of B-CLL cells on 
bone marrow stromal cells (Ringshausen et al., 2004). In addition, p38 
signalling is required for the production of metalloproteinase-9 (MMP-9) 
(Ringshausen et al., 2004). B-CLL cells produce metalloproteinase-9 (MMP-
9) which is required for angiogenesis and homing to the bone marrow 
(Bauvois, Dumont, Mathiot, & Kolb, 2002). This suggests an alternative role of 
p38 signalling in leukaemogenesis: p38 is involved in leukaemia angiogenesis.  
Collectively these studies suggest an important role of p38 signalling in 
the migration and survival of leukemic cells, in particular in lymphocytic 
leukaemias (ALL and CLL). Inhibition of p38 signalling may therefore be a 
useful therapeutic strategy to prevent the survival of ALL and CLL cells. The 
role of p38 signalling in myeloid leukaemias (AML and CML) however appears 
to be less well understood. p38 plays a critical role in tumour necrosis factor-
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alpha (TNF-α)-mediated survival and proliferation of AML cells (Liu, Fan, Liu, 
Olashaw, & Zuckerman, 2000). Inhibition of p38 signalling, using the p38 
inhibitor SB203580, inhibits the TNF-α supported growth of Mo7e cells (acute 
megakaryoblastic leukaemia cell line). It is evident that further research is 
needed in order to gain a greater understanding of the role of p38 in the 
survival of leukemic cells, in particular, in AML and CML cells.   
 
1.6.3 Role of p38 in response to leukaemia therapy  
Given the important role of p38 signalling in response to stress stimuli, such 
as chemotherapeutic agents, it is not surprising that similarly as for JNK 
signalling, p38 signalling has been implicated in the response of leukemic cells 
to therapy. Interferon-α (IFN-α), is a chemotherapeutic agent which inhibits the 
growth of BCR/ABL-expressing CML cells (Grumbach et al., 2001; 
Yanagisawa et al., 1998). p38 signalling plays an important role in the anti-
leukemic effects of IFN-α  in CML cells (Mayer et al., 2001). Treatment of KT-
1 cells (a CML cell line) and primary progenitors from CML patients with IFN-
α, results in the activation of p38. Inhibition of p38 signalling, using the p38 
inhibitors SB202190 and SB203580, prevented the anti-proliferative effects of 
IFN-α in both the KT-1 cells and in the primary CML cells.  Activation of p38 
signalling is also essential in CML cells for the anti-leukemic effects of the 
tyrosine kinase inhibitors imatinib and dasatinib (Dumka et al., 2009; Parmar 
et al., 2004). Imatinib resulted in the activation of p38 in the BCR/ABL-
expressing CML cell lines (KIT-1, EM2 and EM3 cells) and in primary 
granulocytes from CML patients (Parmar et al., 2004). Inhibition of p38 
signalling in the primary CML cells, using SB203580 and SB202190, 
prevented the growth-inhibitory effects of imatinib. Dasatinib resulted in the 
activation of p38 in BCR/ABL-expressing CML cell lines (KBM7, K562 and 
BAF3/p210 cells) and also the activation of other p38 signalling components 
such as MLK3, MKK3/6 and MAPKAPK-2, as demonstrated in BAF3/p210 
cells (Dumka et al., 2009). Inhibition of p38 signalling, using either the 
chemical p38 inhibitor SB203580 or knockdown of p38α using siRNA prevents 
dasatinib-induced apoptosis and cell cycle arrest and reverses the anti-
proliferative effects induced by dasatinib. This highlights the important role of 
the p38α isoform. p38 is activated  in KT-1 CML cells in response to arsenic 
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trioxide treatment (Giafis et al., 2006). Inhibition of p38 signalling, using 
SB203580, enhances arsenic-trioxide-induced apoptosis, by a pathway which 
appears to enhance the activation of JNK signalling. Taken together, these 
studies suggest p38 activation is essential for the anti-leukemic effects of 
several chemotherapeutic agents (IFN-α, imatinib, dasatinib and arsenic 
trioxide) in CML cells (Dumka et al., 2009; Giafis et al., 2006; Mayer et al., 
2001; Parmar et al., 2004).  
p38 signalling has also been implicated in the response of CLL cells to 
chemotherapeutic agents. p38 signalling is essential for apoptosis in B-cell 
chronic leukaemia (B-CLL) cells, induced by rituximab (anti-CD20 antibody) 
(Pedersen, Buhl, Klausen, Geisler, & Jurlander, 2002). Inhibition of p38 
signalling using SB203580, prevents the activation of MAPKAPK-2, and 
reduces rituximab-induced apoptosis in primary B-CLL cells. 
Activation of p38 is also important in AML cells for the anti-leukemic 
effects of chemotherapeutic agents; p38 is activated in NB-4 cells (acute 
promyelocytic leukaemia cell line) in response to all-trans-retinoic acid  
(Alsayed et al., 2001) and arsenic trioxide (Giafis et al., 2006; Verma et al., 
2002). Inhibition of p38 signalling prevented arsenic trioxide-induced 
apoptosis in NB-4 cells (Giafis et al., 2006). p38 is also activated in response 
to cytarabine (Ara-C) and daunorubicin in AML cells and p38 activation is 
essential for cell death in chemosensitive patients induced by these 
chemotherapeutic agents (Maha, Cheong, Leong, & Seiw, 2009).  
In addition to the role of p38 signalling in the response of leukemic cells to 
conventional chemotherapies, p38 has also been implicated in the response 
of AML cells to novel chemotherapeutic agents. TW-92, a novel anti-leukemic 
agent, activates p38 signalling and induces cell death in U937 cells (Hallak et 
al., 2009). The activation of p38 is essential for cell death induced by TW-92; 
inhibition of p38 prevented TW-92-induced apoptosis. In contrast, p38 
signalling is involved in the resistance of primary AML cells to birinapant, a 
smac-mimetic, a group of agents currently in early trials as anti-leukemic 
agents (Lalaoui et al., 2016). p38 inhibition, overcomes the resistance of 
primary AML cells to birinapant; p38 inhibition increases TNF production 
induced by smac mimetics. This highlights the importance of understanding 
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the role of p38 signalling in response to specific chemotherapeutic agents in 
specific cells.  
 Although it is not always the case, it is evident that p38 activation is a 
common event following the treatment of leukaemic cells with 
chemotherapeutic agents, and p38 activation is essential for chemotherapy-
induced leukemic cell death. Similarly as for JNK signalling, failure to activate 
p38 signalling, or constitutive activation of p38 are therefore possible 
mechanisms for chemoresistance. p38 signalling has been implicated in the 
chemoresistance of leukemic cells to cytarabine (Ara-C) (Lobo et al., 2005). In 
U937 cells, AML cells which have low basal levels of p38, the apoptotic effect 
of Ara-C requires the activation of p38. In contrast, in BCR/ABL expressing 
K562 cells, p38 is constitutively activated and p38 activation is not altered by 
Ara-C; Ara-C has minimal effect on the death of K562 cells. Development of 
novel therapies to enhance p38 activation in response to chemotherapeutic 
agents may be an approach to induce cell death in leukemic cells.  
 
1.6.4 Inhibitors of p38 signalling  
Although therapies to enhance p38 activation may be clinically beneficially, 
inhibitors of p38 signalling are important for in vitro studies, in order to gain an 
understanding of the role of the p38 pathway in leukemogenesis and in the 
response to leukaemia therapy. p38 signalling inhibitors have been developed 
which target the p38 pathway at the level of the p38 kinases. Given the 
important role of p38α in inflammation and cancer, the focus has been on 
designing p38 inhibitors which target the p38α. The majority of p38 inhibitors 
are small molecule ATP-competitive inhibitors (Table 1.5). Less attention has 
been paid to the development of peptide p38 inhibitors.  
 Small molecule p38 inhibitors can be broadly classified into two groups 
depending on the sites targeted on the p38 kinase: inhibitors which target only 
the ATP binding site and inhibitors which target the ATP binding site and/or an 
adjacent allosteric site (Akella, Moon, & Goldsmith, 2008). The first ATP-
competitive molecules designed were small molecule pyridinyl imidazoles 
such as SB203580, SB202190 and SB2039063 (Table 1.5) Further ATP-
competitive inhibitors have been more recently developed, such as VX-745, 
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papinod, skepinone-L and LY2228820, which are more selective than the 
initial pyridinyl imidazoles molecules. ATP-competitive p38 inhibitors however 
lack the desired efficacy and selectivity, as discussed for ATP-competitive JNK 
inhibitors (Section 1.5.4). 
 p38 inhibitors which target allosteric binding sites, provide a more 
selective method of inhibition. Adjacent to the ATP-binding site is an allosteric 
binding site, termed the DFG site as is contains the Asp-Phe-Gly motif at the 
N-terminus of the activation loop (Treiber & Shah, 2013). Dorapimod (BIRB-
896) is a small molecule inhibitor which targets both the ATP-binding site and 
the DFG site. Binding of the inhibitor to the DFG site causes a conformational 
change in the activation loop of the p38 kinase, preventing ATP binding 
(Pargellis et al., 2002). 
A limited number of peptide p38 inhibitors have been developed and the 
usage of these inhibitors appears to be restricted. Peptide p38 inhibitors also 
target different sites of the p38 kinase; peptide p38 inhibitors include TAT-
MKK3b (targets docking groove), VWCS (targets ATP-binding site) and FWCS 
(targets allosteric binding site). Given the success of peptide JNK inhibitors, 
future research needs to focus on the development of novel peptide p38 
inhibitors.  
The small molecule p38 inhibitors, SB202190 and SB203580, which 
have been extensively used in previous in vitro studies in a wide range of cells, 
will be used to target p38 signalling in this thesis.   
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Inhibitor Mechanism of action Additional information References 
ATP-site directed 
small molecule  
inhibitors 
   
SB203580 Inhibits p38 catalytic activity by competitively 
binding in the ATP pocket  
Does not inhibit p38 activation. Inhibits phosphorylation of 
MAPKAPK-2 and HSP27. Most widely used p38 inhibitor in 
in vitro studies 
 
[1-3] 
SB202190 ATP-competitive inhibitor of p38α/β Similar structure and specificity to SB203580. SB202190 
does inhibit phosphorylation of p38 by upstream kinases   
 
[2,3,4] 
SB239063 Potent and selective ATP-competitive inhibitor of 
p38α/β 
Second-generation inhibitor. 3-fold more selective than 
SB203580. No inhibition of p38γ/δ 
 
[5,6] 
 
VX-745 Potent ATP-competitive inhibitor of p38α/β 22-fold greater selectivity for p38α over p38β.  No inhibition 
of p38γ   
 
[7,8] 
Pamapimod ATP-competitive inhibitor of p38α/β enzymatic 
activity  
No inhibition of p38γ/δ. 30-fold greater selectivity for p38α 
over p38β. No inhibition of  p38γ/δ 
 
[9,10] 
 
Skepinone-L Potent ATP-competitive inhibitor of p38α/β First ATP-competitive inhibitor with excellent in vivo efficacy 
and selectivity. Minimal inhibition of p38γ/δ 
 
[11,12] 
LY2228820 Potent ATP-competitive inhibitor of p38α/β Does not inhibit p38 activation. Inhibits the phosphorylation 
of MAPKAPK-2   
[13] 
Allosteric-site directed 
small molecule 
inhibitors 
   
Doramapinod  
(BIRB 796)  
Interacts with allosteric binding site and ATP-
binding site, causing a conformational change in 
the DFG site in the activation loop, which 
produces a structure unable to bind ATP 
Potent inhibitor of p38α/β/γ/δ with slow dissociation rate. 
First p38 inhibitor to be tested in a phase 3 clinical trial  
 
  
[14-16] 
 Table 1.5: Inhibitors of p38 signalling 
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Pargellis et al., 2002, [15] Regan et al., 2003, [16] Kuma et al., 2005, [17] Fu, Meng, He, & Gu, 2008, [18] Gill et al., 2013, [19] Gill et al., 2014. 
 
 
 
 
Inhibitor Mechanism of action Additional information References 
Peptide inhibitors    
TAT-MKK3b Cell permeable peptide inhibitor binds to p38α 
docking groove, inhibiting interactions between 
p38 and downstream substrates 
Fusion peptide containing 12 residues from the docking 
sequence derived from MKK3b and 11 residues from HIV-
TAT sequence. Prevents p38 phosphorylation by upstream 
kinases and prevents phosphorylation of downstream 
substrates 
 
[17] 
VWCS Tetrapeptide inhibitor which targets the ATP 
binding site of p38α 
 
Limited use in head and neck squamous cell carcinoma [18] 
FWCS 
 
Peptide inhibitor which targets the allosteric-site 
of p38α 
Limited use in head and neck squamous cell carcinoma [19] 
Table 1.5: Inhibitors of p38 signalling 
Continued 
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1.7 Cell death 
Cell death is defined as a process by which a cell loses the ability to function 
and is a critical process in the development and homeostasis of the 
haematopoietic system. Deregulation of cell death as a result of altered 
signalling pathways which control cell death, allow leukaemia cells to evade 
apoptosis and survive. The main types of cell death are: apoptosis (type 1 cell 
death), autophagy (type 2 cell death) and necrosis (type 3 cell death) (Shimizu, 
Yoshida, Tsujioka, & Arakawa, 2014). Apoptosis, and to a lesser extent 
necrosis, will be studied in this thesis.  
 
1.7.1 Apoptosis 
Apoptosis, a form of programmed cell death, is mediated by energy-dependent 
biochemical mechanisms which programme cells to die (Elmore, 2007). 
Morphological features of apoptosis include cell shrinkage and chromatin 
condensation (pyknosis) (Kerr, Wyllie, & Curriet, 1972; Saraste & Pulkki, 
2000). In the early stages of apoptosis, plasma membrane integrity is 
maintained but phosphatidylserine is exposed on the outer leaflet of the 
plasma membrane (Segawa & Nagata, 2015). In later stages, the nucleus 
fragments (karyorrhexis) and the plasma membrane protrudes (membrane 
blebbing) (Jian Hua, 2000; Saraste & Pulkki, 2000). The plasma membrane 
eventually buds off to form a separate membrane around nuclear fragments 
and cytoplasmic components, forming apoptotic bodies (Elmore, 2007). 
Apoptotic bodies are then engulfed by macrophages which degrade the 
contents. In the absence of phagocytosis, apoptotic cells and bodies are 
removed by secondary necrosis (late apoptosis/secondary necrosis), an 
autolytic  necrotic process (Silva, 2010).  
The two main apoptotic pathways are the extrinsic (death receptor-
mediated) and the intrinsic (mitochondrial) pathways (Figure 1.7). The 
extrinsic and intrinsic pathways are activated by different stimuli but do no act 
in isolation; there is cross-talk between the pathways. The extrinsic apoptotic 
pathway is initiated by the binding of  external ligands to death receptors (TNF-
TNFR1, FasL-Fas, TRAIL-DR4) (Guicciardi & Gores, 2009). The intrinsic 
apoptotic pathway is activated by a range of stress stimuli including heat 
shock, UV-radiation, DNA damage and chemotherapeutic drugs, which 
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causes the release of factors from the mitochondria (Fulda & Debatin, 2006; 
Stephen & Green, 2010). Both the intrinsic and extrinsic apoptotic pathways 
are mediated by the action of caspases, enzymes which cleave proteins at 
aspartic acid residues (Riedl & Shi, 2004). Caspases are usually expressed 
as inactive procaspases, which once activated by cleavage, can activate other 
caspases, initiating a caspase cascade and irreversibly committing a cell to 
death. Caspases can be classified as either initiator caspases (caspases-2,-
8,-9,-10) or executioner caspases (caspases-3, -6, -7) (Chen & Wang, 2002; 
Li & Yuan, 2008; Walsh et al., 2008). 
 
1.7.2 Necrosis 
In contrast to apoptosis, necrosis is an energy-independent form of cell death 
(Elmore, 2007). Necrosis typically occurs in response to exposure of cells to 
excessive external stressors, for example heat or infection (Festjens, Berghe, 
& Vandenabeele, 2006). Necrosis is characterised by morphological changes 
such as: organelle and cell swelling, formation of cytoplasmic vacuoles and 
loss of membrane integrity (Ziegler, 2004). Disruption of the membrane causes 
the release of intracellular contents, which can act as danger signals and 
activate an inflammatory response (Proskuryakov, Konoplyannikov, & Gabai, 
2003).   
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Figure 1.7: Extrinsic and intrinsic pathways of apoptosis 
The extrinsic apoptotic pathway is initiated by the binding of ligands to death receptors. 
Ligand-receptor binding causes receptor oligomerisation and recruitment of procaspase-8 to 
the membrane via adaptor molecules such as Fas-associated death domain (FADD).  The 
intrinsic apoptotic pathway is initiated by cell stresses which results in changes in 
mitochondrial membrane permeabilisation. This causes release of proapoptotic molecules, 
such as cytochrome c, from the mitochondrial intermembrane space into the cytosol.  
Released cytochrome c interacts with apoptotic protease activating factor 1 (Apaf-1), 
triggering assembly of the apoptosome and the subsequent activation of caspase-9. Active 
caspase-8 and caspase-9 can cleave and activate caspase-3 and caspase-7, leading to the 
induction of apoptosis. (Adapted from Cuda, Pope, & Perlman, 2016; Vuci, Dixit, & Wertz, 
2011). 
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1.8 Experimental approaches for inducing cellular stress and cell death 
in leukemic cells 
In order to investigate the role of MAPK signalling pathways in leukemic cell 
death, it is necessary to develop an experimental system for inducing cellular 
stress and/or cell death in leukemic cells. U937 cells, a human monocytic cell 
line for studying AML will be used in this thesis  
Apoptosis can be induced by a range of stimuli: ultraviolet light, heat 
shock, hypoxia, nutrient deprivation, growth factors, cytokines, infection and 
chemotherapy drugs (Elmore, 2007). To gain a thorough understanding of the 
role of MAPK signalling pathways in leukemic cell death, the role of the 
pathways in response to a range of stimuli will be investigated. Ultraviolet light, 
heat and chemotherapeutic agents (doxorubicin and vincristine) are the cell 
stressors which will be investigated in this thesis and the reasons for selecting 
these cell stressors are outlined below.  
 
1.8.1 Ultraviolet light  
Radiation therapy is a type of cancer treatment which uses high-energy 
ionising radiation to kill cancer cells or shrink tumours. Radiation therapy 
induces cell death by causing DNA damage; the most lethal lesion generated 
by radiation is DNA double-strand breaks (DSBs) (Lomax, Folkes, & O’Neill, 
2013; Santivasi & Xia, 2014). Chemotherapy is an alternative type of cancer 
treatment and many chemotherapeutic agents also function by causing DNA 
damage and inducing cell death (Kahlin Cheung-Ong, Giaever, & Nislow, 
2013; Woods & Turhci, 2013). DNA-damage in cells initiates cell recovery 
mechanisms which are collectively termed the DNA-damage response (DDR) 
(Jackson & Bartek, 2009). The DDR involves DNA repair pathways (base 
excision repair, nucleotide excision repair, mismatch repair, double strand 
break repair), activation of cell cycle checkpoints and cell cycle arrest. If DNA 
damage cannot be repaired, cell death is induced. However, the DDR 
response is often defective in cancers, including leukaemia and cells with 
damaged DNA are able to progress through the cell cycle (Nilles & 
Fahrenkrog, 2017). 
Ultraviolet (UV) light will be used as an apoptotic stimulus in this thesis 
as cell exposure to UV light is an ideal system to study cell death in response 
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to DNA damage. Treatment of cells with UV light generates reactive oxygen 
species (ROS) such as: singlet oxygen (1O2), superoxide radicals (O2•-), 
hydroxyl radicals (•OH), peroxyl radicals (RO2•) and hydrogen peroxide (H2O2) 
(Prasad, Gupta, & Tyagi, 2017). The oxidative stress induced by UV light can 
result in DNA damage by causing single and double-stranded DNA breaks, 
tandem base lesions and by forming DNA-protein crosslinks (Avery, 2011; 
Cadet, Ravanat, Porro, Menoni, & Angelov, 2012). Oxidative stress also 
affects proteins and lipids by causing lipid peroxidation and protein oxidation 
(Avery, 2011).  
 
1.8.2 Heat treatment  
Heat treatment, in particular hyperthermia (temperatures are typically 
increased to between 40°C and 43°C) is an alternative cancer therapy which 
is effective at killing cancer cells and shrinking tumours. Sub-lethal heat 
treatments, which alone are often insufficient to cause cell death, are able to 
sensitise cancer cells to radiation therapy and to chemotherapy (Falk & Issels, 
2001; Hildebrandt et al., 2002; Jolly & Morimoto, 2000). This means lower 
doses of radiation or chemotherapy are still effective and negative side effects 
are reduced. The therapeutic benefits of heat treatment have been established 
for a long time, but more recent research has focused on developing methods 
to deliver heat treatment specifically to cancer cells. Magnetic nanoparticles 
coated with targeting agents, which are heated using alternating magnetic 
fields have been successful in providing cancer cell-directed heat treatment 
(Chatterjee, Diagaradjane, & Krishnan, 2011; DeNardo & DeNardo, 2008; 
Giustini et al., 2010). Although utilisation of heat treatment has been 
established as an effective cancer therapy, the mechanisms associated with 
hyperthermia are not fully understood. It is known that exposure of cells to heat 
treatment results in cell cycle arrest at two main cell cycle checkpoints: G1/S 
and G2/M checkpoint (Kuhl & Rensing, 2000). Many chemotherapeutic 
agents, particularly microtubule-disrupting agents (Section 1.8.3) also function 
by causing cell cycle arrest and induction of apoptosis. Heat treatment will 
therefore be used as a cell stressor in U937 cells in this thesis. Heat treatment, 
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42°C for 1 h, has been selected for investigation based on previous work in 
the lab (Dempsey, 2009). 
 
1.8.3 Chemotherapy  
Chemotherapy is a type of cancer therapy which involves the use of one or 
more chemotherapeutic agents to induce death in cancer cells. The 
effectiveness of chemotherapy is limited due the ability of chemotherapeutic 
agents to non-specifically affect cancer and non-cancer cells; cancer cells can 
also evolve mechanisms to resist the chemotherapeutic agent, which is termed 
chemoresistance. As U937 cells are being utilised in this thesis, only 
chemotherapeutic agents used in the treatment of AML will be considered 
here. 
Classes of chemotherapeutic agents used in the treatment of AML 
include: anti-metabolites, DNA-damaging agents, microtubule-targeting 
agents, monoclonal antibodies and FLT3 inhibitors (Table 1.6). The mainstay 
treatment for AML is cytarabine, an antimetabolite, in combination with an 
anthracycline. 50 to 75% of adults with AML achieve remission following 
combination treatment with cytarabine and an anthracycline (Tallman, 
Gilliland, & Rowe, 2005). Anthracyclines, such as daunorubicin, doxorubicin 
and idarubicin are DNA-damaging agents, which directly damage DNA 
(Cheung-Ong, Giaever, & Corey, 2013). Microtubule-targeting agents, such as 
the vinca alkaloids vincristine and vinblastine, inhibit microtubule 
polymerisation causing cells to undergo mitotic arrest (Moudi, Go, Yien, & 
Nazre, 2013). A greater understanding of the molecular changes involved in 
AML has led to the development of more targeted therapies, such as the 
monoclonal antibody gemtuzumab, which targets CD33, a molecule 
expressed on 80-90% of blasts in AML patients (Stadtmauer, 2002). Mutations 
in the FMS-like tyrosine kinase 3 (FLT3) occurs in a third of AML, and result in 
the constitutive activation of FLT3 which enables the survival of AML cells 
(Knapper et al., 2006). The FLT3 inhibitors, Sorafenib, Midostaurin, 
Lestauritnib and Quizartinib, are therefore novel chemotherapeutic agents for 
the treatment of AML (Larrosa-Garcia & Baer, 2017). 
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Doxorubicin and vincristine, two conventional chemotherapeutic agents 
used in the treatment of AML have been selected for investigation in this 
thesis. Doxorubicin and vincristine induce cell death via different mechanisms 
and therefore will provide a more thorough understanding of the role of MAPK 
signalling pathways in leukemic cell death induced by chemotherapy 
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 Table 1.6: Chemotherapeutic agents used in the treatment of acute myeloid leukaemia (AML) 
Drug Mechanism of action References 
Anti-metabolites    
Cytarabine (cytosine arabinoside, Ara-C) Inhibits DNA synthesis. Intracellularly converted to cytarabine triphosphate, which 
competes with deoxycytidine triphosphate for DNA polymerase 
 
[1,2] 
DNA-damaging agents    
Doxorubicin (Adriamycin®) Intercalates into DNA and inhibits topoisomerase-II. Generation of free radicals and 
oxidative stress which causes cellular damage 
 
[3,4] 
 
Daunorubicin (Cerubidine) Intercalation into DNA and inhibition of topoisomerase-II 
  
[5,6] 
Idarubicin (Idamycin) Intercalation into DNA and inhibition of topoisomerase-II [7,8] 
   
Microtubule-targeting agents    
Vincristine  Binds to β-tubulin and inhibits microtubule polymerisation 
 
[9, 10] 
Vinblastine  Binds to β-tubulin and inhibits microtubule polymerisation 
 
[10,11] 
Monoclonal antibodies   
Gemtuzumab Ozogamicin (Mylotarg®) Recombinant antibody which binds to CD33 
 
[12,13] 
FLT3 inhibitors   
Sorafenib Inhibits FMS-like tyrosine kinase  3 (FLT3)  
 
[14-16] 
Midostaurin (PKC412) Inhibits FLT3 kinase  
 
[17,18]  
 
Lestauritnib (CEP-701) Inhibits FLT3 kinase  
 
[19, 20] 
 
Quizartinib (AC220) Inhibits FLT3 kinase [21,22]  
[1] Löwenberg et al., 2011, [2] Momparler, 2013, [3] Schwartz, Preisler, & Kanter, 1981, [4] Yang, Teves, Kemp, & Henikoff, 2014, [5] Gong et al., 2015, [6] Luskin et al., 
2016, [7] Carella, Berman, Marone, & Ganzina, 1990, [8] Bradstock et al., 2017 , [9] Ozgen, Savaan, Stout, Buck, & Ravindranath, 2000,  [10]  Moudi, Go, Yien, & Nazre, 
2013, [11]   Salerni, Bates, Albershardt, Lowrey, & Eastman, 2010, [12] Stadtmauer, 2002, [13]  Giles & Estey, 2003, [14] Weiguo Zhang et al., 2008, [15] Pratz et al., 2010, 
[16] Fathi & Chen, 2011,  [17] Stone et al., 2005, [18] Fischer et al., 2010, [19] Smith et al., 2004, [20] Knapper et al., 2006, [21] Cortes et al., 2013 [22]  Levis, 2013.
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1.9 Aims of the thesis  
Deregulation of signalling pathways contributes to leukemogenesis. The 
MAPK signalling pathways, ERK, p38 and JNK are the focus of this thesis. It 
is evident constitutive activation of ERK signalling is involved in 
leukemogenesis by promoting cell survival and therefore inhibiting ERK 
signalling is an approach to induce cell death in leukemic cells. The role of 
ERK signalling is particularly well understood in AML cells, yet there is limited 
confirmation of the involvement of ERK signalling in the survival of U937 cells. 
In contrast to ERK signalling, the role of the JNK and p38 signalling pathways 
in leukemogenesis are less well understood and hence the p38 and JNK 
signalling pathways will be approached first in this thesis. There is limited 
evidence implicating JNK and p38 signalling in the progression and 
development of leukaemia, in particular AML. The JNK and p38 signalling 
pathways are activated by stress, such as chemotherapy so it is not surprising 
these pathways have been implicated in the response to leukaemia therapy. 
The evidence regarding the role of JNK and p38 in response to therapy 
however is contradictory. A number of studies suggest constitutive activation 
of JNK or p38 signalling mediates chemoresistance whereas others suggest 
failure to activate JNK or p38 signalling contributes chemoresistance. It is likely 
that the role of JNK and p38 signalling in leukemic death in cell-specific and 
agent-specific, but this requires further investigations.  
 
Therefore, the overall aim of this thesis is to investigate the role of MAPK 
signalling pathways in leukemic cell death using the U937 model cell line.  
 
The objectives of this thesis are:  
• To optimise the treatment of U937 cells with cell stressors  
• To determine the role of the JNK signalling pathway in U937 cell death 
• To determine the role of the p38 signalling pathway in U937 cell death 
• To determine the role of the ERK signalling pathway in U937 cell death 
• To determine the role of the MAPK signalling pathways in ex vivo 
peripheral blood monocytes from healthy humans  
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Chapter 2: Materials and Methods 
2.1 Cell culturing 
All cell culturing was performed in a class II tissue culture hood using aseptic 
technique to ensure sterility. Cells were maintained at 37°C in a humidified 
environment, supplemented with 5% CO2. 
 
2.1.1 U937 cell line 
2.1.1.1 Subculturing of U937 cell line 
Human caucasian histoyctic lymphoma, U937 cell line was purchased from 
European Collection of Cell Cultures (85011440). U937 cells were cultured 
in RPMI-1640 medium supplemented with 10% FBS. Prior to subculturing, 
cell viability was determined using the trypan blue exclusion test (Section 
2.1.3). Cells were passaged every 3 to 4 days to maintain a cell density 
between 1 x 105 and 8 x 105 cells/mL.  
 
2.1.1.2 Cryopreservation of U937 cell line 
Cryopreservation of cell lines was carried out to enable stocks of cells to be 
stored. It avoids loss by contamination, reduces the cell passage number and 
subsequent genetic drift. Cells were frozen down in the log phase of growth 
(5 x 105 cells/mL) and no microbial contamination was present. Cells were 
centrifuged at 500 g, 25°C for 5 min. Following the removal of the 
supernatant, the cell pellet was gently re-suspended in 1 mL ice-cold freeze 
medium (90% FBS + 10% DMSO) in a cryogenic storage vial. Cryovials were 
incubated in liquid nitrogen vapour phase for at least 2 h before being 
transferred to liquid nitrogen in the cryostat at -196°C. Cells were 
cryopreserved until required. 
 
 
 
 
 
 
  Chapter 2: Materials and Methods 
61 
 
2.1.2 Peripheral blood mononuclear cells (PBMCs) 
2.1.2.1 Blood collection and processing 
Ethical approval (Application 1204/16/MC/IoM) was obtained from the 
Faculty of Medicine, Dentistry & Life Sciences Research Ethics Committee. 
Participants were informed of the details of the study and each participant 
provided informed consent. Whole blood was collected from healthy 
volunteers aged between 18 and 60 years by venepuncture in 10 mL 
Vacutainer EDTA tubes. A full blood count on whole blood was performed 
using DxH 500 Haematology System.  
 
2.1.2.2 Isolation of PBMCs from whole blood 
PBMCs were isolated from whole blood by density centrifugation using 
Histopaque-1077. Freshly collected blood (3 mL) was added to an equal 
volume of DPBS without Ca++ or Mg++ (3 mL) and mixed by gently inverting 
the tubes several times. The blood-DPBS mixture (3 mL) was carefully 
overlaid on Histopaque-1077 (3 mL) which had been equilibrated to room 
temperature in 15 mL centrifuge tubes. The blood was centrifuged at 400 g 
(without brake), room temperature, for 30 min. Using a Pasteur pipette, the 
upper layer, containing plasma, was removed to within 0.5 cm of the opaque 
interface. The opaque interface, containing PBMCs, was collected using a 
Pasteur pipette and transferred to a fresh 15 mL centrifuge tube containing 
DPBS (10 mL). The PBMCs were gently mixed and then centrifuged at 250 
g, room temperature, for 10 min. The supernatant was removed and the 
PBMC pellet was re-suspended in 5 mL DPBS. PBMCs were centrifuged at 
250 g, room temperature, for 10 min. The DPBS was discarded and the 
DPBS wash was repeated once more. After discarding the supernatant, the 
cell pellet was re-suspended in complete RPMI supplemented with 10% FBS 
and 1% antibiotic solution and a cell count was performed using trypan blue 
exclusion assay (Section 2.1.3). A full blood count was also performed post-
isolation. 
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2.1.3 Cell counting and viability testing 
Trypan blue exclusion assay was performed to determine cell concentration 
and cell viability. Typically, 50 µL of cell suspension was diluted 1:1 in 0.4% 
trypan blue solution. The sample was incubated with the dye at room 
temperature for around 2 min (incubations exceeding 10 min can cause 
decreased viability due to trypan toxicity).  A small amount of cell-trypan blue 
solution was added to both chambers of a haemocytometer. Cells were 
visualised microscopically using 10 X objective; live cells possess intact cell 
membranes which exclude the dye whereas non-viable cells take up the dye 
and stain blue. 
 
2.1.4 Preparation of cells for treatment   
Around 24 h prior to treatment, U937 cells were subcultured, typically using a 
1:1 split ratio, to ensure the cells were in the log phase of growth for treatment. 
Before use in experiments, the cell count was adjusted to 5 x 105 cells/mL by 
centrifuging the cells at 500 g, room temperature, for 5 min and re-suspending 
the cell pellet in the appropriate volume of complete RPMI.  
 
2.2 Cell treatments 
2.2.1 MAPK inhibitors  
Sterile stock solutions of MAPK inhibitors were prepared as shown in Table 
2.1. Under sterile conditions, dilutions of each MAPK inhibitor were prepared 
fresh before each experiment by diluting stock MAPK inhibitor in the 
appropriate volume of complete RPMI media.  
 
Table 2.1: Stock solutions of MAPK inhibitors 
Inhibitor  Manufacturer Product 
number 
Stock 
concentration 
(mM) 
Solvent Storage 
(°C) 
SP600125 Sigma-Aldrich Co. S5567 50  DMSO 4   
JNK-IN-8  Selleck Chemicals 420150 10  DMSO -20  
SB202190 Sigma-Aldrich Co. S7076 50 DMSO 4   
SB203580 Sigma-Aldrich Co. S8307 25 DMSO -20 
PD184352 Sigma-Aldrich Co. PZ0181 50 DMSO 20 
U0126 Sigma-Aldrich Co. U120 25 DMSO 4 
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2.2.2 UV light treatment 
The UVP Ultra Violet ProductTM Variable Intensity Transilluminator was 
allowed to warm up for 15 min prior to use. Cells were exposed to UV light for 
0-50 s and then incubated at 37°C, 5% CO2 for 24 h.  
 
2.2.3 Preparation of drug treatments 
Stock solutions of drugs were prepared under sterile conditions as shown in 
Table 2.2. Dilutions of the drug treatments were prepared fresh before each 
experiment, by diluting the stock solution in the appropriate volume of 
complete RPMI-1640 media. Cells were typically treated with between 0 and 
200 µM doxorubicin and between 0 and 200 nM vincristine.  
 
Table 2.2: Stock solution of drug treatments 
 
 
2.2.4 Heat treatment  
Heat treatment was performed by incubating cells at 42°C in a circulating water 
bath for 1 h. Control cells were incubated at 37°C, 5% CO2 in an incubator for 
1 h.  
 
2.2.5 Anisomycin treatment 
As anisomycin is an inducer of apoptosis and an agonist of MAPK signalling, 
it was used in experiments to act as a positive control for the induction of 
MAPK signalling. A stock of anisomycin was prepared under sterile conditions 
as shown in Table 2.3. Dilutions of anisomycin were prepared fresh by diluting 
the stock solution in the appropriate volume of complete RPMI-1640 media. 
Cells were typically treated with 1 µM anisomycin for 30 min.  
 
 
 
Drug Manufacturer Product 
number 
Stock 
concentration 
(mM) 
Solvent Storage 
(°C) 
Doxorubicin Sigma-Aldrich Co. D1515 10 dH2O - 20 
Vincristine Sigma-Aldrich Co. V8879 5 DMSO - 20 
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Table 2.3: Stock solution of anisomycin 
 
 
 
 
2.3 Methods to assess MAPK phosphorylation  
2.3.1 Polyacrylamide gel electrophoresis and Western blotting 
2.3.1.1 Cell lysis and protein extraction 
This protocol was carried out to extract proteins from the whole cell. Cells 
were transferred to centrifuge tubes and centrifuged at 500 g, room 
temperature, for 5 min. Following the removal of the supernatant, cells were 
re-suspended in 1 ml ice-cold PBS and centrifuged again at 500 g, 4°C for 5 
min.  Samples were kept on ice at all times to avoid dephosphorylation. The 
supernatant was removed and the cell pellet was vigorously suspended in 
ice-cold cell extraction buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris, 
pH supplemented with HaltTM Protease and Phosphatase Inhibitor Cocktail).  
Cells were lysed on ice for 30 min with occasional agitation and then 
centrifuged at 13,500 g, 4°C for 20 min. The supernatant was collected and 
transferred to a fresh centrifuge tube. Where possible, the sample was 
aliquoted to avoid freeze-thaw cycles and stored at -80°C. The quantity of 
protein extracted was determined using bicinchoninic acid protein assay 
(Section 2.3.1.2). 
 
2.3.1.2 Determination of protein concentration 
Many detergents interfere with traditional Bradford assay reagents such as 
Coomassie, by inhibiting colour development and causing precipitation. Due 
to the high TritonX-100 content in the cell extraction buffer, a Bradford assay 
could not be used to determine the protein concentration in samples. 
Bicinchoninic acid (BCA) protein assay, an alternative detergent-compatible 
protein assay was used.  
The BCA protein assay was performed using PierceTM BCA Protein 
Assay Kit, following the kit instructions for microplates. BCA protein 
Drug Manufacturer Product 
number 
Stock 
concentration 
(mM) 
Solvent Storage 
(°C) 
Anisomycin Sigma-Aldrich Co. A9789 25 DMSO 4 
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standards (0-2000 µg/mL) were prepared fresh in cell extraction before each 
assay. The BCA working reagent was prepared freshly by mixing 50 parts of 
reagent A with 1 part of reagent B. 2.5 µL of standard or unknown sample 
and 20 µL of working reagent were added in triplicate to each well of a 384-
well microplate. The plate was shaken on a plate shaker for 30 s and then 
incubated at 37°C for 30 min. After allowing the plate to cool to room 
temperature, the absorbance was measured at 562 nm using VarioskanTM 
LUX multimode microplate reader. 
The protein concentrations of the unknown samples were determined 
using the standard curve. If the protein concentration of the sample was not 
within the working range, samples were diluted in extraction buffer until within 
range. 
 
2.3.1.3 Sample preparation 
The concentrations of the samples were adjusted in extraction buffer to 
ensure all samples contained equal concentrations of total protein. The 
samples were then diluted 1:1 in 2X reducing sample buffer (62.5 mM Tris-
HCl, pH 6.8, 20% glycerol, 2% SDS, 0.01% bromophenol blue, 150 mM DL-
dithiotreitol). The samples were heated to 85°C for 10 min. Samples were 
cooled for at least 10 min before loading onto the gels.  
 
2.3.1.4 SDS-PAGE electrophoresis  
Proteins were separated by sodium dodecyl polycacrylamide gel 
electrophoresis (SDS- PAGE), using an acrylamide concentration 
appropriate for the size of the target protein. 4-15% Mini-PROTEAN®TGXTM 
Precast Protein Gels (Bio-Rad Laboratories, Inc.) were used or discontinuous 
polyacrylamide gels were cast using FisherbrandTM Vertical Gel 
Electrophoresis System, according to manufacturer’s instructions. The 
resolving gel solution was prepared by combining all reagents in Table 2.4 
(except APS and TEMED), degassing under vacuum for 15 min and then 
adding APS and TEMED. Once set, the stacking gel was prepared in a similar 
way (Table 2.5). 
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Table 2.4: Recipe for 12. 5% resolving gel 
* enough for two 1 mm spaced gels 
 
 
Table 2.5: Recipe for 3% stacking gel 
* enough for  two 1 mm spaced gels 
 
 
The gels were assembled in the gel tank following manufacturer’s 
instructions. Typically 20-40 µg total protein was loaded into each well of the 
gel alongside 2.5 µL Precision Plus ProteinTM WesternCTM Standard pre-
stained broad range protein standards. Samples were electrophoresed at 
100 V in running buffer (25mM Tris, 192mM glycine, 0.1% SDS, pH 8.3) until 
the dye front reached 2 mm from the bottom of the resolving gel. The 
resolving gel was then either stained for total protein (Section 2.3.1.5) or 
transferred to a nitrocellulose membrane for Western blotting (Section 
2.3.1.6). 
 
2.3.1.5 Total protein staining 
The total protein content was visualised using CooBlue MAX Protein Gel 
Stain, a high sensitivity (below 10 ng protein/band) stain. The gels were 
washed three times with 100 mL dH2O at room temperature, for 15 min with 
Reagent Volume 
1.5 M Tris HCl pH 8.8 3.75 mL 
dH2O 4.8 mL 
Acrylamide 6.25 mL 
10% SDS 150 µL 
 10% APS 50 µL 
TEMED 50 µL 
Reagent Volume 
0.5 M Tris HCl pH 6.8 1.35 mL 
dH2O 3.15 mL 
Acrylamide 500 µL 
10% SDS 50 µL 
10% APS 50 µL 
TEMED 5 µL 
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gentle shaking. After discarding the water, the gel was incubated with 20 mL 
CooBlue MAX Protein Gel Stain at 4°C overnight.  
After discarding the stain, the gels were typically washed three times 
with 100 ml dH2O at room temperature, for 15 min with gentle shaking. 
Further washes were performed if required so that clear gels with blue bands 
were obtained. The gels were visualised and recorded using GBox Chemi-
XRQ Gel Documentation System. 
 
2.3.1.6 Western blotting 
2.3.1.6.1 Electrotransfer  
After SDS-PAGE electrophoresis, the proteins were electro-transferred to 
nitrocellulose membranes using iBlot® 2 Dry Blotting System following 
manufacturer’s instructions. The dry blotting was performed using a pre-
programmed protocol called ‘P0’, a protocol designed to efficiently transfer a 
wide variety of proteins over a broad range of molecular weights (30-150 
kDa).  This protocol runs for 7 min at 20 V for 1 min, 23 V for 4 min and 25 V 
for the remainder.  
 
2.3.1.6.2 Membrane blocking and antibody incubations 
After transfer and disassembly of transfer pack, the nitrocellulose membrane 
was then incubated in 5% milk blocking buffer at room temperature, with 
gentle shaking for 1 h. The blocking buffer was then discarded. The 
membrane was washed three times with 15 mL TTBS, at room temperature 
with gentle shaking for 5 min per wash. The membrane was incubated with 
the appropriate primary antibody (Table 2.6) in 5% BSA blocking buffer at 
4°C overnight.  
 The membrane was washed three times with 15 mL TTBS, at room 
temperature with gentle shaking for 5 min per wash.  Membrane was 
incubated with secondary antibody (Table 2.6) in 5% milk blocking solution 
with gentle shaking at room temperature for 1 h. Precision Plus ProteinTM 
StrepTactin-HRP Conjugate was also added into the blocking solution to 
detect the protein standards, typically using a 1:10,00 dilution. The 
membrane was washed five times with 15 mL TTBS, at room temperature 
with gentle shaking for 5 min per wash before proceeding to detection.  
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Table 2.6: Dilutions of antibodies for measurement of MAPK phosphorylation 
by Western blotting 
  
 
2.3.1.6.3 Chemiluminescent detection 
SuperSignalTM West Femto Maximum Sensitivity Substrate, a 
chemiluminescent substrate for low-femtogram-level detection of HRP 
immunoblots was used. The working solution was prepared by mixing equal 
volumes (300 µL of each) of the Stable Peroxide Solution and the 
Luminol/Enhancer Solution. 
The chemiluminescent working solution was applied to the membrane 
and incubated in the dark at room temperature for 5 min. The blot was 
removed from the working solution and excess reagent drained away. The 
chemiluminescent signal was captured using GBox Chemi-XRQ Gel 
Documentation System.  
 
 
Antibody Manufacturer Product 
number 
Species Dilution 
 
 
 
 
 
Primary 
Phospho-
SAPK/JNK 
(Thr183/Tyr185) 
 
 
 
Cell 
Signaling 
Technology, 
Inc. 
 
9251  
 
 
Rabbit 
 
 
 
1:1,000 
Phospho-c-Jun  
(Ser 73) 
9164 
Phospho-p38 
(Thr180/Tyr182) 
9215 
Phospho-
MAPKAPK-2 
(Thr222) 
3316 
Phospho-
p44//42 
(Thr202/Tyr204) 
4377 
 
Secondary 
 
Anti-rabbit IgG, 
HRP-linked 
 
Cell 
Signaling 
Technology, 
Inc. 
 
7074 
 
Goat 
 
1:20,000 
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2.3.2 Measurement of intracellular phosphorylated MAPKs using flow 
cytometry 
Typically, 96-well plates contained 200 μL of treated cells at a concentration 
of 5 x 105 cell/mL, along with a negative control (untreated cells) and a positive 
control (1 µM anisomycin, 37°C, 30 min). All cells were transferred to a V-
bottomed 96-well plate, centrifuged at 500g, room temperature for 5 min and 
the supernatant removed. 
  Cells were fixed using 4% formaldehyde solution to ensure 
modifications,  such as phosphorylation,  were optimally  cross-linked and 
cells were permeabilised using methanol to maintain structural integrity 
without denaturing the post translational modifications. This was achieved by 
resuspending the cell pellet in 100 µL 4% formaldehyde solution. Cells were 
incubated at 37°C for 10 min before centrifugation at 500 g, room temperature 
for 5 min and removal of supernatant. The cell pellet was re-suspended in 100 
µL ice-cold 90 % methanol and incubated at 4°C for 30 min. If not proceeding 
with immunostaining immediately, cells were stored in the methanol at -20°C, 
overnight.   
  After permeabilisation, cells were centrifuged at 500 g, room 
temperature for 5 min and the supernatant removed. 100 µL flow cytometry 
incubation buffer (0.5% BSA in DPBS) was added to each well and the cells 
were centrifuged at 500 g, room temperature for 5 min. The supernatant was 
removed, and the incubation buffer wash was repeated once more. The 
appropriate phospho-MAPK antibody was prepared in flow cytometry 
incubation buffer (Table 2.7). Following the addition of 10 µL diluted antibody 
to each well (incubation buffer only added to unstained cells), cells were 
incubated in the dark, at room temperature for 1 h. 100 µL flow cytometry 
incubation buffer was added on top of each well to dilute any unbound 
antibody. The cells were centrifuged at 500 g, room temperature for 5 min and 
the supernatant removed. The cell pellets were re-suspended in 100 µL DPBS 
(without Ca2+ and Mg2+). Stained cells were analysed immediately if possible, 
otherwise cells were stored in the dark at 4°C and analysed within 3 days.  
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Table 2.7: Antibodies for the measurement of MAPK phosphorylation by flow 
cytometry 
 
 
Cells were analysed on a BD Accuri C6 flow cytometer; fluidics set to 
medium. Viable cells only were gated (P1 in Figure 2.1). 10,000 events were 
collected within the viable gate and future analyses were performed only on 
viable cells. The negative/positive gate was set using the AlexaFluor647 
histogram for the no stain control, setting the gate to include 1% of 
AlexaFluor647-positive cells (Figure 2.1B).  
 
 
  
Antibody Manufacturer Product number Antibody 
dilution 
Phospho-SAPK/JNK 
AlexaFluor® 647 
 
 
 
Cell Signaling 
Technology, Inc. 
9257  
 
 
1: 50 
Phospho- c-Jun 
AlexaFluor® 488 
12714 
Phospho-p38 
AlexaFluor® 647 
4552 
Phospho-p42/44  
AlexaFluor® 647 
4375 
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A B 
  
C D 
  
E F 
  
 
Figure 2.1: Gating strategy for measurement of MAPK phosphorylation using 
flow cytometry 
U937 cells were treated with (A, B, C and D) 0 µM or (E,F) 1 µM anisomycin and then 
incubated at 37°C for 30 min. (A, C and E) show example FSC vs SSC dot plots and the 
gating set to only include viable cells. (B, D and F) show example histograms and the gate 
set to determine changes in MAPK phosphorylation.  
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2.4 Methods to assess cell viability 
2.4.1 Plate-based assays 
2.4.1.2 Preparation of dead cells for plate-based assays  
Dead cells were prepared fresh prior to MTS and PI assays. U937 cells, at a 
concentration of 5 x 105 cells/mL were placed in liquid nitrogen for 1 min and 
then thawed at 37°C. The freeze-thaw cycle was repeated once more. Cell 
viability was observed microscopically; freeze-thawing the cells in liquid 
nitrogen caused cell death by necrosis.  
 
2.4.1.3 Determination of metabolic activity by MTS assay 
MTS assay was used to assess the metabolic activity of U937 cells. 20 μL of 
MTS/PES working solution (333μg/mL MTS and 25 µM PES) was added to 
each well containing 100 μL U937 cells. The plate was then shaken on the 
plate reader for 10 s and then incubated in the dark at 37°C, 5% CO2 for 2 h. 
Absorbance was measured at 490 nm using VarioskanTM LUX multimode 
microplate reader. Metabolic activity, expressed as a percentage, was 
calculated by normalising the data using absorbance’s for live and dead cells. 
 
2.4.1.4 Determination of necrosis by propidium iodide staining 
Propidium iodide (PI) staining was used to assess U937 cell necrosis. 100 
μL PI working solution (5 μg/mL) was added to each well containing 100 μL 
U937 cells. The plate was shaken on the plate reader for 10 s and then the 
plate was incubated in the dark at room temperature for 20 min. 
Fluorescence intensity was measured at λex 530 nm/ λem 645 using 
VarioskanTM LUX multimode microplate reader. The percentage of necrotic 
cells was calculated by normalising the data using absorbance’s for live and 
dead cells.  
 
2.4.1.5 Determination of apoptosis using caspase-3/7 fluorometric 
assay 
Caspases 3 and 7 are effector caspases involved in apoptosis and were 
measured to confirm the effects of treatments on apoptosis in U937 cells. 
SensoLyte® Homogeneous Rh110 Caspase-3/7 Assay Kit), a fluorometric 
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assay, was used. The assay was performed following the kit instructions, 
using the microplate protocol. Kit components were thawed at room 
temperature prior to use. Typically, 96-well plates contained 150 μL of treated 
cells. A working substrate solution was prepared by adding 40 μL of 1M DTT 
and 10 μL caspase-3/7 substrate per ml of assay buffer. 50 μL of working 
substrate solution was added to each well. Reagents were mixed on plate 
shaker for 30 s, avoiding bubbles. The plate was incubated in the dark, at 
room temperature for 1 h. Fluorescence intensity was measured at λex 
496nm/ λem 520 nm using VarioskanTM LUX multimode microplate reader. 
 
2.4.2 Flow cytometry 
2.4.2.1 Determination of cell viability using Annexin V & PI 
Staining cells with Annexin V in combination with PI was used to distinguish 
between viable (annexin V-, PI -), necrotic (annexin V-, PI +), early apoptotic 
(annexin V+, PI -) and late apoptotic (annexin V +, PI +) cells. Cell viability 
was measured using FITC Annexin V FITC Apoptosis Detection Kit I. 
Recommended protocol for tube layout was adapted for 96-well plate as 
described. Typically, each well of 96-well plates contained 200 μL of treated 
cells or untreated cells at a concentration of 5 x 105 cell/mL. All cells were 
transferred to a V-bottomed 96-well plate, centrifuged at 500g, room 
temperature, for 5 min and the supernatant removed.  The cell pellet was re-
suspended in 100 µL ice-cold PBS and centrifuged at 500 g, room 
temperature for 5 min. The PBS wash was repeated once more. 
  The cell pellet was re-suspended in 50 µL 1 x binding buffer. 2.5 µL PI 
stain and 2.5 µL FITC Annexin V was added to each sample well. 
Compensation controls were also included: untreated, unstained cells (55 µL 
1x binding buffer, no stain), untreated PI-only stained cells (52.5 µL binding 
buffer, 2.5 µL PI stain), untreated, annexin V-only stained cells (52.5 µL 1 x 
binding, 2.5 µL FITC Annexin V only). All cells were incubated in the dark, at 
room temperature for 15 min. 200 µL 1 x binding buffer was added on top of 
each well and gently mixed.  
Cells were analysed immediately on BD Accuri C6 flow cytometer; 
fluidics set to medium. Cells were gated to exclude debris (Figure 2.2) and 
10,000 events were collected within the gate. The quadrant gate, to 
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determine the different stages of apoptosis, was set using a PI vs Annexin V 
FITC plot for the no stain control (NS Ctl) (Figure 2.2B) Colour compensation 
was performed using individual stain controls, and applied to all the samples. 
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Figure 2.2: Gating strategy for FITC Annexin V Apoptosis Detection Kit 
U937 cells were treated with (A, B, C and D) 0s UV or (E and F) 12 s UV and then incubated 
at 37°C for 24 h. Cell viability was measured using BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I. (A, C and E) show example FSC vs SSC dot plots and the gating 
set to exclude cell debris. (B, D and F) show example annexin V FITC vs PI dot plots and the 
quadrant gate set to determine the stages of cell death. 
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2.5 Microscopy 
2.5.1 Phase-contrast microscopy 
Phase-contrast microscopy was used to identify changes in morphological 
features of U937 cells, and hence asses the viability of U937 cells. Phase-
contrast microscopy images were also collected using EVOSTMFL Auto Cell 
Imaging System and a 40 X objective lens. Viable cells appear relatively 
circular in shape, as shown in Figure 2.3.  
 
 
 
Figure 2.3: Phase-contrast microscopy image of viable U937 cells 
U937 cells were visualised using EVOSTMFL AutoCell Imaging System at 40X magnification. 
Image shown is representative of 3 individual images collected.  
 
2.5.2 Fluorescence microscopy 
2.5.2.1 Propidium iodide staining  
Propidium iodide (PI) is a red-fluorescent, DNA stain which was used to 
identify necrotic and late apoptotic U937 cells. In viable and early apoptotic 
cells, cell membrane integrity excluded the PI stain (Figure 2.4). In necrotic 
and late apoptotic cells (dead cells), the increased membrane permeability 
allows the PI stain to bind to DNA, increasing the fluorescence by 20- to 30-
fold. PI staining allows for the visualisation of fragmented nuclei (Figure 2.4).  
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2.5 µL propidium iodide staining solution (50 µg/mL) was added to 100 
µL untreated and treated cells. Cells were incubated in the dark, at room 
temperature, for 15 min. Cells were visualised microscopically using 
EVOSTMFL Auto Cell Imaging System. Images were collected using RFP light 
cube and 40 X objective lens. 
 
 
Figure 2.4: PI staining to assess cell viability 
Viable (untreated) and dead (treated with 15 s UV and incubated at 37°C for 24 h) U937 
cells were stained with PI staining solution and visualised using EVOSTMFL AutoCell Imaging 
System at 40 x magnification.  Images shown are representative of 3 individual images 
collected.  
 
 
2.5.2.2 DAPI staining 
DAPI (4’,6-diamidino-2-phenylindole) is an alternative DNA stain that was 
used to visualise doxorubicin-treated cells where PI staining could not be 
used due to fluorescent spectral overlap. Viable cells exclude the DAPI stain, 
whereas for necrotic and late apoptotic cells (dead cells), where cell 
membrane integrity has been compromised, the nuclear material stains with 
DAPI (Figure 2.5). 
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For DAPI staining, 1 µL DAPI solution (100 µg/mL) was added to 100 
µL untreated and treated cells. Cells were incubated in the dark for 5 min. 
Cells were visualised microscopically using EVOSTM FL Auto Cell Imaging 
System. Images were collected using DAPI light cube and 40 X objective 
lens. 
 
Figure 2.5: DAPI staining to assess cell viability 
Viable (untreated) and dead (treated with 25 µM doxorubicin at 37°C for 24 h). U937 cells 
were stained with DAPI and visualised using EVOSTMFL AutoCell Imaging System at 40 x 
magnification.  Images shown are representative of 3 individual images collected. 
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2.6 Statistical analysis 
All statistical analyses were performed using GraphPad Prism® 7.03 software. 
All data presented as mean ± standard deviation (SD), unless otherwise 
stated. Number of replicates (n) is stated in the figure legends where 
appropriate. Appropriate statistical tests were performed including: 
 
• Unpaired t-test - used to determine statistical differences between two 
independent samples, for example difference between heat treatment and 
no heat treatment.  
 
• One-way ANOVA with Dunnet’s post hoc test – one-way ANOVA used 
to determine a statistical difference between the means of two or more 
independent groups. Dunnet’s post hoc test used as a multiple comparison 
procedure to compare each of a number of treatments with a single control, 
for example to determine the dose-dependent effect of doxorubicin. 
 
• Two-way ANOVA with Sidak’s post hoc test – two-way ANOVA used to 
compare the mean difference between two groups that have been split on 
two independent variables. Sidaks’s post hoc used to make a comparison 
between two values at each point, for example to determine the statistical 
difference between inhibitor and no inhibitor at mean vincristine 
concentration points.  
 
• Two-way ANOVA with Tukey’s post hoc test - Tukey’s post hoc test is 
a multiple comparison test used to compare every mean with every other 
mean, used to make a comparison between more than two values at each 
point, for example to determine the difference between three 
concentrations of inhibitor at mean UV time points.  
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Chapter 3: Optimisation of the treatment of U937 cells 
with cell stressors 
 
3.1 Introduction 
Cells respond to cell stressors by altering signalling pathways, such as MAPK 
signalling pathways, in order to either promote cell survival or induce cell death 
(Simone Fulda, Gorman, Hori, & Samali, 2010). Future chapters will 
investigate the role of MAPK signalling pathways in U937 cell death which will 
be achieved by using MAPK signalling inhibitors in combination with cell 
stressors. Therefore in this chapter, the treatment of U937 cells with various 
cell stressors will be optimised.  
UV light, heat treatment and chemotherapeutic agents (doxorubicin and 
vincristine) have been selected for investigation as the dosage of these cell 
stressors can be tightly controlled in an in vitro experimental system. UV light 
has previously been shown to induce apoptosis in U937 cells (Liu, You, 
Tashiro, Onodera, & Ikejima, 2005; Francesca Luchetti et al., 2006; Shin, Park, 
Yang, & Park, 2008). Although the mechanisms of action differ, both 
doxorubicin and vincristine are chemotherapeutic agents capable of inducing 
cell death in U937 cells (Ampasavate, Okonogi, & Anuchapreeda, 2010; César 
Ortiz-Lazareno et al., 2014; Demidenko et al., 2006; Kiburg et al., 1994). It has 
also been demonstrated that U937 cells are able to survive mild heat treatment 
(42°C) (Li, Lee, Ko, Kim, & Seo, 2000; Marfe et al., 2009) whilst lethal heat 
treatment (43°C and above) results in cell death (Lasunskaia et al., 2010;  Li 
et al., 2000).  Whilst the effect of these cell stressors on U937 cell death is well 
established, dosages of these treatments, which are effective in the 
experimental system used in this thesis, need to be determined. 
In addition, a MAPK signalling agonist is required in future chapters in 
order to confirm the inhibition of MAPK signalling by selected signalling 
inhibitors. Anisomycin, an antibiotic which inhibits protein synthesis (Grollman, 
1967), has been used in previous studies and its potential use in U937 cells 
will be investigated in this chapter. Anisomycin activates JNK and p38 in a 
range of cancer cell lines (Mauro et al., 2002; Stadheim & Kucera, 2002; 
Törocsik & Szeberényi, 2000) whilst the effect on ERK appears to be cell-type 
dependent (Bébien et al., 2003; Eriksson, Taskinen, & Leppä, 2006; Zhou et 
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al., 2016). Specifically in U937 cells, JNK has been reported to be activated 
following anisomycin treatment (Hori et al., 2008), however there is limited 
evidence for the effect of anisomycin on p38 and ERK phosphorylation in U937 
cells. Therefore the effect of anisomycin on the JNK, p38 and ERK MAPK 
signalling pathways will also be investigated in this chapter. 
 
Aims 
The overall aim of this chapter is to optimise the treatment of U937 cells with 
cell stressors. This will be achieved by: 
• studying the effects of UV light, doxorubicin, vincristine and heat treatment 
on U937 cell death 
• determining the effects of anisomycin treatment on U937 cell death and 
MAPK phosphorylation 
 
The effect of UV light, doxorubicin and vincristine on U937 cell death will firstly 
be assessed as it is believed these stressors will induce cell death. The effect 
of heat treatment will then be investigated as a stimulus to induce cell stress 
rather than directly inducing cell death. For all treatments, the effect on cell 
death will be confirmed using a range of assays. An MTS assay will provide 
an initial indication of the effect on cell death, by assessing metabolic activity. 
A PI assay will measure the percentage of PI-positive cells and hence will 
assess the effect on cell death by necrosis. Measuring annexin V binding and 
PI staining by flow cytometry and microscopy will confirm the effects of the 
treatments on cell death, more specifically on the stages of apoptosis.  
 The time-dependent effect of anisomycin on cell death will initially be 
assessed in order to provide an indication of the likely time period of MAPK 
activation. Following this, the effect of anisomycin on the phosphorylation of 
JNK, c-Jun, p38 and ERK will be measured by flow cytometry and Western 
blotting. Using two alternative techniques to measure MAPK activation will 
provide confidence in the results obtained.  
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3.2 Methods 
3.2.1 Cell culturing 
U937 cell line was cultured and maintained as described in Section 2.1.1. Prior 
to treatments, cells were prepared as described in Section 2.1.4.  
 
3.2.2 Treatment of U937 cells with cell stressors 
U937 cells were treated with the following cell stressors:  
• UV light – 0 to 50 s (Section 2.2.2) 
• doxorubicin – 0 to 200 µM (Section 2.2.3) 
• vincristine – 0 to 200 nM (Section 2.2.3) 
• heat treatment - 42°C for 1 h (Section 2.2.4) 
• anisomycin (Section 2.2.5) 
 
3.2.3 Measurement of the effects of cell stressors on cell viability  
The effect of cell stressors on U937 cell viability was assessed using: 
• MTS assay to measure metabolic activity (Section 2.4.1.3) 
• PI assay to measure necrosis (Section 2.4.1.4) 
• FITC Annexin V FITC Apoptosis Detection Kit I to measure cell viability 
(Section 2.4.2.1) 
• SensoLyte® Homogeneous Rh110 Caspase-3/7 Assay Kit to measure 
active caspase 3/7 levels (Section 2.4.1.5) 
• microscopy to determine changes in cell morphology (Section 2.5) 
 
3.2.4 Measurement of the effects of anisomycin on MAPK activation 
The effect of anisomycin on the phosphorylation of JNK, c-Jun, p38 and ERK 
was measured by: 
• Western blotting (Section 2.3.1) 
• flow cytometry (Section 2.3.2) 
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3.3 Results 
3.3.1 Effect of UV light on U937 cell death 
In order to examine the effect of UV light treatment on U937 cell death, U937 
cells were treated with various durations of UV light and initially the effect on 
metabolic activity was assessed 24 h after treatment (Figure 3.1A). UV 
resulted in a dose-dependent reduction in metabolic activity, with metabolic 
activity significantly (P<0.0001) reduced to less than 50% following 15 s or 
more UV light treatment.  
To determine if the observed reductions in metabolic activity were due 
to necrosis, a PI assay was performed (Figure 3.1B). Treatment with 15 to 50 
s UV light, caused a significant (P<0.001) increase in the percentage of PI-
positive cells compared to untreated cells. Whilst metabolic activity was 
reduced to 0% following treatment with 50 s UV (Figure 3.1A), only 21% of 
cells were PI-positive, suggesting cell death induced by UV occurs by a 
mechanism other than necrosis.  
To identify the type of cell death induced by UV light, flow cytometry 
was performed to measure annexin V binding and PI staining (Figures 3.1C-
E). Flow cytometry results confirmed UV light caused a significant (P<0.05) 
reduction in cell viability (Figure 3.1C). For untreated cells, cell viability was 
80% (Figure 3.1C) compared to 100% metabolic activity (Figure 3.1A). This 
difference can be explained by the differences in the methods used, in 
particular with regards to the analysis. An MTS assay relies on normalisation 
of the data, using a live cell control, which although taken to be 100% 
metabolic activity, is often difficult to achieve. In comparison, flow cytometry 
provides a more reliable, single-cell analysis. This difference in the methods 
of these two assays, also explains differences between metabolic activities 
and viabilities observed in subsequent sections. The reductions in cell 
viabilities were mainly due apoptosis (Figure 3.1D). A lower percentage of cells 
were late apoptotic/secondary necrotic (Figure 3.1E), which accounts for the 
percentage of PI-positive cells observed in the PI assay (Figure 3.1B).  
Microscopy images confirmed UV induced apoptosis in U937 cells 
(Figure 3.1F). Following UV treatment, cells were misshapen, membrane 
blebbing and formation of apoptotic bodies were observed, and PI staining 
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showed fragmented nuclei. Collectively, the results show UV light treatment 
induces cell death in U937 cells, by inducing apoptosis.  
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Figure 3.1: Effect of UV light on U937 cell death  
U937 cells were treated with various durations of UV light and then incubated at 37°C for 24 
h before an (A) MTS assay, (B) PI assay, (C-E) BD PharmingenTM FITC Annexin V Apoptosis 
Detection Kit I or (F) microscopy were performed. (A-E) Data presented as mean ± SD; n=3. 
Statistical differences shown to untreated cells, calculated using one-way ANOVA with 
Dunnett’s post hoc test: * (P<0.05), *** (P<0.001), **** (P<0.0001). (F) Cells were stained with 
PI staining solution and visualised using EVOSTMFL AutoCell Imaging System at 40 X 
magnification. Arrows indicate apoptotic cells. Images shown are representative of 3 individual 
images collected.  
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3.3.2 Effect of chemotherapeutic agents on U937 cell death 
3.3.2.1 Effect of doxorubicin on U937 cell death  
To determine concentrations of doxorubicin which induce cell death, U937 
cells were treated with a range of concentrations of doxorubicin and an MTS 
assay was performed (Figure 3.2A). Doxorubicin resulted in a decrease in 
metabolic activity in a concentration-dependent manner. Treatment with 50 µM 
resulted in a significant (P<0.0001) reduction in metabolic activity to 1%. A 
slight increase in metabolic activities were observed for concentrations greater 
than 50 µM due to the spectral overlap for doxorubicin and the MTS reagent.  
As treatment with 3.13 µM to 50 µM doxorubicin resulted in reductions in 
metabolic activities to between 57 and 1% (Figure 3.2A), the effect of 
concentrations within this range, on active caspase-3/7 levels, were measured 
to determine if the observed reductions were specifically due to apoptosis 
(Figure 3.2B). Concentrations of doxorubicin greater than 5 µM resulted in a 
significant (P<0.01) increase in active caspase-3/7 levels, indicating cell death 
via apoptosis. Based on the data from the MTS assay (Figure 3.2A), it was 
expected that 5 µM doxorubicin would result in the activation of caspase-3/7, 
however this was not observed (Figure 3.2B). It is possible that the activation 
of caspase-3/7 by low concentrations of doxorubicin, takes longer than 9 h.  
Microscopy images confirmed doxorubicin causes apoptosis in U937 
cells (Figure 3.2C). Untreated cells appeared relatively circular and showed 
no DAPI fluorescence. Doxorubicin treatment increased the permeability of 
U937 cells to DAPI stain which showed fragmented nuclei. Collectively the 
results demonstrate doxorubicin induces apoptosis in U937 cells. 
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Figure 3.2: Effect of doxorubicin on U937 cell death 
U937 cells were treated with various concentrations of doxorubicin and then incubated at 37°C 
for 24 h before (A) an MTS assay and (C) microscopy were performed or incubated for 9 h 
before (B) active caspase-3/7 levels were measured using SensoLyte® Homogeneous Rh110 
Caspase-3/7 Assay Kit. (A, B) Data presented as mean ± SD; n=3. Statistical differences 
shown to untreated cells, calculated using one-way ANOVA with Dunnett’s post hoc test: ** 
(P<0.01), **** (P<0.0001). (C) Cells were stained with DAPI and visualised using EVOSTMFL 
AutoCell Imaging System at 40 x magnification. Arrows indicate apoptotic cells. Images shown 
are representative of 3 individual images collected. 
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3.3.2.2 Effect of vincristine on U937 cell death  
In order to examine the effects of vincristine treatment on U937 cell death, 
U937 cells were treated with various concentrations of vincristine and the 
effect on metabolic activity was assessed 24 h after treatment (Figure 3.3A). 
As the concentration of vincristine increased from 0 to 0.8 nM, metabolic 
activities were reduced in a concentration-dependent manner (Figure 3.3A). 
Metabolic activity was significantly (P<0.0001) reduced to 44% following 
treatment with 0.8 nM vincristine but concentrations of vincristine greater than 
0.8 nM did not cause any further reductions in metabolic activities.  
 To determine if the observed reductions in metabolic activities were due 
to necrosis, a PI assay was performed (Figure 3.3B). Although treatment with 
0.8 to 200 nM vincristine resulted in a statistically significant (P<0.01) increase 
in the percentage of PI-positive cells, vincristine had little effect on necrosis. 
Vincristine resulted in no more than a 7% increase in PI-positive cells 
suggesting that the reductions in cell metabolic activities measured (Figure 
3.3A) were due to cell death mechanisms other than necrosis.  
To identify the type of cell death induced by vincristine, flow cytometry 
was performed to measure annexin V binding and PI staining (Figure 3.3C-E). 
Flow cytometry results confirmed reductions in cell viabilities (Figure 3.3C) 
were due to cell death via apoptosis (Figure 3.3D), in particular, a large 
percentage of cells were in the late stages of apoptosis/secondary necrosis 
(Figure 3.3E). Vincristine treatment had no effect on necrosis (data not 
shown). 
Microscopy images showed the characteristic morphological features 
of apoptosis, such as membrane blebbing and nuclear fragmentation, 
confirming vincristine induces apoptosis in U937 cells (Figure 3.3F). A small 
number of vincristine-treated U937 cells appeared to have an altered structure, 
either due to the effects of microtubule disarray or the activation of U937 cells 
to macrophages. From the results presented, it is evident that vincristine 
induces apoptosis in U937 cells. 
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Figure 3.3: Effect of vincristine on U937 cell death  
U937 cells were treated with various concentrations of vincristine for 24 h at 37°C and then 
incubated at 37°C for 24 h before an (A) MTS assay, (B) PI assay, (C-E) BD PharmingenTM 
FITC Annexin V Apoptosis Detection Kit I or (F) microscopy were performed. (A-E) Data 
presented as mean ± SD; n=3. Statistical differences shown to untreated cells, calculated 
using one-way ANOVA with Dunnett’s post hoc test: ** (P<0.01) *** (P<0.001), **** 
(P<0.0001). (F) Cells were stained with PI staining solution and visualised using EVOSTMFL 
AutoCell Imaging System at 40 X magnification. Arrows indicate apoptotic cells. Images 
shown are representative of 3 individual images collected.  
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3.3.3 Effect of heat treatment on U937 cell death 
The effect of heat treatment on U937 cell death was assessed after both 24 
and 48 h. After 24 h there was a significant (P<0.05) decrease, by around 30%, 
in the metabolic activity of heat treated cells compared to non-heat treated 
cells (Figure 3.4A). The percentages of viable, necrotic, apoptotic and late 
apoptotic/ secondary necrotic cells were similar between heat treated and non-
heat treated cells, 24 h after treatment (Figure 3.4B). Microscopy images 
showed heat treatment had no effect on U937 viability after 24 h; heat treated 
cells appeared morphologically similar to non-heat treated cells and neither 
heat treated nor non-heat treated cells stained with PI (Figure 3.4C).  
After 48 h, there were no significant difference in the percentage of 
metabolically active cells between heat treated and non-heat treated cells 
(Figure 3.4D). The percentages of viable, necrotic, apoptotic and late 
apoptotic/ secondary necrotic cells were similar between heat treated and non-
heat treated cells, 48 h after treatment (Figure 3.4E). Microscopy images 
confirmed heat treatment had no effect on U937 viability after 48 h (Figure 
3.4F), heat treated and non-heat treated cells appeared morphologically 
similar 48 h after treatment; a very limited number of heat treated and non-
heat treated cells stained with PI.  
Collectively, these results suggest that heat treatment does not induce 
cell death in U937 cells. Although a decrease in metabolic activity was 
observed 24 h after treatment, confirmation was provided by the other tests 
that the reduction in metabolic activity was not due to apoptosis. It is likely that 
results observed were due to the effect of heat on other metabolically active 
cellular processes, which the cells were able to adapt and recover from after 
48 h.  
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Figure 3.4: Effect of heat treatment on U937 cell death 
U937 cells were incubated at either 37°C or 42°C for 1 h and then incubated at 37°C for (A,C) 
24 h or (D,F) 48h before an (A,D) MTS assay, (B,E) BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I or (C-F) microscopy were performed. (A,D) Data presented as mean 
± SD; n=3. Statistical differences shown to untreated cells, calculated using an unpaired t-test: 
* (P<0.05). (C,F) Cells were stained with PI staining solution and visualised using EVOSTMFL 
AutoCell Imaging System at 40 X magnification. Images shown are representative of 3 
individual images collected.  
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3.3.4 Effect of anisomycin on U937 cell death 
Anisomycin was selected as a signalling agonist, to act as a positive control 
for the activation of MAPK signalling. A concentration of anisomycin and 
incubation time needed to be established for future experiments. The effect of 
anisomycin on cell death was initially studied, as it was believed that MAPK 
signalling would be activated prior to any changes in cell death being 
measured. U937 cells were treated with various concentrations of anisomycin 
and changes in metabolic activities were measured over time (Figure 3.5). 
Within 2 h, metabolic activities were significantly (P<0.0001) lower for 
anisomycin-treated cells compared to untreated cells, for all concentrations of 
anisomycin tested (Table 3.1). 
 U937 cells were treated with a wider range of concentrations of 
anisomycin and metabolic activity was assessed after 2 h (Figure 3.6). As the 
concentration of anisomycin increased, the metabolic activities of U937 cells 
decreased in a concentration-dependent manner. Metabolic activities were 
significantly (P<0.0001) reduced to less than 50% for cells treated with 1 µM 
or higher of anisomycin. These results indicated that MAPK signalling 
components are likely to be activated by 1 µM anisomycin, within 2 h of 
treatment. 
 
 
 
 
  
Chapter 3: Optimisation of the treatment of U937 cells with cell stressors  
 
 
94 
 
 
 
 
 
 
 
 
 
Figure 3.5: Time-dependent effect of anisomycin on U937 metabolic activity 
U937 cells were treated with 0, 0.1, 1 or 10 µM concentration of anisomycin and then 
incubated at 37°C. MTS assays were performed after various times. Data presented as mean 
± SD; n=3.  
 
 
Table 3.1: Statistical analysis to show the effects of anisomycin on U937 
metabolic activity  
Data presented as mean ± SD; n=3. Significance shown as differences anisomycin and no 
treatment at time points, calculated through use of a two-way ANOVA with Tukey’s post hoc 
test:** (P<0.01), **** (P<0.0001). 
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Figure 3.6: Dose dependent effect of anisomycin on U937 metabolic activity  
U937 cells were treated with varying concentration of anisomycin and then incubated at 37°C 
for 2 h before a MTS assay was performed. Data presented as mean ± SD; n=3. Statistical 
differences shown to untreated cells, calculated using one-way ANOVA with Dunnett’s post 
hoc test: * (P<0.05), **** (P<0.0001).  
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3.3.5 Effect of anisomycin on MAPK signalling components in U937 cells  
Based on the data in Section 3.3.4, the dose-dependent activation of JNK 
following 0 to 1 µM anisomycin for 30 min was assessed (Figure 3.7). Results 
suggested that JNK1 and JNK2 were both phosphorylated following treatment 
with 0.5 and 1 µM anisomycin but JNK1/2 were not activated by lower 
concentrations. Whilst the bands at 46 kDa and 54 kDa indicate the presence 
of phospho-JNK1 and phospho-JNK2, respectively, without a positive control 
for phospho-JNK1/2 or a Western blot measuring total JNK, the dose-
dependent effect of anisomycin on JNK phosphorylation cannot be confirmed. 
The effect of 1 µM anisomycin for 30 min on MAPK activation was further 
investigated using Western blotting and flow cytometry as a confirmatory 
technique.  
 
 
 
 
   
 
 
 
 
 
 
 
 
Figure 3.7: Dose dependent effect of anisomycin on JNK phosphorylation 
U937 cells were treated with various concentration of anisomycin and then incubated at 37°C 
for 30 min. Total protein was extracted and separated with SDS-PAGE electrophoresis using 
12.5% acrylamide gels. Proteins were electro-transferred to nitrocellulose membrane and 
phospho-JNK was detected by Western blotting using phospho-JNK/SAPK (Thr183/Tyr185) 
and anti-rabbit peroxidase.  
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Assessment of the time-dependent activation of MAPKs following anisomycin 
treatment showed 24% of untreated cells, expressed phosphorylated JNK 
(Figure 3.8A). Incubating U937 cells with 1 µM anisomycin for 0 min caused a 
significant increase (P<0.01) by 13%, in the percentage of cells expressing 
phosphorylated JNK compared to untreated cells. Incubation with 1 µM 
anisomycin for 15 min caused a further increase in the percentage of cells 
expressing phosphorylated JNK, to around 98%; the high levels of 
phosphorylation JNK were sustained after 30 and 60 min. Western blotting 
confirmed that JNK was activated following 15 min incubation with 1 µM 
anisomycin, and levels of phosphorylated JNK were sustained up to 60 min 
(Figure 3.8B).  
 Figure 3.8 highlights the importance of using multiple techniques to 
measure the phosphorylation of MAPK signalling components. Western 
blotting is a less sensitive technique than flow cytometry, as evident by the fact 
that 24% of untreated U937 cells expressed phosphorylated JNK (Figure 3.8A) 
but phosphorylated JNK was not detected in untreated cells when measured 
by Western blotting (Figure 3.8B). The use of Western blotting to detect MAPK 
signalling components, expressed at low levels, is restricted. Western blotting 
is however, able to detect changes in different MAPK isoforms which cannot 
not be achieved by the flow cytometry methods used in this study. Given the 
important role of different MAPK isoforms in cancer, it is important to consider 
the effects of treatments on each MAPK isoform.  
Both techniques have limited use in the measurement of rapid 
activation of MAPK signalling components. Both techniques involve a 
processing time (the time taken for the centrifugation and wash steps between 
the end of the incubation time and the point of fixation or protein extraction), in 
which MAPKs can be activated, as demonstrated by the increase in JNK after 
0 min incubation with anisomycin, compared to untreated cells (Figure 3.8A). 
No difference in the percentage of cells expressing phospho c-Jun were 
observed between untreated cells and cells incubated with anisomycin for 0 
min (Figure 3.9A). The percentage of cells expressing phosphorylated c-Jun 
was significantly (P<0.0001) increased after 30 min incubation with 
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anisomycin, and activation was sustained for up to 60 min. Western blotting 
confirmed c-Jun was activated following 15 min incubation with anisomycin 
(Figure 3.9B). Increased levels of phosphorylated JNK were observed after 30 
min incubation with anisomycin and were sustained up to 75 min.  
The percentage of cells expressing phosphorylated p38 was 
significantly (P<0.0001) higher for cells incubated with anisomycin for 0 min 
compared to untreated cells (Figure 3.10A). This difference can be explained 
by the rapid activation of p38 during the processing time, as previously 
discussed. The percentage of cells expressing phosphorylated p38 was 
further increased after 15 min incubation with anisomycin, and similar levels 
were observed after 30 and 60 min. Western blotting results were consistent 
with the flow cytometry data, confirming that p38 is rapidly activated following 
anisomycin treatment (Figure 3.10B).  
95% of untreated U937 cells expressed phosphorylated ERK (Figure 
3.11A). The percentage of cells expressing phosphorylated ERK, following 
treatment with anisomycin for 0 min was reduced to 87%, but this was not 
statistically different to untreated cells. Significant reductions in the 
percentages of cells expressing phosphorylated ERK were observed following 
incubation with anisomycin for 15 min or more. Western blotting confirmed 
anisomycin caused a decrease in the levels of phosphorylated ERK 15 min 
after treatment and continued to decrease up to 60 min (Figure 3.11B). 
Western blotting was unable to detect the effects of anisomycin on the different 
isoforms of ERK. Together, it is evident that anisomycin results in decreased 
levels of phosphorylated ERK. 
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Figure 3.8: Effect of anisomycin on JNK phosphorylation 
U937 cells were incubated with 1 µM anisomycin at 37°C for various times and then prepared 
for (A) flow cytometry or (B) Western blotting to measure JNK phosphorylation. (A) Cells were 
fixed with 4% paraformaldehyde, permeabilised with 90% ice-cold methanol and then stained 
with phospho-SAPK/JNK (Thr183/Tyr185) Alexa Fluor 647-conjugated antibody. Data 
presented as mean ± SD, n=3. Statistical differences shown to 0 min, calculated using one-
way ANOVA with Dunnett’s post hoc test: ** (P<0.01), **** (P<0.0001). (B) Total protein was 
extracted and separated with SDS-PAGE electrophoresis using 12.5% acrylamide gels. 
Proteins were electro-transferred to nitrocellulose membrane and phospho-JNK was detected 
by Western blotting using phospho-JNK/SAPK (Thr183/Tyr185) and anti-rabbit peroxidase.   
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Figure 3.9: Effect of anisomycin on c-Jun phosphorylation 
U937 cells were incubated with 1 µM anisomycin at 37°C for various times and then prepared 
for (A) flow cytometry or (B) Western blotting to measure c-Jun phosphorylation. (A) Cells 
were fixed with 4% paraformaldehyde, permeabilised with 90% ice-cold methanol and then 
stained with phospho-c-Jun (Ser73) Alexa Fluor 488-conjugated antibody. Data presented as 
mean ± SD, n=3. Statistical differences shown to 0 min, calculated using one-way ANOVA 
with Dunnett’s post hoc test: **** (P<0.0001). (B) Total protein was extracted and separated 
with SDS-PAGE electrophoresis using 4-15% precast gels. Proteins were electro-transferred 
to nitrocellulose membrane and phospho-c-Jun was detected by Western blotting using 
phospho-c-Jun (Ser73) and anti-rabbit peroxidase.   
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Figure 3.10: Effect of anisomycin on p38 phosphorylation 
U937 cells were incubated with 1 µM anisomycin at 37°C for various times and then prepared 
for (A) flow cytometry or (B) Western blotting to measure p38 phosphorylation. (A) Cells were 
fixed with 4% paraformaldehyde, permeabilised with 90% ice-cold methanol and then stained 
with phospho-p38 (Thr180/Tyr182) Alexa Fluor 647-conjugated antibody. Data presented as 
mean ± SD, n=3. Statistical differences shown to 0 min, calculated using one-way ANOVA 
with Dunnett’s post hoc test: ** (P<0.01), *** (P<0.001), **** (P<0.0001). (B) Total protein was 
extracted and separated with SDS-PAGE electrophoresis using 12.5% acrylamide gels. 
Proteins were electro-transferred to nitrocellulose membrane and phospho-p38 was detected 
by Western blotting using phospho-p38 (Thr180/Tyr182) and anti-rabbit peroxidase.    
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Figure 3.11: Effect of anisomycin on ERK phosphorylation 
U937 cells were incubated with 1 µM anisomycin at 37°C for various times and then prepared 
for (A) flow cytometry or (B) Western blotting to measure ERK phosphorylation. (A) Cells were 
fixed with 4% paraformaldehyde, permeabilised with 90% ice-cold methanol and then stained 
with phospho-p44/42 (ERK1/2) (Thr202/Tyr204) Alexa Fluor 647-conjugated antibody. Data 
presented as mean ± SD, n=3. Statistical differences shown to 0 min, calculated using one-
way ANOVA with Dunnett’s post hoc test: * (P<0.05), *** (P<0.001), **** (P<0.0001). (B) Total 
protein was extracted and separated with SDS-PAGE electrophoresis using 12.5% acrylamide 
gels. Proteins were electro-transferred to nitrocellulose membrane and phospho-ERK was 
detected by Western blotting using phospho-p44/42 (Thr202/Tyr204) and anti-rabbit 
peroxidase.  
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3.4 Discussion 
The overall aim of this chapter was to optimise the treatment of U937 cells with 
various cell stressors to include: UV light, chemotherapeutic agents 
(doxorubicin and vincristine), heat treatment and anisomycin.  
 
3.4.1 UV light 
The effect of UV light on U937 cell death was investigated (Section 3.3.1). UV 
light induced apoptosis in U937 cells in a dose-dependent manner. The 
apoptotic effect of UV has previously been reported in U937 cells (Liu et al., 
2005; Francesca Luchetti et al., 2006; Shin et al., 2008). Different UV exposure 
times were tested and a range of UV times were established, which resulted 
in differences in cell viabilities between 0 and 100%. The main limitation of the 
system used was that although the duration of UV exposure could be 
controlled, it was not possible to measure or control the dosage of UV light. It 
therefore could not be ensured that the cells were treated with equivalent 
dosages of UV light between experiments.  
 
3.4.2 Chemotherapeutic agents 
Doxorubicin and vincristine are both chemotherapeutic agents widely used in 
the treatment of different types of cancer, including leukaemia. The effects of 
doxorubicin and vincristine on U937 cell death were investigated in this 
chapter (Section 3.3.2).  
 
3.4.2.1 Doxorubicin 
Doxorubicin has previously been reported to induce apoptosis in U937 cells 
(César Ortiz-Lazareno et al., 2014; Demidenko et al., 2006). Doxorubicin 
induces apoptosis in U937 cells by a mechanism involving caspases 9, 8 and 
3 (César Ortiz-Lazareno et al., 2014). The results presented in this chapter are 
in agreement with these previous findings (Section 3.3.2.1). Doxorubicin 
induced cell death in a concentration-dependent manner and the decreased 
cell viability was attributed to apoptosis, due to the involvement of caspase-
3/7 activation.  
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The IC50 for doxorubicin in this experimental system was calculated to be 
3.8 µM. This differs to previously published IC50 values  for doxorubicin on 
U937 cells: 0.22 µM (1 h exposure) (Hanada, Noguchi, & Yamaoka, 2006), 0.1 
µM (48 h exposure) (Trendowski, Wong, Yu, & Fondy, 2015) and 0.4 µM (72 
h exposure) (Hazlehurst et al., 2001). Based on the published IC50 values, it 
was predicted that the IC50 would be lower than 3.8 µM. A direct comparison 
however cannot be made between previously reported IC50 values and the IC50 
value calculated in this chapter due to differences in exposure times and 
experimental systems. Most importantly, a concentration range of doxorubicin, 
which resulted in a range of metabolic activities between 0 and 100%, was 
established, for use in future chapters.  
 
3.4.2.2 Vincristine 
Vincristine induced cell death in U937 cells by apoptosis (Section 3.3.2.2). 
Metabolic activities and cell viabilities were reduced in a concentration-
dependent manner following vincristine treatment. U937 cells appeared to 
show a degree of resistance to vincristine, as concentrations of vincristine 
greater than around 5 nM did not cause any further reductions in cell viabilities 
below 30%. It was believed 24 h was insufficient time for vincristine to have 
full effects on the cells. This theory is supported by the time-dependent 
reduction in cell growth, following vincristine treatment, in an alternative 
leukemic cell line, CCRF-CEM (Huschtscha, Bartierl, Ross, & Tattersall, 
1996). After 24 h, growth inhibition was not decreased below 50% following 
treatment with high concentrations of vincristine, but after 48 and 72 h, growth 
was inhibited further. The IC50 value for vincristine in U937 cells was calculated 
to be 0.5 nM in this chapter. Previously reported IC50 values for vincristine 
treatment on U937 cells are: 0.1 nM (0.09 ng/mL) (48 h treatment) (Chadarat 
Ampasavate, Okonogi, & Anuchapreeda, 2010), 4 nM (48 h treatment) 
(Trendowski et al., 2015), 1.2 nM (48 h treatment) and 0.8 nM (96 h treatment) 
(Kiburg et al., 1994). The reporting of IC50 values after treatment for 48 h or 
more, provides further confirmation that the effects of vincristine on U937 cells 
are typically studied after 48 h. However, 24 h was selected as suitable for use 
in this thesis, as future chapters look at altering the sensitivity of U937 cells to 
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vincristine and the effects of MAPK signalling inhibitors were only studied after 
24 h.  
 
3.4.3 Heat treatment 
Exposure of cells to heat, can induce the expression of heat shock proteins 
and result in protection against apoptosis (Creagh, Sheehan, & Cotter, 2000; 
Mosser, Caron, Bourget, Denis-Larose, & Massie, 1997). The aim here was 
therefore not to establish a heat treatment which induces cell death, but rather 
a treatment which causes minimal cell death. Heat treatments such as 43°C 
for 60 min or 44°C for 30 min, have been termed lethal heat  treatments due 
to the ability of these treatments to induce apoptosis in U937 cells (Lasunskaia 
et al., 2010; Li et al., 2000). In contrast, previous studies have shown that mild 
heat treatment at 42°C for 1 h does not cause apoptosis in U937 cells (Li et 
al., 2000; Marfe et al., 2009). Heat treatment at 42°C for 1 h was therefore 
investigated in this study (Section 3.3.3).   
After 24 h, heat treatment caused a decrease in metabolic activity but 
flow cytometry and microscopy showed heat treatment had no effect on cell 
viability. Heat treatment had no effect on metabolic activity or cell viability after 
48 h. Collectively these results suggest that heat treatment at 42ºC for 1 h has 
minimal effect on U937 cell death. These results are consistent with previous 
studies (Li et al., 2000; Marfe et al., 2009), although a study has shown that 
this heat treatment can induce low levels of apoptosis (less than 20%) (Samali 
& Cotter, 1996). These previous studies assessed the effect of heat treatment 
on apoptosis in U937 cells after a short recovery incubation (less than 6 h) 
whereas this study measured the effect on cell death after longer periods: 24 
and 48 h. The main limitation is that changes in heat shock proteins following 
treatment were not measured, so it can only be assumed that the heat 
treatment used induced the expression of HSPs based on previous literature. 
 
3.4.4 Anisomycin 
Further research presented in this thesis requires the use of a signalling 
agonist to act as a positive control for the activation of MAPK signalling. 
Anisomycin was selected as a potential molecule as it is an inducer of 
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apoptosis and an activator of JNK and p38 signalling in several human cancer 
cell lines (Hori et al., 2008; Mauro et al., 2002; Stadheim & Kucera, 2002; 
Törocsik & Szeberényi, 2000; Zhou et al., 2016).  
Anisomycin treatment induced cell death in U937 cells (Section 3.3.4). 
Following anisomycin treatment, reductions in metabolic activities were 
observed within 2 h and 1 µM anisomycin was sufficient to reduce metabolic 
activity to less than 50% after 24 h. These results are in agreement with 
another study utilising U937 cells (Hori et al., 2008). Involvement of the 
apoptotic mitochondrial caspase pathway is required for anisomycin-induced 
cell death in U937 cells (Hori et al., 2008).  
The dose-dependent and time-dependent activation of JNK was 
assessed in U937 cells following anisomycin treatment (Section 3.3.5). 
Treatment with 1 µM anisomycin for 15 min was sufficient to activate JNK and 
activation was sustained up to 60 min. The observed effects of anisomycin on 
JNK activation in U937 cells are consistent with the findings of a previous study 
(Hori et al., 2008), but the effects of anisomycin on c-Jun, p38 and ERK were 
not investigated by Hori et al. The results presented here show c-Jun was 
activated to a certain extent 15 min after anisomycin treatment but the levels 
of phosphorylated c-Jun were increased further after 30 min. The delayed 
phosphorylation of c-Jun, compared to JNK, can be expected as c-Jun is a 
downstream target of JNK. Anisomycin caused a rapid activation in p38, with 
phosphorylated p38 levels being increased immediately after anisomycin 
treatment and being sustained up to 60 min. Taken together, these results 
suggest that treatment with 1 µM anisomycin for 30 min, is the most suitable 
concentration and incubation time to use to induce the activation of JNK and 
p38 in combination with MAPK inhibitors in Chapters 4 and 5. 
High levels of phosphorylated ERK were measured in untreated U937 
cells, which can be expected given the important role of ERK cell survival, 
differentiation and proliferation. Whilst it is well established that anisomycin 
activates JNK and p38 in a wide range of cancer cell lines, (Hori et al., 2008; 
Mauro et al., 2002; Stadheim & Kucera, 2002; Törocsik & Szeberényi, 2000; 
Zhou et al., 2016) the effect on ERK remains unclear and appears to be cell-
specific. ERK signalling is unaffected by anisomycin treatment in Jurkat cells 
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(Zhou et al., 2016). Following anisomycin treatment, ERK is weakly activated 
in PC12 cells (Eriksson et al., 2006) and strongly activated in HOS cells 
(Bébien et al., 2003). The results of this chapter showed anisomycin inhibits 
the phosphorylation of ERK in U937 cells.  
 
3.5 Summary  
Collectively, the work presented in this chapter shows that UV light, 
doxorubicin, vincristine and anisomycin are able to induce cell death in U937 
cells whereas heat treatment does not. In addition, anisomycin activates 
components of the JNK and p38 signalling pathways but inhibits ERK 
signalling. The following chapters will investigate the role of MAPK signalling 
pathways in response to the cell stressors optimised in this chapter. Based on 
the results of this chapter, the following doses of cell stressors will be used in 
Chapters 4, 5 and 6:  
• UV treatment - 0 to 50 s 
• doxorubicin - 0 to 50 µM 
• vincristine - 0 to 100 nM 
• heat treatment - 42°C for 1 h 
• anisomycin - 1 µM for 30 min 
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Chapter 4: Targeting JNK signalling in U937 cell line 
4.1 Introduction  
The previous chapter demonstrated the effects of various cell stressors on 
U937 cell death. In this chapter, the c-Jun N-terminal kinase (JNK) signalling 
pathway is targeted, in order to understand the role of JNK signalling in the 
response of U937 cells to these stressors.  
The JNK signalling pathway is typically activated by stress stimuli and is 
involved in mediating both cell survival and cell death (Bubici & Papa, 2014). 
The role of JNK signalling in the development and progression of solid cancers 
is well-established, with evidence JNK can act as both a tumour promoter and 
a tumour suppressor (Tournier, 2013). The role of JNK signalling in 
leukemogenesis however remains poorly understood. There is limited 
evidence which suggests JNK signalling is involved in the development of 
chronic myeloid leukaemia; the constitutive activation of JNK in CML cells is 
essential for the transforming ability and survival of BCR/ABL-expressing cells 
(Dickens et al., 1997; Hess et al., 2002; Raitano et al., 1995). The role of JNK 
signalling in the development and survival of other types of leukaemia however 
remains unclear. Further research is required to establish the role of JNK 
signalling in mediating cell survival in alternative types of leukaemia, including 
AML. This chapter will therefore investigate the role of JNK signalling in U937 
cell death, by targeting JNK signalling in combination with the cell stressors: 
UV light and heat treatment.  
Activation of JNK signalling in leukemic cells is a common event following 
chemotherapy treatment (Bates, Salerni, Lowrey, & Eastman, 2011; Davison 
et al., 2004; Peng et al., 2016). Previous studies have shown JNK activation 
is essential for cell death induced by anti-leukemic agents, such as ceramide 
and PBOX-6 (Mc Gee et al., 2002; Nica et al., 2008). Failure to activate JNK 
signalling in leukemic cells may therefore be a possible mechanism of 
chemoresistance, which has been shown to be the case for the resistance of 
AML cells to daunorubicin (Lagadinou et al., 2008). Previous studies have 
suggested high levels of activated JNK could provide an alternative 
mechanism of chemoresistance in leukemic cells (Cripe et al., 2002; Leung et 
al., 2008; Liou et al., 2017). The role of JNK signalling in mediating 
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chemoresistance therefore appears to be cell- and agent- specific. Gaining a 
greater understanding of the role of JNK signalling in response to specific 
chemotherapeutic agents will aid future therapies, by understanding how 
these pathways can be targeted in order to reduce chemoresistance. In this 
chapter the role of JNK signalling in doxorubicin and vincristine-induced cell 
death in U937 cells will be investigated.  
  
Aims 
The overall aim of this chapter is to gain a greater understanding of the role of 
JNK signalling in leukemic cell death using the model U937 cell line. This will 
be achieved by:  
• targeting JNK signalling using the chemical inhibitors SP600125 and JNK-
IN-8; 
• determining the effects of JNK signalling inhibition on the susceptibility of 
U937 cells to various cell stressors (UV light, heat and chemotherapeutic 
agents). 
 
Targeting JNK signalling using two different inhibitors will allow for a more 
thorough understanding of the role of JNK signalling and will provide 
confidence in the results obtained. Prior to using the JNK inhibitors in 
combination with cell stressors, the effect of each inhibitor on cell death and 
its ability to inhibit JNK signalling must be tested. A concentration of each 
inhibitor, which results in inhibition of JNK signalling, but causes minimal cell 
death, needs to be established. The ability of each inhibitor to inhibit JNK 
signalling will be investigated using two alternative techniques: flow cytometry 
and Western blotting. The effect of each inhibitor on cell death will be studied 
using multiple techniques including: MTS assay, PI assay and flow cytometry 
to measure annexin V binding and PI staining. These techniques to assess 
cell death, in addition to caspase-3/7 assay and microscopy, will be used to 
confirm the effects of JNK inhibition and cell stressors on U937 cell death.  
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4.2 Methods 
4.2.1 Cell culturing 
U937 cell line was cultured and maintained as described in Section 2.1.1. Prior 
to treatments, cells were prepared as described in Section 2.1.4.  
 
4.2.2 Treatment of U937 cells with JNK inhibitors 
The JNK inhibitors, SP600125 and JNK-IN-8, prepared as described in 
Section 2.2.1, were used in this chapter. U937 cells were treated with 
SP600125 and JNK-IN-8 as described in Section 2.2.1. 
 
4.2.3 Measurement of the effects of JNK inhibition on U937 cell death 
The effect of JNK inhibition on U937 cell death was assessed using: 
• MTS assay to measure metabolic activity (Section 2.4.1.3) 
• PI assay to measure necrosis (Section 2.4.1.4) 
 
4.2.4 Treatment of U937 cells with JNK inhibitor and anisomycin 
U937 cells were treated with the JNK inhibitors and anisomycin as described 
in Section 2.2.  
 
4.2.5 Measurement of the effects of JNK inhibition on MAPK activation 
The effect of JNK inhibition and anisomycin on the phosphorylation of JNK and 
c-Jun was measured by 
• Western blotting (Section 2.3.1) 
• flow cytometry (Section 2.3.2) 
 
4.2.6 Treatment of U937 cells with JNK inhibitors and cell stressors 
U937 cells were treated with the JNK inhibitors in combination with the cell 
stressors, as described in Section 2.2. 
 
4.2.7 Measurement of the effects of JNK inhibition and cell stressors on 
U937 cell death  
The effect of JNK inhibition and cell stressors on U937 cell viability was 
assessed using: 
• MTS assay to measure metabolic activity (Section 2.4.1.3) 
• PI assay to measure necrosis (Section 2.4.1.4) 
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• FITC Annexin V FITC Apoptosis Detection Kit I to measure cell viability 
(Section 2.4.2.1) 
• SensoLyte® Homogeneous Rh110 Caspase-3/7 Assay Kit to measure 
active caspase 3/7 levels (Section 2.4.1.5) 
• microscopy to determine changes in cell morphology (Section 2.5) 
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4.3 Results 
4.3.1 Inhibition of JNK signalling  
4.3.1.1 Effect of SP600125 on U937 cell death  
Initially the dose-dependent effect of SP600125 on U937 cell death was 
investigated. As the concentration of SP600125 increased, metabolic activity 
was reduced in a concentration-dependent manner (Figure 4.1A). A DMSO 
vehicle control confirmed that the observed effects were due to SP600125 and 
not the DMSO carrier (data not shown). To establish if the observed reductions 
in metabolic activity were due to cell death, the effect on necrosis and 
apoptosis was investigated using a PI assay and flow cytometry to measure 
annexin V binding and PI staining. Treatment with SP600125 had no effect on 
necrosis in U937 cells (data not shown).  
 Cell viability was significantly reduced for cells treated with 10 µM 
(P<0.01) and 25 µM SP600125 (P<0.05) (Figure 4.1B). Although cell viability 
was significantly reduced, it was only reduced by 22% for cells treated with 10 
µM SP600125. The observed differences in cell viabilities were due to cells 
both in the early and late stages of apoptosis (Figure 4.1C & 4.1D).  For similar 
concentrations of SP600125, greater reductions in metabolic activities were 
measured (Figure 4.1A) compared to the changes in cell viabilities (Figure 
4.1B), which suggests the reductions in metabolic activities were due to the 
ability of SP600125 to affect cellular processes other than cell death. 
Collectively, these results suggest that although concentrations of SP600125 
up to 25 µM do cause some cell death in U937 cells, the effect is minimal.  
 
 
 
 
 
 
 
 
Chapter 4: Targeting JNK signalling in U937 cell line 
 
114 
 
A   B 
 
 
 
 
 
 
 
C             D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Effect of SP600125 treatment on U937 cell death 
U937 cells were treated with various concentrations of SP600125 and then incubated at 37ºC 
for 24 h before an (A) MTS assay or (C-E) BD PharmingenTM FITC Annexin V Apoptosis 
Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical differences 
shown to untreated cells, calculated using one-way ANOVA with Dunnett’s post hoc test: * 
(P<0.05), ** (P<0.01), *** (P<0.001), **** (P<0.0001).  
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4.3.1.2 Effect of SP600125 on MAPK phosphorylation  
Based on the viability data in the previous section, the ability of 0 to 25 µM 
SP600125 to inhibit JNK signalling was measured by flow cytometry and 
Western blotting. Phosphorylation of JNK was significantly (P<0.0001) 
induced following anisomycin treatment; pre-treatment with SP600125 had no 
effect on the percentage of cells expressing phosphorylated JNK (Figure 
4.2A). Measurement of Alexa Fluor 647 mean fluorescence intensity (MFI) 
showed pre-treatment with 5 to 25 µM SP600125 caused a decrease in the 
MFI compared to anisomycin-untreated cells but this was only significantly 
(P<0.05) lower for cells pre-treated with 25 µM SP600125 (Figure 4.2B). 
Western blotting however indicated that JNK phosphorylation was partially 
inhibited by 10 and 25 µM SP600125 (Figure 4.2C). Whilst total protein 
staining (data not shown) indicated equal total protein loading, the results of 
the Western blotting are limited due to the lack of a total-JNK Western blot.  
 Due to the minimal effects of SP600125 on JNK phosphorylation, 
further confirmation was required to confirm the ability of SP600125 to inhibit 
JNK signalling. The effect of SP600125 on c-Jun phosphorylation, a 
downstream target of JNK, was measured by flow cytometry. The percentages 
of cells expressing phosphorylated c-Jun were significantly (P<0.0001) lower 
for cells pre-treated with SP600125 compared to anisomycin-only treated cells 
(Figure 4.2D); the mean fluorescence intensity showed similar patterns of 
change (Figure 4.2E). These results show that although SP600125 has 
minimal effects on JNK phosphorylation per se, inhibition of JNK signalling 
occurs, as evidenced from the inhibition of c-Jun phosphorylation. Whilst the 
percentage of cells expressing phosphorylated c-Jun was significantly 
(P<0.0001) reduced for cells pre-treated with 5 µM, the effect was minimal and 
was greater for 10 µM, hence 10 µM SP600125 or higher was used in future 
experiments.  
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Figure 4.2: Effect of SP600125 and anisomycin on JNK and c-Jun 
phosphorylation  
U937 cells were pre-treated with various concentrations of SP600125 at 37°C for 1 h and then 
incubated with 1 µM anisomycin at 37°C for 30 min. Cells were then prepared for (A,B,D,E) 
flow cytometry or (C) Western blotting. (A,B,D,E) Cells were fixed with 4% paraformaldehyde, 
permeabilised with 90% ice-cold methanol and stained with (A,B) phospho-SAPK/JNK 
(Thr183/Tyr185) Alexa Fluor 647-conjugated antibody or (D,E) phospho-c-Jun (Ser73) Alexa 
Fluor 488-conjugated antibody. (A,D) shows the percentage of cells expressing phospho-
JNK/c-Jun and (B,E) shows phospho-JNK/c-Jun mean fluorescence intensity (MFI). Data 
presented as mean ± SD, n=3. Statistical differences shown to anisomycin-only treated cells, 
calculated using one-way ANOVA with Dunnett’s post hoc test: * (P<0.05), *** (P<0.001), **** 
(P<0.0001). (C) Total protein was extracted and separated with SDS-PAGE electrophoresis 
using 4-15% precast gels. Proteins were electro-transferred to nitrocellulose membrane and 
phospho-JNK was detected by Western blotting using phospho-JNK/SAPK (Thr183/Tyr185) 
and anti-rabbit peroxidase. 
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4.3.1.3 Effect of JNK-IN-8 on U937 cell death 
Assessment of the dose-dependent effect of JNK-IN-8 on U937 metabolic 
activity showed that treatment with 0.05 to 6.25 µM JNK-IN-8 caused 
significant (P<0.01) increases in metabolic activities compared to untreated 
cells (Figure 4.3A). Treatment with greater than 12.5 µM JNK-IN-8 caused a 
significant (P<0.0001) decrease in metabolic activity compared to untreated 
cells. A DMSO vehicle control confirmed that the observed effects were due 
to JNK-IN-8 and not the DMSO carrier (data not shown). Treatment with up to 
25 µM JNK-IN-8 had no effect on U937 necrosis, however necrosis was 
observed by the PI assay (Figure 3.4B) and flow cytometry (Figure 4.3D) for 
25 µM of JNK-IN-8 or higher.  
The effects of concentrations of JNK-IN-8 between 1 and 25 µM on U937 
cell death were investigated further using flow cytometry (Figure 4.3C-F). 
Treatment with 1.0, 2.5 and 5.0 µM JNK-IN-8 had minimal effect on U937 
viability (Figure 4.3C). Reduced cell viabilities were measured for cells treated 
with higher concentrations of JNK-IN-8, due to cells in the late stage of 
apoptosis (Figure 4.3F).  
 
 
  
Chapter 4: Targeting JNK signalling in U937 cell line 
 
118 
 
A B           
 
 
 
 
 
 
 
 
 
 
 
 
 
C           D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E            F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Effect of JNK-IN-8 on U937 cell death 
U937 cells were treated with varying concentrations of JNK-IN-8 and then incubated at 37°C 
for 24 h before an (A) MTS assay, (B) PI assay or (C-F) BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical 
differences shown to untreated cells, calculated using one-way ANOVA with Dunnett’s post 
hoc test: * (P<0.05), *** (P<0.001), **** (P<0.0001). 
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4.3.1.4 Effect of JNK-IN-8 on MAPK activation 
To confirm the effect of JNK-IN-8 on JNK signalling, the effect of 0 to 10 µM 
JNK-IN-8 on JNK phosphorylation was measured using flow cytometry and 
Western blotting (Figures 4.4A-C). Flow cytometry results showed the 
percentages of cells expressing phosphorylated JNK were unaffected by JNK-
IN-8 treatment (Figure 4.4A). In the presence of JNK-IN-8, the cells expressing 
phosphorylated JNK did however express phosphorylated JNK at significantly 
(P<0.001) lower levels (Figure 4.4.B). Western blotting indicated JNK-IN-8 had 
no effect on JNK phosphorylation (Figure 4.4C).   
 The effect of JNK-IN-8 on JNK signalling was further investigated by 
studying the effects of JNK-IN-8 on c-Jun phosphorylation (Figures 4.4D-F). 1 
µM JNK-IN-8 did not result in a significant change in the percentage of cells 
expressing phosphorylated c-Jun (Figure 4.4E) but did cause a significant 
(P<0.0001) decrease in phospho c-Jun MFI (Figure 4.4.F). For 2.5 µM and 
higher of JNK-IN-8, a dose-dependent inhibition of c-Jun phosphorylation was 
observed (Figures 4.4E & 4.4F). Western blotting also indicated that c-Jun 
phosphorylation was inhibited by 1 µM or higher JNK-IN-8 (Figure 4.4D). 
Taken together, these results suggest that JNK-IN-8, at concentrations as low 
as 1 µM, inhibit JNK signalling as evidenced by the inhibition of c-Jun 
phosphorylation, despite limited effect on JNK phosphorylation per se. 
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Figure 4.4: Effect of JNK-IN-8 and anisomycin on JNK and c-Jun 
phosphorylation  
U937 cells were pre-treated with various concentrations of JNK-IN-8 at 37°C for 1 h and then 
incubated with 1 µM anisomycin at 37°C for 30 min. Cells were then prepared for (A,B,E,F) 
flow cytometry or (C,D) Western blotting. (A,B,E,F) Cells were fixed with 4% 
paraformaldehyde, permeabilised with 90% ice-cold methanol and stained with (A,B) 
phospho-SAPK/JNK (Thr183/Tyr185) Alexa Fluor 647-conjugated antibody or (E,F) phospho-
c-Jun (Ser73) Alexa Fluor 488-conjugated antibody. (A,E) show the percentage of cells 
expressing phospho-JNK/c-Jun and (B,F) shows phospho-JNK/c-Jun mean fluorescence 
intensity (MFI). Data presented as mean ± SD, n=3. Statistical differences shown to 
anisomycin-only treated cells, calculated using one-way ANOVA with Dunnett’s post hoc test: 
*** (P<0.001), **** (P<0.0001). (C,D) Total protein was extracted and separated with SDS-
PAGE electrophoresis using 4-15% precast gels. Proteins were electro-transferred to 
nitrocellulose membrane and (C) phospho-JNK was detected by Western blotting using 
phospho-JNK/SAPK (Thr183/Tyr185) and (D) phospho-c-Jun was detected using phospho c-
Jun (Ser73), and anti-rabbit peroxidase.   
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4.3.2 Effect of JNK inhibition and UV light  
4.3.2.1 Effect of SP600125 and UV light on U937 cell death 
To study the role of JNK signalling in UV-induced cell death, U937 cells were 
treated with a range of UV treatment times in the presence and absence of 10 
µM SP600125, and the effect on metabolic activity was assessed. Metabolic 
activities were significantly (P<0.0001) lower for cells pre-treated with 10 µM 
SP600125 for cells treated with 15 to 50 s UV compared to cells not pre-treated 
with SP600125 (Figure 4.5A). Results of the PI assay showed that for cells 
treated with 20 to 40s UV, the percentage of PI-positive cells was significantly 
(P<0.0001) higher for cells treated with SP600125 (Figure 4.5B). The 
differences observed in the percentage of PI-positive cells (Figure 4.5B) were 
however less than the differences in metabolic activities (Figure 4.5A) 
suggesting cell death occurred by a mechanism other than necrosis.  
Flow cytometry confirmed that inhibition of JNK signalling, using 
SP600125, increased the susceptibility of U937 cells to UV-induced reductions 
in cell viability (Figure 4.5C). The observed differences in cell viabilities were 
due to differences in the percentages of late apoptotic/ secondary necrotic 
cells (Figure 4.5E) 
Fluorescence microscopy images are consistent with the results of the 
plate based assays and flow cytometry. In the absence of UV light, U937 cells 
appeared healthy and did not stain with PI (Figure 4.5F). The majority of cells 
treated with 6 s UV and not pre-treated with SP600125 appeared apoptotic 
and PI staining showed these cells had fragmented nuclei. However, a small 
number of cells appeared viable. For cells treated with 10 µM SP600125, prior 
to UV light treatment, all cells appeared apoptotic and a large number stained 
with PI and showed fragmented nuclei. Collectively, these results show 
SP600125 increases the susceptibility of U937 cells to cell death induced by 
UV light.  
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Figure 4.5: Effect of SP600125 and UV light treatment on U937 cell death 
U937 cells were pre-treated with 0 or 10 µM SP600125 at 37°C for 1 h to inhibit JNK signalling 
and then treated with various durations of UV light. After 24 h, (A) MTS assay, (B) PI assay, 
(C-E) BD PharmingenTM FITC Annexin V Apoptosis Detection Kit I or (F) microscopy was 
performed. (A-E) Data presented as mean ± SD, n=3. Statistical differences shown between 
SP600125 and no treatment at UV time points, calculated using two-way ANOVA with Sidak’s 
post hoc test: * (P<0.05), ** (P<0.01), *** (P<0.001), **** (P<0.0001). (F) Cells were stained 
with PI staining solution and visualised using EVOSTMFL AutoCell Imaging System at 40 X 
magnification. Black and white arrows indicate late apoptotic cells. Images shown are 
representative of 3 individual images collected.
0
1
0
2
0
3
0
4
0
5
0
0
5 0
1 0 0
U V  T re a tm e n t, s
M
e
ta
b
o
li
c
 a
c
ti
v
it
y
, 
%
0 M
10 M
* * * *
* * * *
* * * *
* * * *
* * * *
0 3 6 9
1
2
1
5
1
8
0
2 0
4 0
6 0
8 0
1 0 0
U V  T re a tm e n t, s
A
p
o
p
to
ti
c
, 
%
  0 M
10 M
* * * ** * * ** * * ** * * *
* * * *
* * *
* * * *
0 3 6 9
1
2
1
5
1
8
0
2 0
4 0
6 0
8 0
1 0 0
U V  T re a tm e n t, s
V
ia
b
il
it
y
, 
%
  0 M
10 M* *
* * * *
* * * *
*
0 3 6 9
1
2
1
5
1
8
0
2 0
4 0
6 0
8 0
1 0 0
U V  T re a tm e n t, s
L
a
te
 a
p
o
 /
 s
e
c
o
n
d
a
ry
 n
e
c
ro
, 
%
  0 M
10 M
* *
* * * *
* * * *
* * * * * * * * * * * *
* * *
0
1
0
2
0
3
0
4
0
5
0
0
5 0
1 0 0
U V  T re a tm e n t, s
P
I-
p
o
s
it
iv
e
 c
e
ll
s
, 
%
0 M
10 M
* * * *
* * * *
* * * * * * * *
Chapter 4: Targeting JNK signalling in U937 cell line 
 
123 
 
4.3.2.2 Effect of JNK-IN-8 and UV light on U937 cell death 
There were no significant differences in metabolic activities between cells 
treated with and without JNK-IN-8, irrespective of UV dose (Figure 4.6A and 
Table 4.1). Hence, for each duration of UV light treatment, there were no 
significant differences in the percentages of necrotic cells, between cells 
treated with and without JNK-IN-8 (Figure 4.6B and Table 4.1). As no 
differences were observed, the effect of JNK-IN-8 and UV light on U937 cell 
death was not investigated further.  
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Figure 4.6: Effect of JNK-IN-8 and UV light treatment on U937 metabolic activity 
and necrosis 
U937 cells were pre-treated with 0, 1, 2.5 or 5 µM JNK-IN-8 at 37°C for 1 h to inhibit JNK 
signalling and then treated with various durations of UV light. After 24 h incubation at 37°C, 
an (A) MTS assay and (B) PI assay were performed. Data presented as mean ± SD; n=3.  
 
 
Table 4.1: Statistical analysis to show the effects of JNK-IN-8 and UV light 
treatment on U937 metabolic activity and necrosis  
Data presented as mean ± SD; n=3. Statistical differences shown between JNK-IN-8 and no 
inhibitor at UV time points, calculated using two-way ANOVA with Tukey’s post hoc test. 
MTS assay 
UV Treatment, s JNK-IN-8 concentration 
 
 
 
0 µM vs 1 µM 0 µM vs 2.5 µM 0 µM vs 5 µM 
0 ns ns ns 
5 ns ns ns 
10 ns ns ns 
15 ns ns ns 
20 ns ns ns 
25 ns ns ns 
30 ns ns ns 
PI assay 
UV Treatment, s JNK-IN-8 concentration 
0 µM vs 1 µM 0 µM vs 2.5 µM 0 µM vs 5 µM 
0 ns ns ns 
5 ns ns ns 
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4.3.3 Effect of JNK inhibition and chemotherapy 
4.3.3.1 Effect of SP600125 and doxorubicin on U937 cell death 
To investigate the role of JNK signalling in doxorubicin-induced cell death, 
U937 cells were treated with SP600125 prior to doxorubicin treatment, and the 
effect on metabolic activity was assessed. For cells treated with 0 to 3.13 µM 
doxorubicin, metabolic activities were significantly (P<0.05) lower for cells pre-
treated with SP600125 compared to cells not treated with SP600125 (Figure 
4.7). As the concentration of doxorubicin increased from 0 to 3.13 µM, the 
differences in metabolic activity between cells pre-treated with and without 
SP600125 decreased. For 6.25 and 12.5 µM doxorubicin, metabolic activities 
were significantly (P<0.001) higher for cells pre-treated with SP600125, 
compared to cells not pre-treated with SP600125. These results suggest that 
inhibition of JNK signalling provides protection against doxorubicin-induced 
cell death at least at concentrations of 12.5 µM doxorubicin.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Effect of SP600125 and doxorubicin on U937 metabolic activity  
U937 cells were pre-treated with 0 or 10 µM SP600125 at 37°C for 1 h to inhibit JNK signalling 
and then treated with various concentrations of doxorubicin. Cells were then incubated at 37°C 
for 24 h before an MTS assay was performed. Data presented as mean ± SD; n=3. Statistical 
differences shown between SP600125 and no inhibitor at doxorubicin concentration points, 
calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), *** (P<0.001), **** 
(P<0.0001). 
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4.3.3.2 Effect of JNK-IN-8 and doxorubicin on U937 cell death 
The role of JNK signalling in doxorubicin-induced cell death was investigated 
further using JNK-IN-8 in combination with doxorubicin. For cells treated with 
0 to 6.25 µM doxorubicin, there were no significant differences in metabolic 
activities between cells treated with JNK-IN-8 and cells not treated with JNK-
IN-8 (Figure 4.8A). For cells treated with 12.5 to 50 µM doxorubicin, metabolic 
activities were significantly (P<0.0001) higher for cells pre-treated with JNK-
IN-8 compared to cells not pre-treated with JNK-IN-8, when treated with 
equivalent concentrations of doxorubicin.  
As differences in metabolic activities were observed for cells treated 
with 12.5 to 50 µM doxorubicin (Figure 4.8A), the effect of JNK-IN-8 and 
treatment with these concentrations of doxorubicin, was investigated further 
(Figure 4.8B).  For doxorubicin treated cells, active caspase levels were lower 
for cells pre-treated with JNK-IN-8 compared to cells treated with equivalent 
concentration of doxorubicin, but not pre-treated with JNK-IN-8. Active 
caspase levels were however only significantly (P<0.05) lower for cells treated 
with 12.5 µM doxorubicin. These results suggest that either the differences 
observed in metabolic activities (Figure 4.8A) were not due to apoptosis, or 
due to the low fluorescence readings for the caspase-3/7 assay (Figure 4.8B), 
it is possible that 9 h was not the correct time point to measure the activation 
of caspase-3/7 following doxorubicin treatment.  
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Figure 4.8: Effect of JNK-IN-8 and doxorubicin on U937 cell death 
U937 cells were pre-treated with 0 or 2.5 µM JNK-IN-8 at 37°C for 1 h to inhibit JNK signalling 
and then treated with various concentrations of doxorubicin. Cells were then incubated at 37°C 
for (A) 24 h before an MTS assay was performed or (B) 9 h before active caspase-3/7 levels 
were measured using SensoLyte® Homogeneous Rh110 Caspase-3/7 Assay Kit. Data 
presented as mean ± SD; n=3. Statistical differences shown between JNK-IN-8 and no 
inhibitor at doxorubicin concentration points, calculated using two-way ANOVA with Sidak’s 
post hoc test: * (P<0.05), **** (P<0.0001).  
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4.3.3.3 Effect of SP600125 and vincristine on U937 cell death 
The effect of SP600125 and an alternative chemotherapeutic agent, vincristine 
on U937 cell death was investigated. For cells treated with 0 to 0.4 nM, 
metabolic activities were significantly (P<0.0001) lower for cells pre-treated 
with SP600125 compared to cells not treated with SP600125 (Figure 4.9A) 
In contrast, for cells treated with 1.56 to 50 nM vincristine, metabolic activities 
were significantly (P<0.001) higher for cells pre-treated with SP600125 
compared to cells not treated with SP600125, when treated with equivalent 
concentrations of vincristine. Results of the PI assay showed that for cells 
treated with 3.13 to 50 nM vincristine, the percentages of necrotic cells were 
significantly (P<0.001) lower for cells pre-treated with SP600125 compared to 
cells not treated with SP600125 (Figure 4.9B). 
 To confirm the effects of SP600125 and vincristine on U937 cell death, 
flow cytometry was performed to measure annexin V binding and PI staining. 
Flow cytometry confirmed inhibition of JNK signalling, using SP600125 
protected U937 cells from vincristine-induced cell death (Figures 4.9C-E). 
Flow cytometry confirmed the differences in cell viabilities (Figure 4.9C) were 
not due to necrosis (data not shown), as suggested by the PI assay (Figure 
4.9B) but were due to differences in the percentages of late apoptotic/ 
secondary necrotic cells (Figure 4.9E). 
These results are further supported by the fluorescence microscopy 
images (Figure 4.9F). For cells treated with 12.5 nM vincristine, and not pre-
treated with SP600125, a large number of cells appeared mis-shapen, 
apoptotic bodies were visible and PI staining showed fragmented nuclei. For 
cells pre-treated with SP600125 prior to vincristine treatment, a few cells 
appeared apoptotic but the majority appeared healthy and did not stain with 
PI.  Taken together, these results show that SP600125 protects U937 cells 
from vincristine-induced cell death.  
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Figure 4.9: Effect of SP600125 and vincristine on U937 cell death 
U937 cells were pre-treated with 0 or 10 µM SP600125 at 37°C for 1 h to inhibit JNK signalling 
and then treated with various concentrations of vincristine. Cells were then incubated at 37°C 
for 24 h before an A) MTS assay, B) PI assay, (C-E) BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I or (F) microscopy were performed. (A-E) Data presented as mean ± 
SD; n=3. Statistical differences shown between SP600125 and no inhibitor at vincristine 
concentration points, calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), 
** (P<0.01), *** (P<0.001), **** (P<0.0001). (F) Cells were stained with PI staining solution and 
visualised using EVOSTMFL AutoCell Imaging System at 40 X magnification. Black and white 
arrows indicate late apoptotic cells. Images shown are representative of 3 individual images 
collected. 
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4.3.3.4 Effect of JNK-IN-8 and vincristine on U937 cell death 
The role of JNK signalling in vincristine-induced cell death was investigated 
further by pre-treating cells with JNK-IN-8 prior to vincristine and measuring 
the effects on metabolic activity and necrosis. For cells treated with 0.1 to 0.8 
nM vincristine, metabolic activities were significantly (P<0.05) lower for cells 
pre-treated with 2.5 µM JNK-IN-8 compared to cells not treated with JNK-IN-8 
(Figure 4.10A). However, a similar difference was measured in the absence of 
vincristine; the cells appeared to be more susceptible to 2.5 µM JNK-IN-8 than 
in Figure 4.3. For cells treated with 1.56 to 100 nM vincristine, there were no 
significant differences in metabolic activities between cells treated with and 
without JNK-IN-8. 
 For cells treated with 0 to 0.8 nM vincristine, there were no significant 
differences in the percentages of necrotic cells between cells treated with and 
without JNK-IN-8 (Figure 4.10B). For cells treated with 1.56 to 100 nM, the 
percentages of necrotic cells were significantly (P<0.05) lower for cells pre-
treated with JNK-IN-8 compared to cells not pre-treated with JNK-IN-8. 
 
 
A B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Effect of JNK-IN-8 and vincristine on U937 metabolic activity and 
necrosis  
U937 cells were pre-treated with 0 or 2.5 µM JNK-IN-8 at 37°C for 1 h to inhibit JNK signalling. 
Cells were then treated with various concentrations of vincristine. Cells were then incubated 
at 37°C for 24 h before an (A) MTS assay or (B) PI assay was performed. Data presented as 
mean ± SD; n=3. Statistical differences shown between JNK-IN-8 and no inhibitor at vincristine 
concentration points, calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), 
** (P<0.01), *** (P<0.001), **** (P<0.0001). 
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4.4.4 Effect of JNK inhibition and heat treatment  
4.4.4.1 Effect of SP600125 and heat treatment on U937 cell death 
To investigate the role of JNK signalling in the response to heat treatment, 
U937 cells were treated with SP600125 prior to heat treatment and the effect 
on metabolic activity was assessed. After 24 h, for cells pre-treated with 0 to 
3.13 µM SP600125, metabolic activities were significantly (P<0.01) lower for 
heat treated cells compared to non-heat treated cells (Figure 4.11A). Metabolic 
activities were significantly (P<0.01) higher for heat treated cells compared to 
non-heat treated cells treated with 12.5 and 50 µM SP600125. Although 
statistically significant, the differences were minimal. Heat treatment also had 
minimal effects on necrosis after 24 h and this was unaffected by SP600125 
(data not shown) 
After 24 h, flow cytometry results showed that the percentages of viable 
cells were lower for heat treated cells compared to non-heat treated cells, for 
both cells treated with and without SP600125 (Figure 4.11B). The differences 
observed were due to small increases in the percentages of apoptotic and late 
apoptotic/secondary necrotic cells for heat treated cells (Figures 4.11C-D).  
As heat shock was selected as a stimulus to stress the cells, rather than 
directly induce cell death, the effect of SP600125 and heat treatment was also 
studied after a longer time period of 48 h. After 48 h, for cells treated with 0 to 
6.25 µM SP600125, there were no significant differences in metabolic 
activities between heat treated and non-heat treated cells (Figure 4.11E). 
Metabolic activities were significantly (P<0.05) higher for heat treated cells 
compared to non-heat treated cells for cells pre-treated with 12.5 to 50 µM 
SP600125 after 48 h. SP600125 and heat treatment had little effect on U937 
necrosis after 48 h (data not shown).  
After 48 h, flow cytometry results showed there were no significant 
differences in cell viabilities between heat treated and non-heat treated cells, 
for all concentrations of SP600125 (Figure 4.11F). For cells treated with 50 
µM SP600125, the percentage of apoptotic cells was significantly (P<0.001) 
lower for heat treated cells, compared to non-heat treated cells, but the 
percentage of late apoptotic/secondary necrotic was significantly (P<0.001) 
higher (Figures 4.11G-H).  
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To further investigate the effects of SP600125 and heat treatment on 
U937 cell death, active caspase-3/7 levels were measured (Figure 4.12).For 
all concentrations of SP600125, active caspase-3/7 levels were increased by 
around 2-fold (P<0.0001) for heat treated cells compared to non-heat treated 
cells. Active caspase-3/7 levels were also significantly (P<0.0001) increased 
to a similar extent in the absence of SP600125. Collectively, these results 
suggest inhibition of JNK signalling using SP600125, has minimal effects on 
U937 cell death following heat treatment.  
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Figure 4.11: Effect of SP600125 & heat treatment on U937 cell death 
U937 cells were pre-treated with SP600125 at 37ºC for 1 h to inhibit JNK signalling and then 
incubated at either 37°C or 42ºC for 1 h. Cells were then incubated at 37°C for (A-D) 24 h or 
(E-H) 48h before an (A,E) MTS assay or (B-D,F-H) BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical 
differences shown between heat treatment and no treatment at SP600125 concentration 
points, calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), 
*** (P<0.001). 
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Figure 4.12: Effect of SP600125 and heat treatment on caspase-3/7 activation,  
U937 cells were pre-treated with SP600125 at 37ºC for 1 h to inhibit JNK signalling and then 
incubated at either 37°C or 42ºC for 1 h. Cells were then incubated at 37°C for 9 h before 
active caspase-3/7 levels were measured using SensoLyte® Homogeneous Rh110 Caspase-
3/7 Assay Kit. Data presented as mean ± SD, n=3. Statistical differences shown between 
mean heat treatment and no treatment at SP600125 concentration points, calculated using 
two-way ANOVA with Sidak’s post hoc test: **** (P<0.0001). 
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4.4.3.2 Effect of JNK-IN-8 and heat treatment on U937 cell death 
The role of JNK signalling in U937 cell death following heat treatment was 
investigated further using JNK-IN-8. In the absence of JNK-IN-8, there was no 
significant difference in metabolic activity between heat treated and non-heat 
treated cells after 24 h (Figure 4.13A). Metabolic activities were significantly 
(P<0.0001) lower for heat treated cells compared to non-heat treated cells for 
cells pre-treated with 5 to 25 µM JNK-IN-8. To determine if the observed 
differences in metabolic activities were due to necrosis, a PI assay was 
performed (Figure 4.13B). After 24 h the percentages of necrotic cells were 
significantly (P<0.0001) higher for heat treated cells compared to non-heat 
treated cells when pre-treated with 10 to 25 µM JNK-IN-8.  
After 24 h, flow cytometry results showed that cell viabilities were 
significantly (P<0.0001) lower for heat treated cells compared to non-heat 
treated cells, for both cells treated with and without JNK-IN-8 (Figure 4.13C). 
The observed differences in cell viabilities (Figure 4.13C) were due to 
differences in the percentage of late apoptotic/secondary necrotic cells (Figure 
4.14D). These differences in the percentages of late apoptotic/secondary 
necrotic cells accounts for the differences in percentages of PI-positive cells, 
measured by the PI assay (Figure 4.13B).  
After 48 h, for 0 and 5 µM JNK-IN-8, the metabolic activity of heat treated 
cells was significantly (P<0.01) higher compared to non-heat treated cells 
(Figure 4.13E). However these differences were minimal, less than a 10% 
difference was measured. Metabolic activities were significantly (P<0.0001) 
lower for heat treated cells compared to non-heat treated cells for cells pre-
treated with 10 to 25 µM JNK-IN-8. JNK-IN-8 and heat treatment had little 
effect on U937 necrosis after 48 h (data not shown). 
Flow cytometry results confirmed that after 48 h cell viabilities were 
significantly (P<0.0001) lower for heat treated cells compared to non-heat 
treated cells, for cells treated with JNK-IN-8 (Figure 4.13F).The percentages 
of apoptotic and late apoptotic/secondary necrotic cells were significantly 
(P<0.05) higher for heat treated cells compared to non-heat treated cells pre-
treated with JNK-IN-8. Collectively, these results indicate JNK-IN-8 makes 
U937 cells more susceptible to heat-induced cell death after 24 and 48 h.   
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Figure 4.13: Effect of JNK-IN-8 and heat treatment on U937 cell death 
U937 cells were pre-treated with JNK-IN-8 at 37ºC for 1 h to inhibit JNK signalling and then 
incubated at either 37°C or 42ºC for 1 h. Cells were then incubated at 37°C for (A-D) 24 h or 
(E-H) 48h before an (A,E) MTS assay, (B) PI assay or (C-D,F-H) BD PharmingenTM FITC 
Annexin V Apoptosis Detection Kit I were performed. Data presented as mean ± SD; n=3. 
Statistical differences shown between heat treatment and no treatment at JNK-IN-8 
concentration points, calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), 
** (P<0.01), *** (P<0.001). 
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To confirm the effects of JNK-IN-8 and heat treatment directly on 
apoptosis, active caspase-3/7 levels were measured following JNK-IN-8 and 
heat treatment. First of all it was necessary to establish an appropriate time to 
measure active caspase-3/7 levels. The time dependent activation of caspase-
3/7 was measured following treatment with 15 µM JNK-IN-8, as results 
presented in figure 4.13 provided a strong indication that this combination of 
treatments induced apoptosis. Active caspase-3/7 levels were around 5-fold 
higher (P<0.0001) for heat treated cells compared to non-heat treated cells 
after 0 h (Figure 4.14A). After 3 h, active caspase-3/7 levels were around 13-
fold higher (P<0.0001) for heat treated cells and these levels were sustained 
up to 12 h. After 24 h, active caspase-3/7 levels were still significantly 
(P<0.0001) higher for heat treated cells compared to non-heat treated cells 
but only by around 3-fold. The levels of active caspase-3/7 prior to JNK-IN-8 
and heat treatment were however not measured. A further experiment was 
therefore performed to measure the levels prior to treatment, and up to 9 h 
after treatment. There was no significant differences in active caspase-3/7 
levels between heat treated cells and non-heat treated cells, prior to JNK-IN-
8 and heat treatment (Figure 4.14B). After 9 h after heat treatment, active 
caspase-3/7 levels were around 10-fold higher for heat treated cells compared 
to non-heat treated cells which is consistent with the previous results (Figure 
4.14A). However, the results in Figure 4.15B suggest that for heat treated 
cells, active caspase-3/7 levels gradually increased in a time-dependent 
manner between 0 and 9 h.  
Active caspase-3/7 levels were therefore measured 9 h after JNK-IN-8 
and heat treatment. There was no significant difference in active caspase-3/7 
levels between heat treated and non-heat treated cells in the absence of JNK-
IN-8 treatment (Figure 4.15). For cells pre-treated with JNK-IN-8, active 
caspase-3/7 levels were significantly (P<0.0001) higher for heat treated cells 
compared to non-heat treated cells. These results confirm that JNK inhibition, 
using JNK-IN-8 makes U937 cells susceptible to heat-induced cell death, in 
particular, susceptible to apoptosis. 
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     A       
 
 
 
 
 
 
 
 
 
 
 
 
 
     B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Time-dependent activation of caspase-3/7 activation following 
JNK-IN-8 and heat treatment 
U937 cells were pre-treated with 15 µM JNK-IN-8 at 37ºC for 1 h to inhibit JNK signalling and 
then incubated at either 37°C or 42ºC for 1 h. Cells were then incubated at 37°C and active 
caspase-3/7 levels were measured over (A) 24 h or (B) 9h using SensoLyte® Homogeneous 
Rh110 Caspase-3/7 Assay Kit. Data presented as mean ± SD, n=3. Statistical differences 
shown between heat treatment and no treatment at time points, calculated using two-way 
ANOVA with Sidak’s post hoc test: **** (P<0.0001). 
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Figure 4.15: Effect of JNK-IN-8 and heat treatment on caspase-3/7 activation  
U937 cells were pre-treated with JNK-IN-8 at 37ºC for 1 h to inhibit JNK signalling and then 
incubated at either 37ºC or 42ºC for 1 h. Cells were then incubated at 37°C for 9 h before 
active caspase-3/7 levels were measured using SensoLyte® Homogeneous Rh110 Caspase-
3/7 Assay Kit. Data presented as mean ± SD, n=3. Statistical differences shown between heat 
treatment and no treatment at JNK-IN-8 concentration points, calculated using two-way 
ANOVA with Sidak’s post hoc test: **** (P<0.0001). 
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4.4 Discussion 
The overall aim of this chapter was to gain a greater understanding of the role 
of JNK signalling in leukemic cell death by studying the effects of JNK inhibition 
and cell stressors on cell death in the model U937 cell line.  
 
4.4.1 Inhibition of JNK signalling 
The JNK inhibitors, SP600125 and JNK-IN-8, were used to target JNK 
signalling in this study (Section 4.3.1). SP600125 is an ATP-competitive 
inhibitor (Bennett et al., 2001) whereas JNK-IN-8 is a covalent, irreversible 
inhibitor which binds to JNK (Zhang et al., 2012); both inhibitors prevent the 
phosphorylation of c-Jun, a downstream target of JNK. A large number of 
studies have published data using SP600125 but its use is restricted due to 
poor specificity. Due to the more recent discovery of JNK-IN-8, a limited 
number of studies have utilised JNK-IN-8. The aim here was to confirm the 
inhibition of JNK signalling in U937 cells using both SP600125 and JNK-IN-8, 
and to establish effective concentrations to use in combination with cell 
stressors. 
 
4.4.1.1 SP600125  
Results showed that although concentrations of SP00125 up to 25 µM do 
cause some cell death in U937 cells, the effect is minimal (Section 4.3.1.1). 
The differences observed in metabolic activities could be due to the ability of 
SP600125 to affect cellular processes other than apoptosis, such as 
proliferation. This theory is supported by previous evidence showing 
SP600125 inhibits proliferation of U937 cells, by causing cells to arrest at 
G2/M stage of the cell cycle, and inducing endoreduplication (Moon et al., 
2009). This is consistent with the ability of SP600125 to inhibit cell growth in 
other cancer cells (Hideshima et al., 2003; Jacobs-Helber & Sawyer, 2004; 
Mingo-Sion, Marietta, Koller, Wolf, & Van Den Berg, 2004). 
The effect of SP600125 on the phosphorylation of JNK was measured 
using both flow cytometry and Western blotting (Section 4.3.1.2). JNK 
phosphorylation was not inhibited by SP600125, as measured by flow 
cytometry but Western blotting showed JNK phosphorylation was inhibited by 
10 and 25 µM SP600125. Therefore, the measurement of JNK 
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phosphorylation following SP600125 treatment, using two alternative 
techniques, produced inconsistent results.  
As SP600125 is an ATP-competitive JNK inhibitor, it was expected that 
JNK phosphorylation would be inhibited by SP600125. Bennett et al. have 
reported that SP600125 inhibits JNK phosphorylation in Jurkat T lymphocyte 
cells, but the evidence to support this conclusion is not convincing (Bennett et 
al., 2001). Inhibition of JNK phosphorylation by SP600125 however has 
previously been reported in U937 cells (Budhraja et al., 2012) and other cancer 
cells lines such as BKS-2 B cell lymphoma cells (Gururajan et al., 2005) and 
Hep G2 hepatocellular carcinoma cells (Kong et al., 2014). As in these studies, 
JNK phosphorylation is typically measured by Western blotting rather than flow 
cytometry. The observed differences are unlikely to be due to the antibodies 
used as the antibodies used in the flow cytometry and Western blotting 
experiments in this chapter, both measured the dual phosphorylation of JNK 
at residues Thr183 and Tyr185.  
Another possible explanation for the observed differences between the 
two techniques could be attributed to cell numbers. Flow cytometry analyses 
individual cells whereas Western blotting involves the extraction of proteins 
from a sample of cells. As SP600125 inhibits cell proliferation (Moon et al., 
2009), it is possible the decreased levels of phosphorylated JNK following 
SP600125 treatment could be due to a lower number of cells compared to 
untreated cells. However the short time course of this experiment was unlikely 
to have a significant effect on proliferation and subsequent cell numbers, to 
cause such effects. The loading of equal concentrations of protein onto the 
gels should also have accounted for differences in cell numbers; measurement 
of total JNK would have provided confirmation of equal loading. 
Western blotting measures the levels of phosphorylated JNK 
expressed by a population of cells, including both viable and non-viable cells. 
The flow cytometry data presented however only measured the percentage of 
viable cells expressing phosphorylated JNK and non-viable cells were 
excluded from analysis. Analysis of the percentage of total cells (data not 
shown) expressing phosphorylated JNK, showed inhibition of JNK 
phosphorylation in SP600125-treated cells, consistent with the Western 
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blotting data. These results therefore suggest JNK phosphorylation is not 
inhibited by SP600125 in viable cells.  
Further confirmation was therefore required regarding the ability of 
SP600125 to inhibit JNK signalling. SP600125 prevents the ability of JNK to 
phosphorylate downstream targets and c-Jun has been identified as an 
affected target; SP600125 inhibits c-Jun phosphorylation in a dose-dependent 
manner (Bennett et al., 2001). The phosphorylation of c-Jun, at Ser73, was 
measured following SP600125 and anisomycin treatment. As expected, flow 
cytometry showed c-Jun phosphorylation was inhibited by all concentrations 
of SP600125 tested. These results provide clarification that SP600125 can 
inhibit JNK signalling in U937 cells by preventing the phosphorylation of c-Jun. 
Due to the minimal effect on cell viability and the ability to inhibit JNK signalling, 
10 µM SP600125 was selected for use in future experiments.  
 
4.4.1.2 JNK-IN-8 
There are a limited number of published studies using JNK-IN-8 in cancer cells 
lines and no reports of its use specifically in U937 cells. High concentrations 
of JNK-IN-8 (greater than 5 µM) caused significant cell death in U937 cells and 
were therefore deemed unsuitable concentrations for this study. Low 
concentrations of JNK-IN-8 (less than 6.25 µM) did cause an increase in 
metabolic activity but this is unlikely to be due to the ability of JNK-IN-8 to 
enhance cell proliferation as c-Jun phosphorylation is critical for cell 
proliferation (Shaulian & Karin, 2001). A small decrease in cell viability and 
increase in late apoptosis/ secondary necrosis was observed following 
treatment with low concentrations of JNK-IN-8, which provides a possible 
explanation for the increase in metabolic activity as apoptosis is a 
metabolically active process (Elmore, 2007).  
During the development of the inhibitor, it was shown that JNK 
phosphorylation was not inhibited by JNK-IN-8 in human embryonic kidney 
293 (HEK293) cell line (Zhang et al., 2012). However a literature search shows 
this is the only cell line tested. Flow cytometry results showed the percentage 
of cells expressing phosphorylated JNK was decreased by JNK-IN-8 whilst 
Western blotting however showed JNK-IN-8 had no effect on JNK 
phosphorylation. Due to the mechanism of action of JNK-IN-8, it was not 
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expected that JNK phosphorylation would be affected by JNK-IN-8 treatment. 
However JNK-IN-8 could affect the phosphorylation of JNK indirectly due to 
signalling feedback mechanisms within the cells.  
The effect of JNK-IN-8 on the phosphorylation of c-Jun was measured. 
Flow cytometry results showed that c-Jun phosphorylation was inhibited by 
JNK-IN-8. Western blotting confirmed c-Jun phosphorylation was inhibited by 
JNK-IN-8, even at 1 µM. Inhibition of c-Jun phosphorylation by 1 µM or higher 
of JNK-IN-8 in U937 cells is in agreement with previous reports of c-Jun 
inhibition using similar concentrations of JNK-IN-8 in other cancer cells lines 
(Cerezo-Guisado et al., 2015; Zhang et al., 2012). Although these previous 
studies measured the phosphorylation of c-Jun at Ser63, whereas the 
antibody used in this study recognised c-Jun phosphorylated at Ser73, the 
results are consistent.  
Concentrations of JNK-IN-8 of less than 5 µM have typically been used 
in the studies utilising JNK-IN-8 in other cancer cell lines (Cerezo-Guisado et 
al., 2015; Fallahi-Sichani et al., 2015; Hsiao et al., 2014; Zhou et al., 2016). As 
the results of this study showed 1 and 2.5 µM JNK-IN-8 inhibited c-Jun 
phosphorylation, without having a large effect on cell viability, these 
concentrations of JNK-IN-8 were selected to use in combination with cell 
stressors.  
 
4.4.2 JNK inhibition and UV  
Inhibition of JNK signalling, using SP600125 made the U937 cells more 
susceptible to cell death induced by UV (Section 4.3.2.1), suggesting a 
protective role of JNK signalling against UV-induced apoptosis in U937 cells.  
Pre-treatment with the alternative JNK inhibitor, JNK-IN-8, however had no 
effect on cell death induced by UV (Section 4.3.2.2). These results were 
surprising, given that such striking differences were observed using SP600125 
(Section 4.3.2.1) and JNK-IN-8 is more effective at inhibiting JNK signalling 
than SP600125 (Section 4.3.1). It could be possible JNK signalling provides 
protection against UV-induced apoptosis via a pathway that involves JNK 
phosphorylation but not c-Jun phosphorylation. However, as JNK-IN-8 showed 
ability to inhibit JNK phosphorylation (Section 4.3.1.4), it was expected similar 
effects would have been observed for JNK-IN-8, as for SP600125. It is 
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possible the different effects observed using SP600125 and JNK-IN-8 could 
be related to differences in the specificities of the inhibitors.   
Whilst, it was originally believed SP600125 was selective for JNK 
(Bennett et al., 2001), other studies have since argued SP600125 is not 
specific for JNK (Bain, Plate, et al., 2007). In fact, SP600125 affects a range 
of other kinases with similar or greater potency than JNK. It is possible 
treatment with SP600125 inhibits JNK phosphorylation but causes activation 
of other signalling pathways involved in apoptosis. In contrast, JNK-IN-8 has 
been reported to be a highly selective inhibitor (Zhang et al., 2012), although 
the specificity has not been directly tested in U937 cells. Measuring the effects 
of JNK inhibition and UV treatment on the activation of JNK and other kinases 
would provide a greater understanding of the role of JNK signalling in UV-
induced apoptosis in U937 cells.  
It is well established UV activates the JNK signalling pathway which 
results in induction of apoptosis. The results presented in this chapter however 
suggest JNK signalling has a protective role against UV-induced apoptosis in 
U937 which contradicts previous findings in other cancer cell lines. JNK 
inhibition prevents UV-induced cell death in MCF-7 and MB-231 breast cancer 
cells (Mingo-Sion, Marietta, Koller, Wolf, Van, et al., 2004). PARP cleavage, 
an indicator of cell death, was induced by UV in both MCF-7 and MB-231 cells, 
and PARP cleavage was inhibited by SP600125. SP600125 was less effective 
at inhibiting UV-induced cell death in MB-231 cells compared to MCF-7 cells, 
which highlights the variability between cell lines within a particular disease. 
The study also demonstrated the involvement of c-Jun in response of MCF-7 
cells to UV; c-Jun was activated following UV treatment and was inhibited by 
SP600125. Inhibition of JNK, using SP600125 also prevented UV-induced 
apoptosis in ASTC-a-1 human lung adenocarcinoma cells (Li, Liu, Xing, & 
Chen, 2010). SP600125 delayed the mitochondrial translocation of the pro-
apoptotic protein Bax following UV treatment. JNK inhibition was achieved in 
both of these studies using SP600125, the same inhibitor as used in this study. 
As the results presented in this chapter conflict the results of these studies, 
and all studies utilised SP600125, the observations in this chapter are unlikely 
to be due to the poor specificity of SP600125 as previously discussed. 
Confirmation of the effects of SP600125 and UV treatment on MAPK 
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phosphorylation would provide clarification on this matter. It however appears 
that the role of JNK in UV-induced apoptosis is cell line specific. SP600125 
had no effect on UV-induced apoptosis in SH-SY5Y neuroblastoma cells. 
Despite inhibition of UV-induced phosphorylation of c-Jun by SP600125 
(Berglund, Radesäter, Persson, & Budd Haeberlein, 2004), caspase-3 activity 
and cytochrome c release were unaffected.  
As very different effects are observed following treatment with the JNK 
inhibitors SP600125 and JNK-IN-8, further investigations are required in order 
to confirm the involvement of JNK signalling in UV-induced cell death in U937 
cells. The use of alternative, selective inhibitors or JNK knockouts would 
provide clarification.  
 
4.4.3 JNK inhibition and chemotherapeutic agents  
Chemotherapy can induce apoptosis in cancer cells through the activation of 
JNK signalling, and the failure to activate JNK has been associated with 
chemotherapy resistance. The role of JNK signalling in response to 
chemotherapy appears to be specific to the type of cancer and the 
chemotherapeutic agent used. The aim here was to gain a greater 
understanding of the role of JNK signalling in doxorubicin and vincristine-
induced apoptosis in U937 cells.  
 
4.4.3.1 Doxorubicin 
Inhibition of JNK signalling, using SP600125, appeared to provide a level of 
protection against the doxorubicin-induced reduction in metabolic activity 
(Section 4.3.3.1). However, in order to draw valid conclusions from this data, 
further confirmation of the effect of SP600125 and doxorubicin on apoptosis is 
required. Protection against doxorubicin-induced reductions in metabolic 
activities were also observed when JNK signalling was inhibited using JNK-
IN-8 (Section 4.3.4.2). Measurement of active-caspase3/7 levels indicated that 
the differences in metabolic activities were due to differences in apoptosis. 
Lower levels of active caspase-3/7 were measured for doxorubicin-treated 
cells pre-treated with JNK-IN-8 compared to cells not pre-treated with JNK-IN-
8. However further work is needed to measure the time-dependent activation 
of caspase-3/7 following doxorubicin treatment.  
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Collectively, the results of JNK signalling inhibition, using SP600125 or 
JNK-IN-8, prior to doxorubicin treatment, provide a strong indication that JNK 
signalling plays an important role in doxorubicin-induced cell death. This study 
however only assessed the effects of JNK signalling inhibition and doxorubicin 
treatment on U937 cell viability. Measurement of the activation of JNK 
signalling components following these treatments would provide a greater 
insight into the mechanisms and involvement of JNK signalling in doxorubicin-
induced apoptosis in U937 cells. The activation of JNK following doxorubicin 
treatment has previously been reported in U937 cells (Lagadinou et al., 2008). 
 Lagadinou et al. (20008) also showed that downregulation of JNK1 
resulted in lower percentages of apoptotic cells following doxorubicin 
treatment compared to cells in which JNK signalling had not been inhibited, 
highlighting the importance of the JNK1 isoform. The results presented in this 
chapter support the findings of Lagadinou et al. (2008) but also suggest an 
important role of c-Jun phosphorylation. There is promising evidence that 
doxorubicin resistance can be reversed by the stimulation of JNK signalling. 
JNK was not activated in doxorubicin-resistant U937 cells but activation of JNK 
signalling in these resistant cells, by constitutive activation of MKK4, sensitised 
the cells to doxorubicin (Lagadinou et al., 2008). In vivo results show JNK 
activation failure in bone marrow cells from AML patients is associated with 
resistance to a similar anthracycline, daunorubicin (Lagadinou et al., 2008).  
 
4.4.3.2 Vincristine 
Collectively, the results presented in Section 4.3.3.3 suggest that inhibition of 
JNK signalling, using SP600125, protects U937 cells from vincristine-induced 
cell death. SP600125 and vincristine have previously been used in pre-B cell 
ALL cell lines and results showed that SP600125 did not alter the sensitivity 
of the cells to vincristine (Saunders, Cisterne, Weiss, Bradstock, & Bendall, 
2011). 
In contrast to SP600125, JNK-IN-8 did not appear to provide any 
protection against the metabolic effects of vincristine (Section 4.3.3.4). JNK-
IN-8 however provided some protection against vincristine-induced necrosis. 
The conclusions which can be drawn from the JNK-IN-8 and vincristine data 
are limited and further experiments are required to confirm the effects of JNK-
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IN-8 and vincristine on U937 cell death. Similarly to doxorubicin, this study is 
limited in the fact that the effects of JNK inhibition and vincristine treatment on 
the activation of JNK signalling components was not tested. Whilst vincristine-
induced activation of JNK has been reported in other cancer cells such as 
human epidermal carcinoma cells (Stone & Chambers, 2000), breast cancer 
cells (Wang et al., 1998) and B-cell lymphoma cells (Muscarella & Bloom, 
2008), the activation in leukaemia cells is less well reported. There appears to 
be no published reports of the effect of vincristine on JNK activation, 
specifically in U937 cells but JNK is activated in an alternative human leukemic 
monocyte cell line, THP-1 cells (Yoshida et al., 2011). JNK activation following 
vincristine treatment has also been reported ex vivo and in vivo in lymphocytes 
isolated from CLL patients (Bates, Lewis, Eastman, & Danilov, 2015).  
 
4.4.3 JNK inhibition and heat treatment 
Inhibition of JNK signalling, using SP600125 prior to heat treatment, had 
minimal effect on cell death after 24 h and 48 h (Section 4.4.4.1). This 
suggests JNK signalling does not have an important role in the response of 
U937 cells to heat treatment.  In contrast, inhibition of JNK signalling, using 
JNK-IN-8, made U937 cells more susceptible to heat treatment-induced cell 
death after 24 and 48 h (Section 4.4.4.2).  
Therefore there appears to be a difference in the ability of SP600125 and 
JNK-IN-8 to alter the susceptibility of U937 cells to heat-induced cell death. 
Heat shock proteins (HSPs) are able to protect cells from apoptosis caused by 
various cell stressors, including heat treatment (Creagh, Sheehan, & Cotter, 
2000; Kennedy, Jäger, Mosser, & Samali, 2014). It has been reported that 
HSPs, in particular HSPA1A provides protection against apoptosis by 
preventing the activation of JNK (Gabai et al., 1997; Mosser et al., 1997; 
Volloch, Mosser, Massie, & Sherman, 1998). SP600125 also prevents the 
activation of JNK signalling and it is therefore possible that SP600125 has no 
effect on heat-induced cell death as JNK activation is already supressed by 
heat shock proteins. The effects of SP600125 and heat treatment on heat 
shock protein expression and JNK activation however is required to confirm 
the involvement of JNK activation in heat-induced cell death in U938 cells. 
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The observation that JNK-IN-8 makes U937 cells susceptible to heat-
induced apoptosis suggests the importance of c-Jun phosphorylation in 
providing protection against heat-induced cell death. c-Jun is a downstream 
target of JNK activation, however as inhibition of JNK activation using 
SP600125 had minimal effect on heat-induced cell death, it is likely that the 
activation of c-Jun in response to heat-treatment is mediated by an alternative 
pathway to JNK signalling.  c-Jun is also a downstream target of ERK 
signalling (Cargnello & Roux, 2011; Leppä, Saffrich, Ansorge, & Bohmann, 
1998), therefore it is possible that the activation of c-Jun mediated by an 
alternative pathway such as ERK signalling, is important for mediating cell 
survival in U937 cells in response to heat treatment. Cross-talk between 
signalling pathways will be discussed further in Chapter 8. 
 
4.5 Summary 
The results presented in this chapter conclude that both SP600125 and JNK-
IN-8 are effective at inhibiting JNK signalling in U937 cells. Although 
SP600125 did not prevent the phosphorylation of JNK as expected, JNK 
signalling inhibition by both inhibitors was evident by the decreased 
phosphorylation of the downstream target c-Jun.  
 Whilst it has been established that JNK signalling is important for the 
transforming ability and survival of BCR/ABL-expressing CML cells (Dickens 
et al., 1997; Hess et al., 2002; Raitano et al., 1995) the role of JNK in the 
survival of other types of leukemic cells is not currently understood. The results 
presented in this chapter show inhibition of JNK signalling using SP600125 
sensitised U937 cells to UV-induced apoptosis, suggesting an important role 
of JNK signalling in mediating cell survival in response to UV, however 
inhibition of JNK using JNK-IN-8 did not alter the sensitivity of U937 cells to 
UV-induced apoptosis. Inhibition of JNK signalling, using JNK-IN-8 showed 
activation of c-Jun is important for mediating U937 cell survival in response to 
heat treatment, but this is likely to be controlled by a pathway other than JNK 
signalling as inhibition of JNK signalling using SP600125 had minimal effects 
on heat-induced cell death. Both JNK inhibitors, SP600125 and JNK-IN-8 
provided protection against doxorubicin and vincristine-induced cell death. 
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These results suggest that JNK signalling is required for U937 cell death-
induced by the chemotherapeutic agents vincristine and doxorubicin.  
 
 
Chapter 5: Targeting p38 signalling in U937 cell line 
 
150 
 
 
 
Chapter 5 
 
Targeting p38 signalling in U937 
cell line 
  
Chapter 5: Targeting p38 signalling in U937 cell line 
 
151 
 
Chapter 5: Targeting p38 signalling in U937 cell line 
5.1 Introduction 
In the previous chapter, the JNK signalling pathway was targeted in U937 cells 
in order to gain a greater understanding of the role of MAPK signalling in 
leukemic cell death. This chapter investigates the role of an alternative MAPK 
signalling pathway, the p38 pathway, which is activated by similar stimuli to 
the JNK signalling pathway.  
p38 signalling has been implicated in leukemogenesis; p38 signalling 
mediates the interaction between leukemic progenitors and the bone marrow 
stroma, which is required for the migration and survival of leukemic cells 
(Bendall et al., 2005; Gaundar et al., 2009; Juarez et al., 2009; Ringshausen 
et al., 2004). These studies however implicate the role of p38 in the 
development of the lymphocytic leukaemias, ALL and CLL. The role of p38 
signalling in the development and progression of myeloid leukaemias however 
remains poorly understood. Although it has been shown that p38 signalling is 
required for TNF-α-mediated survival and proliferation of AML cells (Liu, Fan, 
Liu, Olashaw, & Zuckerman, 2000), further research is needed to gain a more 
thorough understanding of the role of p38 signalling in the survival of myeloid 
leukemic cells.  
 The p38 signalling pathway is activated by stress stimuli, including 
chemotherapy drugs. It is therefore not surprising that activation of p38 is a 
common event following the treatment of leukemic cells with 
chemotherapeutic agents including: arsenic trioxide, interferon-α, rituximab 
and dasatinib (Dumka et al., 2009; Giafis et al., 2006; Maha et al., 2009; Mayer 
et al., 2001; Pedersen et al., 2002). The U937 model cell line will be used in 
this chapter to investigate the role of p38 signalling in the response of AML 
cells to chemotherapy. p38 activation has previously been shown to be 
essential for the induction of AML cell death in response to chemotherapeutic 
agents such as all-trans-retinoic-acid, arsenic trioxide, cytarabine and 
daunorubicin (Alsayed et al., 2001; Giafis et al., 2006; Maha et al., 2009). 
Inhibition of p38 signalling prevents cell death induced by these 
chemotherapeutic agents. Development of novel therapies to enhance p38 
activation in response to chemotherapy may be an approach to induce cell 
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death in leukemic cells. However in order for this to be successful, it is 
necessary to understand the role of p38 signalling in the response to specific 
chemotherapeutic agents; in this chapter the role of p38 in the response to 
vincristine and doxorubicin will be investigated. 
 
Aims 
The overall aim of this chapter is to gain a greater understanding of the role of 
p38 signalling in leukemic cell death using the model U937 cell line. This will 
be achieved by:  
• targeting p38 signalling using the small-molecule p38 inhibitors SB202190 
and SB203580; 
• determining the effects of p38 signalling inhibition on the susceptibility of 
U937 cells to various cell stressors (UV light, chemotherapeutic agents and 
heat treatment). 
 
A similar approach to that taken in Chapter 4 for JNK signalling will be taken 
in this chapter to investigate the role of p38 signalling in leukemic cell death. 
To gain a thorough understanding of the role of p38 signalling two inhibitors, 
SB202190 and SB203580, will be utilised. The effect of SB202190 and 
SB203580 on cell death and the activation of p38 signalling components will 
initially be tested. Following this, the inhibitors will each be used in combination 
with a range of cell stressors, and the effect on U937 cell death will be 
measured using multiple techniques.   
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5.2 Methods  
5.2.1 Cell culturing 
U937 cell line was cultured and maintained as described in Section 2.1.1. Prior 
to treatments, cells were prepared as described in Section 2.1.4.  
 
5.2.2 Treatment of U937 cells with p38 inhibitors 
The p38 inhibitors, SB202190 and SB203580, prepared as described in 
Section 2.2.1, were used in this chapter. U937 cells were treated with 
SB202190 and SB203580 as described in Section 2.2.1. 
 
5.2.3 Measurement of the effects of p38 inhibition on U937 cell death 
The effect of p38 inhibition on U937 cell death was assessed using: 
• MTS assay to measure metabolic activity (Section 2.4.1.3) 
• PI assay to measure necrosis (Section 2.4.1.4) 
 
5.2.4 Treatment of U937 cells with p38 inhibitor and anisomycin 
U937 cells were treated with the p38 inhibitors and anisomycin as described 
in Section 2.2.  
 
5.2.5 Measurement of the effects of p38 inhibition on MAPK activation 
The effect of p38 inhibition and anisomycin on the phosphorylation of p38 was 
measured by: 
• Western blotting (Section 2.3.1) 
• flow cytometry (Section 2.3.2) 
 
5.2.6 Treatment of U937 cells with p38 inhibitors and cell stressors 
U937 cells were treated with p38 inhibitors in combination with cell stressors, 
as described in Section 2.2. 
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5.2.7 Measurement of the effects of p38 inhibition and cell stressors on 
U937 cell death  
The effect of p38 inhibition and cell stressors on U937 cell viability was 
assessed using: 
• MTS assay to measure metabolic activity (Section 2.4.1.3) 
• PI assay to measure necrosis (Section 2.4.1.4) 
• FITC Annexin V FITC Apoptosis Detection Kit I to measure cell viability 
(Section 2.4.2.1) 
• SensoLyte® Homogeneous Rh110 Caspase-3/7 Assay Kit to measure 
active caspase 3/7 levels (Section 2.4.1.5) 
• microscopy to determine changes in cell morphology (Section 2.5) 
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5.3 Results 
5.3.1 Inhibition of p38 signalling 
5.3.1.1 Effect of SB202190 on U937 cell death  
In order to determine the effect of SB202190 on U937 cell death, the dose-
dependent effect of SB202190 on U937 metabolic activity was initially 
assessed. Treatment with 12.5 µM or less SB202190 did not cause a decrease 
in metabolic activity compared to untreated cells (Figure 5.1A). Metabolic 
activities were significantly reduced (P<0.001) following treatment with 25 to 
100 µM SP600125.  
In order to establish if the observed reductions in metabolic activity were 
due to cell death by necrosis, a PI assay was performed. Treatment with 50 
and 100 µM SB202190 resulted in a significant (P<0.0001) increase in the 
percentage of PI-positive cells, however treatment with 25 µM SB202190 or 
less had no significant effect on U937 necrosis (Figure 5.1B).  
The effect of 0 to 25 µM SB202190 on U937 cell death was investigated 
further by measuring annexin V binding and PI staining on the flow cytometer. 
Results confirmed concentrations of SB202190, 25 µM or less, had no 
significant effect on U937 cell viability (Figure 5.1C) and hence no effect on 
apoptosis (Figure 5.1D). Collectively, these results show 25 µM or less of 
SB202190 does not induce cell death in U937 cells and therefore these 
concentrations were selected to investigate the effect on p38 signalling.    
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C        D 
 
 
 
 
 
 
Figure 5.1: Effect of SB202190 on U937 cell death  
U937 cells were treated with various concentrations of SB202190 and then incubated at 37ºC 
for 24 h before an (A) MTS assay, (B) PI assay or (C,D)  BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical 
differences shown to untreated cells, calculated using one-way ANOVA with Dunnett’s post 
hoc test: * (P<0.05), ** (P<0.01), *** (P<0.001), **** (P<0.0001).  
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5.3.1.2 Effect of SB202190 on MAPK phosphorylation 
The effect of 0 to 25 µM SB202190 on MAPK phosphorylation was measured 
by flow cytometry and Western blotting. Pre-treatment with 3 µM SB202190 
had no significant effect on the percentage of cells expressing phosphorylated 
p38, compared to anisomycin-only treated cells (Figure 5.2A). Although 
phosphorylated-p38 MFI was significantly (P<0.01) reduced following 
treatment with 3 µM SB202190, the effects were minimal (Figure 5.2B). The 
percentages of cells expressing phosphorylated p38 were significantly 
reduced (P<0.0001) following pre-treatment with 12.5 and 25 µM SB202190 
(Figure 5.2A). Phospho-p38 MFIs were also significantly (P<0.01) decreased 
for cells pre-treated with 12.5 and 25 µM SB202190 (Figure 5.2B). These 
results showed 12.5 and 25 µM SB202190 can inhibit p38 phosphorylation. 
Western blotting confirmed 10 µM SB202190 inhibited p38 phosphorylation, 
and that this inhibition was not complete (Figure 5.2C).   
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Figure 5.2: Effect of SB202190 and anisomycin on p38 phosphorylation 
U937 cells were pre-treated with various concentrations of SB202190 at 37ºC for 1 h and then 
incubated with 1 µM anisomycin at 37ºC for 30 min. Cells were then prepared for (A,B) flow 
cytometry or (C) Western blotting. (A,B) Cells were fixed with 4% paraformaldehyde, 
permeabilised with 90% ice-cold methanol and stained with phospho-p38 (Thr180/Tyr182) 
Alexa Fluor 647-conjugated antibody. (A) shows the percentage of cells expressing phospho-
p38 and (B) shows phospho-p38 mean fluorescence intensity (MFI). Data presented as mean 
± SD, n=3. Statistical differences shown to anisomycin-only treated cells, calculated using 
one-way ANOVA with Dunnett’s post hoc test: ** (P<0.01), **** (P<0.0001). (C) Total protein 
was extracted and separated with SDS-PAGE electrophoresis using 4-15% precast gels. 
Proteins were electro-transferred to nitrocellulose membrane and phospho-p38 was detected 
by Western blotting using phospho-p38 (Thr180/Tyr182) and anti-rabbit peroxidase. 
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5.3.1.3 Effect of SB203580 on U937 cell death  
The effect of SB023580, an alternative p38 inhibitor, on U937 cell death was 
investigated. Assessment of the dose-dependent effect of SB203580 on U937 
metabolic activity showed treatment with up 25 µM SB202190 had no 
significant effect on metabolic activity compared to untreated cells (Figure 
5.3A). Metabolic activity was significantly (P<0.001) reduced following 
treatment with 50 and 100 µM SB203580. Treatment with 100 µM SB203580 
also caused a significant (P<0.0001) increase in the percentage of PI-positive 
cells (Figure 5.3B).  
Flow cytometry, assessing cell viability by measuring annexin V binding 
and PI staining, confirmed that treatment with 25 µM or less SB203580, had 
no significant effect on U937 cell viability and hence no effect on apoptosis 
(Figures 5.3C-D) 
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Figure 5.3: Effect of SB203580 on U937 cell death 
U937 cells were treated with various concentrations of SB203580 and then incubated at 37ºC 
for 24 h before an (A) MTS assay, (B) PI assay or (C,D) BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical 
differences shown to untreated cells, calculated using one-way ANOVA with Dunnett’s post 
hoc test: *** (P<0.001), **** (P<0.0001).  
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5.3.1.4 Effect of SB203580 on MAPK phosphorylation 
As 0 to 25 µM SB203580 had no effect on U937 cell death, the effect of 
concentrations of SB203580 up to 25 µM, on p38 phosphorylation, was 
assessed. Treatment with 3 to 25 µM SB203580 caused significant (P<0.05) 
decreases in the percentages of cells expressing phosphorylated p38, 
compared to anisomycin-only treated cells (Figure 5.4A). Although statistically 
significant, the reductions were minimal; the difference to untreated cells was 
only around 10%. Phospho-p38 MFIs were significantly (P<0.001) lower for 
cells pre-treated with 3 to 25 µM SB203580 prior to anisomycin treatment, 
compared to anisomycin-only treated cells, but the differences in phospho-p38 
MFIs were also minimal (Figure 5.4B). Western blotting showed that p38 
phosphorylation induced by anisomycin treatment, was not inhibited by 3 to 25 
µM SB203580 (Figure 5.4C).  
 To further investigate the effect of SB203580 on p38 signalling, the 
effect of SB203580 on MAPKAPK-2 phosphorylation, a downstream target of 
p38, was measured by Western blotting (Figure 5.4D). The bands of 
phosphorylated MAPKAPK-2 however were not clear. This, combined with the 
lack of a total MAPKAPK-2 blot limits the interpretation of these results. While 
no band corresponding to MAPKAPK-2 was detected in untreated U937 cells, 
a faint signal at <50 kDa was detected following anisomycin treatment. Due to 
the weakness of this signal, it is unclear if 10 µM SB203580 inhibited 
MAPKAPK-2 phosphorylation.  
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Figure 5.4: Effect of SB203580 and anisomycin on MAPK phosphorylation  
U937 cells were pre-treated with various concentrations of SB203580 at 37°C for 1 h and then 
incubated with 1 µM anisomycin at 37°C for 30 min. Cells were then prepared for (A,B) flow 
cytometry or (C,D) Western blotting. (A,B) Cells were fixed with 4% paraformaldehyde, 
permeabilised with 90% ice-cold methanol and stained with phospho-p38 (Thr180/Tyr182) 
Alexa Fluor 647-conjugated antibody. (A) shows the percentage of cells expressing phospho-
p38 and (B) shows phospho-p38 mean fluorescence intensity (MFI). Data presented as mean 
± SD, n=3. Statistical differences shown to anisomycin-only treated cells, calculated using 
one-way ANOVA with Dunnett’s post hoc test: * (P<0.05), ** (P<0.01), *** (P<0.001), **** 
(P<0.0001). (C,D) Total protein was extracted and separated with SDS-PAGE electrophoresis 
using 4-15% precast gels. Proteins were electro-transferred to nitrocellulose membrane and 
(C) phospho-p38 was detected by Western blotting using phospho-p38 (Thr180/Tyr182) and 
anti-rabbit peroxidase or (D) phospho-MAPKAPK-2 was detected by Western blotting using 
phospho-MAPKAPK-2 (Thr222) and anti-rabbit peroxidase. 
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5.3.2 Effect of p38 inhibition and UV light  
5.3.2.1 Effect of SB202190 and UV light on U937 cell death  
To investigate the role of JNK signalling in UV-induced cell death, U937 cells 
were treated with 10 µM SB202190 prior to treatment with various durations 
of UV light. For cells treated with 15 to 30 s UV, metabolic activities were 
significantly (P<0.0001) lower for cells pre-treated with 10 µM SB202190 
compared to those not pre-treated with SB202190 (Figure 5.5A). Results of 
the PI assay showed SB202190 had no significant effect on the percentages 
of PI-positive cells (Figure 5.5B) and therefore the differences observed in 
metabolic activities (Figure 5.5A) were not due to necrosis.  
Flow cytometry results confirmed inhibition of p38 signalling by 
SB202190 increased the susceptibility of U937 cells to UV-induced cell death. 
For cells treated with 10 and 15 s UV, cell viability was significantly (P<0.001) 
lower for cells pre-treated with SB202190 compared to cells not treated with 
SB202190 (Figure 5.5.C). These differences were not due to early apoptotic 
cells (Figure 5.5D) but were due to significant (P<0.001) increases in the 
percentages of late apoptotic/secondary necrotic cells (Figure 5.5.E).  
Microscopy images provided further confirmation of the effects of 
SB202190 and UV on U937 cell death (Figure 5.5F). In the absence of UV 
light, cells not pre-treated with SB202190 appeared healthy and did not stain 
with PI, whereas whilst the majority of cells pre-treated with SB202190 also 
appeared healthy, a few were misshapen and stained with PI. Some of the 
cells treated with 9 s UV, but not pre-treated with SB202190, appeared 
apoptotic and stained with PI, however, a small number of cells appeared 
viable. For cells treated with 10 µM SB202190 prior to UV light treatment, all 
cells appeared apoptotic and the majority stained with PI and showed 
fragmented nuclei. Taken together, these results show that inhibition of p38 
signalling using SB202190 increases the susceptibility of U937 cells to UV-
induced cell death.  
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Figure 5.5: Effect of SB202190 and UV light treatment on U937 cell death 
U937 cells were pre-treated with 0, 10 or 25 µM SB202190 at 37°C for 1 h to inhibit p38 
signalling. Cells were then treated with various durations of UV light. After 24 h incubation at 
37°C, an (A) MTS assay, (B) PI assay, (C-E) BD PharmingenTM FITC Annexin V Apoptosis 
Detection Kit I or (F) microscopy were performed. Data presented as mean ± SD; n=3. 
Statistical differences shown between SB202190 and no inhibitor at UV time points, calculated 
using two-way ANOVA with Sidak’s post hoc test: *** (P<0.001), **** (P<0.0001). (F) Cells 
were stained with PI staining solution and visualised using EVOSTMFL AutoCell Imaging 
System at 40 X magnification. Arrows indicate apoptotic cells. Images shown are 
representative of 3 individual images collected. 
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5.3.2.2 Effect of SB203580 and UV light on U937 cell death  
To further investigate the role of p38 signalling in UV-induced cell death, U937 
cells were pre-treated with SB203580 prior to treatment with various durations 
of UV light. Due to the inconclusive data showing the ability of SB203580 to 
inhibit p38 signalling, the effect of both 10 and 25 µM SB203580 were 
investigated. For cells treated with 15 to 40 s UV, pre-treatment with either 10 
or 25 µM SB203580, caused significant (P<0.05) reductions in metabolic 
activities compared to cells treated without SB203580 (Figure 5.6A and Table 
5.1). There were no significant differences in necrosis between SB203580-
treated cells and those treated without SB203580, when treated with 0 to 10 s 
UV light (Figure 5.6B and Table 5.1). For 15 to 50 s UV, there were significantly 
(P<0.05) more PI-positive cells for SB203580-treated cells compared to cells 
not treated with SB203580, when treated with equivalent durations of UV light. 
The differences in metabolic activities and the percentages of PI-positive cells 
were however minimal.  
Flow cytometry results showed that cell viability was only significantly 
(P<0.0001) lower for cells pre-treated with SB203580 compared to cells not 
treated with SB203580, when treated with 6 s UV light (Figure 5.7A). For other 
durations of UV light, no significant differences in viabilities were measured as 
the percentages of apoptotic cells were higher (Figure 5.7B), but the 
percentages of late apoptotic cells were lower (Figure 5.7C), for cells not pre-
treated with SB203580 compared to cells treated with SB203580.  
Microscopy images also indicated that pre-treating cells with SB203580 
prior to UV treatment resulted in increased cell death (Figure 5.7D). For cells 
pre-treated with SB203580 prior to 6 s UV light, a greater number of cells 
appeared apoptotic and the majority stained with PI and showed fragmented 
nuclei. Taken together, the results indicate that SB203580 can increase the 
susceptibility of U937 cells to UV, however the effect is minimal.   
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Figure 5.6: Effect of SB203580 and UV light treatment on U937 metabolic 
activity and necrosis, measured by MTS and PI assays 
U937 cells were pre-treated with 0, 10 or 25 µM SB203580 at 37°C for 1 h to inhibit p38 
signalling and then treated with various durations of UV light. After 24 h incubation at 37°C, 
an (A) MTS assay and (B) PI assay were performed. Data presented as mean ± SD; n=4.  
 
 
Table 5.1: Statistical analysis to show the effects of SB203580 and UV light 
treatment on U937 metabolic activity and necrosis 
Data presented as mean ± SD; n=4. Statistical differences shown between SB203580 and no 
inhibitor at UV time points, calculated using two-way ANOVA with Tukey’s post hoc test: * 
(P<0.05), ** (P<0.01), *** (P<0.001), **** (P<0.0001). 
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Figure 5.7: Effect of SB203580 and UV light treatment on U937 cell death 
U937 cells were pre-treated with 0 or 10 µM SB203580 at 37°C for 1 h to inhibit p38 signalling 
and then treated with various durations of UV light. After 24 h, (A) cell viability, (B) apoptosis 
and (C) late apoptosis/secondary necrosis were measured using BD PharmingenTM FITC 
Annexin V Apoptosis Detection Kit Ior (D) microscopy was performed. Data presented as 
mean ± SD, n=3. Statistical differences shown between SB203580 and no inhibitor at UV time 
points, calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), 
*** (P<0.001), **** (P<0.0001).  (D) Cells were stained with PI staining solution and visualised 
using EVOSTMFL AutoCell Imaging System at 40 X magnification. Arrows indicate apoptotic 
cells. Images shown are representative of 3 individual images collected. 
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5.3.3 Effect of p38 inhibition and chemotherapy 
5.3.3.1 Effect of SB202190 and doxorubicin on U937 cell death 
The role of p38 signalling in doxorubicin-induced cell death was initially 
assessed by measuring metabolic activity following SB202190 and 
doxorubicin treatment. For cells treated with 0 to 0.8 doxorubicin, there were 
no significant differences in metabolic activities between cells pre-treated with 
and without SB202190 (Figure 5.8A). For cells treated with 1.56 to 50 µM 
doxorubicin, metabolic activities were significantly (P<0.01) lower for cells pre-
treated with SB2021290 compared to cells not pre-treated with SB202190, 
when treated with equivalent concentrations of doxorubicin.  
 To determine if the observed differences in metabolic activities were 
due to differences in apoptosis, active caspase-3/7 levels were measured 
following SB202190 and doxorubicin treatment. For cells treated with 0 to 15 
µM doxorubicin, no significant differences in active caspase-3/7 levels were 
measured between cells treated with SB202190 and cells not treated with 
SB202190 (Figure 5.8B). Active caspase levels were significantly (P<0.0001) 
higher for U937 cells pre-treated with SB202190 compared to cells not treated 
with SB202190, when treated with 25 µM doxorubicin; however, the levels 
were only around 2-fold higher. It is possible that 9 h was not the most 
appropriate time point to measure caspase-3/7 activation.  
For cells treated with 10 and 25 µM doxorubicin, there did not appear to 
be any morphological differences in U937 cells, between cells pre-treated with 
and without SB202190 (Figure 5.8C). All doxorubicin-treated cells appeared 
apoptotic; cells appeared misshapen and some, but not all cells stained with 
DAPI. Taken together, there is limited evidence to suggest the direct role of 
p38 in doxorubicin-induced cell death in U937 cells.   
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A                   B  
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Figure 5.8: Effect of SB202190 and doxorubicin on U937 cell death  
U937 cells were pre-treated with 0 or 10 µM SB202190 at 37°C for 1 h to inhibit p38 signalling 
and then treated with various concentrations of doxorubicin. Cells were then incubated at 37°C 
for (A) 24 h before an MTS assay or (B) 9h before active caspase-3/7 levels were measured 
using SensoLyte® Homogeneous Rh110 Caspase-3/7 Assay Kit. Statistical differences shown 
between SB2021900 and no inhibitor at doxorubicin concentration points, calculated using 
two-way ANOVA with Sidak’s post hoc test: ** (P<0.01), *** (P<0.001), **** (P<0.0001). (C) 
Cells were stained with DAPI 24h after treatment and visualised using EVOSTMFL AutoCell 
Imaging System at 40 X magnification. Black and white arrows indicate late apoptotic cells. 
Images shown are representative of 3 individual images collected 
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5.3.3.2 Effect of SB203580 and doxorubicin on U937 cell death  
The effect of SB203580 and doxorubicin treatment on U937 metabolic activity 
was assessed and results showed no significant differences in metabolic 
activities between cells pre-treated with SB203580 and cells not pre-treated 
with SB203580, when treated with equivalent concentrations of doxorubicin, 
apart from 1.56 µM doxorubicin (Figure 5.9A). For all concentrations of 
doxorubicin tested, there were no significant differences in active caspase-3/7 
levels between cells pre-treated with and without SB203580 (Figure 5.9B). 
These results confirm SB203580 has no significant effect on doxorubicin-
induced cell death in U937 cells. This however could be due to the 
ineffectiveness of SB203580 to inhibit 38 signalling. 
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A       B 
 
 
 
 
 
 
 
Figure 5.9: Effect of SB203580 and doxorubicin on U937 cell death  
U937 cells were pre-treated with 0 or 10 µM SB203580 at 37°C for 1 h to inhibit p38 signalling 
and then treated with various concentrations of doxorubicin. Cells were then incubated at 37°C 
for (A) 24 h before an MTS assay was performed or (B) 9h before active caspase-3/7 levels 
were measured using SensoLyte® Homogeneous Rh110 Caspase-3/7 Assay Kit. Data 
presented as mean ± SD; n=3. Statistical differences shown between SB203580 and no 
inhibitor at doxorubicin concentration points, calculated using two-way ANOVA with Sidak’s 
post hoc test: ** (P<0.01). 
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5.3.3.3 Effect of SB202190 and vincristine on U937 cell death 
The role of p38 signalling in response to vincristine, an alternative 
chemotherapeutic agent was investigated. Initially the effect of SB202190 and 
vincristine treatment on U937 metabolic activity was measured. For U937 cells 
treated with 0.2 and 0.4 nM vincristine, metabolic activities were significantly 
(P<0.01) lower for cells pre-treated with SB202190 compared to cells not pre-
treated with SB202190, when treated with equivalent concentrations of 
vincristine (Figure 5.10A). For U937 cells treated with 1.56 to 100 nM 
vincristine, metabolic activities for SB202190-treated cells were significantly 
(P<0.01) higher than cells not treated with SB202190, when treated with 
equivalent concentrations of vincristine. It was shown that the differences in 
metabolic activities were not due to cell death by necrosis (data not shown).  
Assessment of cell viability, using flow cytometry, confirmed cell 
viabilities were significantly (P<0.0001) higher for cells pre-treated with 
SB202190 prior to vincristine treatment compared to cells not pre-treated with 
SB202190 (Figure 5.10B). The differences in cell viabilities were due mainly 
to lower percentages of apoptotic cells for cells pre-treated with SB202190, 
prior to vincristine treatment (Figure 5.10C), but also small differences in the 
percentages of late apoptotic/secondary necrotic cells (Figure 5.10D). 
Fluorescence microscopy images were consistent with the results of the 
MTS assay and flow cytometry. For cells treated with 25 nM vincristine, without 
SB202190, the majority of cells appeared misshapen and PI staining showed 
fragmented nuclei (Figure 5.10D). For cells treated with SB202190 prior to 
vincristine, fewer cells appeared apoptotic and several cells which appeared 
healthy and did not stain with PI, were present. Taken together, these results 
suggest inhibiting p38 signalling using SB202190 provides U937 cells with 
protection against cell death.  
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Figure 5.10: Effect of SB202190 and vincristine on U937 cell death 
U937 cells were pre-treated with 0 or 10 µM SB202190 at 37°C for 1 h to inhibit p38 signalling 
and then treated with various concentrations of vincristine. Cells were then incubated at 37°C 
for 24 h before an A) MTS assay or (B-D) BD PharmingenTM FITC Annexin V Apoptosis 
Detection Kit I or (E) microscopy were performed. Data presented as mean ± SD; n=3. 
Statistical differences shown between SB202190 and no inhibitor at vincristine concentration 
points, calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), 
*** (P<0.001), **** (P<0.0001). (E) Cells were stained with PI staining solution 24h after 
treatment and visualised using EVOSTMFL AutoCell Imaging System at 40 X magnification. 
Black and white arrows indicate late apoptotic cells. Images shown are representative of 3 
individual images collected 
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5.3.3.4 Effect of SB203580 and vincristine on U937 cell death  
The role of p38 signalling in response to vincristine was investigated further 
utilising SB203580. Significant differences (P<0.05) between cells treated with 
and without SB203580 were only observed for cells treated with 0.1 and 0.8 
nM (Figure 5.11A). The differences were however minimal; differences in 
metabolic activities for these concentrations were less than 10%. Results of 
the PI assay showed that for cells treated with 0.8 to 100 nM vincristine, the 
percentages of necrotic cells were significantly (P<0.05) higher for cells pre-
treated with SB203580 (Figure 5.11B). Although significant, the differences 
were less than 5%. SB2023580 therefore has minimal effect on vincristine-
induced cell death.  
 
A B 
 
 
 
 
 
Figure 5.11: Effect of SB203580 and vincristine on U937 cell death 
U937 cells were pre-treated with 0 or 10 µM SB203580 at 37°C for 1 h to inhibit p38 signalling. 
Cells were then treated with various concentrations of vincristine. Cells were then incubated 
at 37°C for 24 h before an (A) MTS assay or (B) PI assay was performed. Data presented as 
mean ± SD; n=3. Statistical differences shown between SB203580 and no inhibitor at 
vincristine concentration points, calculated using two-way ANOVA with Sidak’s post hoc test: 
* (P<0.05), ** (P<0.01), **** (P<0.0001). 
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5.4.4 Effect of p38 inhibition and heat treatment  
5.4.4.1 Effect of SB202190 and heat treatment on U937 cell death  
The effect of p38 inhibition and heat treatment was initially investigated using 
SB202190. Assessment of metabolic activity after 24 h showed this was 
significantly (P<0.0001) lower for heat treated cells compared to non-heat 
treated cells, when pre-treated with equivalent concentrations of SB202190 
(Figure 5.12A). However, there was a similar difference in metabolic activity 
between heat treated and non-heat treated cells in the absence of SB202190.  
A greater difference was observed for 50 µM SB202190.  
Results of flow cytometry (Figures 5.12B-D), assessing cell viability 24 h 
after treatment are consistent with the results observed by the MTS assay. 
Cell viabilities were significantly (P<0.01) lower for heat treated cells compared 
to non-heat treated cells, in both the presence and absence of SB202190, with 
the greatest difference being observed for 50 µM SB202190 (Figure 5.12B). 
SB202190 and heat treatment had minimal effect on early apoptosis (Figure 
5.12C), the lower cell viabilities were due to significant (P<0.01) increases in 
the percentages of late apoptotic/secondary necrotic cells (Figure 5.12D).   
After 48 h, there were no significant differences in metabolic activities 
between heat treated and non-heat treated cells pre-treated with 0 to 25 µM 
SB202190 (Figure 5.12E). For cells pre-treated with 50 µM SB202190, the 
metabolic activity for heat treated cells was significantly (P<0.0001) lower. 
SB202190 and heat treatment also had minimal effects on necrosis after 48 h 
(data not shown).  
Assessment of cell viability after 48 h using flow cytometry however 
showed that for cells pre-treated with 12.5 to 50 µM SB202190, cell viabilities 
were significantly (P<0.01) lower for heat treated cells compared to non-heat 
treated cells (Figure 5.12F). The decrease in cell viabilities for heat treated 
cells, pre-treated with SB202190, was due to increases in both the 
percentages of apoptotic (Figure 5.12G) and late apoptotic/secondary necrotic 
(Figure 5.12H).   
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Figure 5.12: Effect of SB202190 & heat treatment on U937 cell death  
U937 cells were pre-treated with SB202190 at 37ºC for 1 h to inhibit p38 signalling and then 
incubated at either 37°C or 42ºC for 1 h. Cells were then incubated at 37°C for (A-D) 24 h or 
(E-H) 48h before an (A,E) MTS assay, (B-D,F-H) BD PharmingenTM FITC Annexin V Apoptosis 
Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical differences 
shown between heat treatment and no treatment at SB202190 concentration points, 
calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), *** 
(P<0.001). 
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5.3.4.2 Effect of SB203580 and heat treatment on U937 cell death  
The role of p38 signalling in the response to heat treatment was further 
investigated using SB203580.  For cells treated with 1.56 to 50 µM SB203580, 
significant (P<0.05) difference in metabolic activities between heat treated and 
non-heat treated cells were measured after 24 h (Figure 5.13A), however the 
differences were minimal. SB203580 and heat treatment also had little effect 
on necrosis after 24 h (data not shown).  
Assessment of cell viability after 24 h, using flow cytometry, showed cell 
viabilities were significantly (P<0.01) lower for heat treated cells compared to 
non-heat treated cells when treated with 12.5 to 50 µM SB203580 (Figure 
5.13B). These observed differences were due to significantly (P<0.05) higher 
percentages of apoptotic and late apoptotic/secondary necrotic cells for heat 
treated cells (Figures 5.13C-D). Cell viability was however also significantly 
(P<0.0001) lower for heat treated cells, compared to non-heat treated cells, in 
the absence of SB203580 treatment (Figure 5.13B).  
After 48 h, inhibiting p38 using SB203580, appeared to have little effect 
on the difference in metabolic activities between heat treated and non-heat 
treated cells (Figure 5.13E). Flow cytometry confirmed there were no 
significant differences in cell viabilities between heat treated and non-heat 
treated cells for cells pre-treated with 0 to 25 µM SB203580, but the cell 
viability was significantly (P<0.001) lower for heat treated cells pre-treated with 
50 µM SB203580 (Figure 5.13F). The observed difference for 50 µM was due 
to significantly higher percentages of apoptotic (P<0.0001) and late apoptotic 
(P<0.001) cells for heat treated compared to non-heat treated cells (Figures 
5.13G-H). Taken together, the results suggest inhibition of p38 signalling using 
SB203580 has minimal effect on heat-induced changes in cell death after both 
24 and 48 h.  
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Figure 5.13: Effect of SB23580 and heat treatment on U937 cell death  
U937 cells were pre-treated with SB203580 at 37ºC for 1 h to inhibit p38 signalling and then 
incubated at either 37°C or 42ºC for 1 h. Cells were then incubated at 37°C for (A-D) 24 h or 
(E-H) 48h before an (A,E) MTS assay, (B-D,F-H) BD PharmingenTM FITC Annexin V Apoptosis 
Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical differences 
shown between heat treatment and no treatment at SB203580 concentration points, 
calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), *** 
(P<0.001). 
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5.4 Discussion 
The overall aim of this chapter was to gain a greater understanding of the role 
of p38 signalling in leukemic cell death by studying the effects of p38 signalling 
inhibition and cell stressors on cell death in the model U937 cell line.  
 
5.4.1 Inhibition of p38 signalling 
The p38 inhibitors, SB202190 and SB203580, were used to target p38 
signalling in this study. SB202190 and SB203580 are structurally similar ATP-
competitive inhibitors and have both been used extensively in in vitro studies 
to investigate the role of p38. SB202190 binds to p38 kinase in the ATP 
binding pocket and prevents the phosphorylation of p38 (Fox et al., 1998). 
SB203580 binds to the ATP binding pocket of p38, and prevents p38 catalytic 
activity (Young et al., 1997), but does not inhibit the phosphorylation of p38 by 
upstream kinases (Sanjay Kumar, Jiang, Adams, & Lee, 1999). The aim here 
was to confirm the inhibition of p38 signalling in U937 cells, using both 
SB202190 and SB203580, and to establish effective concentrations to use in 
combination with cell stressors.  
 
5.4.1.1 SB202190 
The effect of SB202190 on U937 cell death was assessed and results showed 
concentrations of SB202190, 25 µM or less, had minimal effects on U937 cell 
death (Section 5.3.1.1). Western blotting and flow cytometry confirmed p38 
phosphorylation was inhibited by 10 µM or higher SB202190 (Section 5.3.1.2). 
Only partial inhibition of p38 phosphorylation was achieved using 10 µM 
SB202190, which was consistent with flow cytometry data for 12.5 µM 
SB202190. SB202190 is selective for p38α and p38β compared to the p38ƴ 
and p38σ isoforms (Davies, Reddy, Caivano, & Cohen, 2000). Neither of the 
techniques used in this study to measure p38 phosphorylation were able to 
establish the effects of SB202190 on the different p38 isoforms as both the 
antibodies used recognise all isoforms of p38 dually phosphorylated at Thr180 
and Tyr182. In order to confirm the ability of SB202190 to specifically inhibit 
the phosphorylation of p38α and p38β isoforms in U937 cells, antibodies 
specific for these isoforms would need to be used.  
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The effect of SB202190 on other MAPKs was not tested in this chapter, 
as it was believed SB202190 is highly selective for p38α and p38β compared 
to a range of other, closely related protein kinases (Davies et al., 2000). Whilst 
kinase assays have shown that SB202190 is selective for p38 inhibition, 
compared to JNK inhibition (Davies et al., 2000), in cell-based experimental 
systems, SB202190 induces activation of JNK in A459 lung carcinoma cells 
and MCF-7 breast cancer cells (Muniyappa & Das, 2008). Although this is the 
case for A459 and MCF-7 cells, it is possible SB202190 could activate JNK in 
U937 cells; further testing is necessary to confirm if this is the case.     
Previous studies have utilised SB202190 in U937 cells, at concentrations 
of 10 µM (Liu & Chang, 2010) and 20 µM (Huh, Kang, Chae, & Kim, 2004). 
Although both studies showed 10 and 20 µM SB202190 had no effect on cell 
viability, which is consistent with the results presented in this chapter, neither 
studies confirmed the inhibition of p38 phosphorylation using these 
concentrations of SB202190. As the results presented here showed that 10 
SB202190 was able to inhibit p38 phosphorylation, but had minimal effect on 
cell viability, 10 µM was selected as an appropriate concentration of SB202190 
to pre-treat cells with prior to treatment with cell stressors. 
 
5.4.1.2 SB203580  
The effect of an alternative p38 inhibitor, SB2035800, on U937 cell death was 
assessed and results showed SB203580 concentrations of 25 µM or less had 
no effect on U937 cell death (Section 5.3.1.3)  
Initially the effect of SB203580 on p38 phosphorylation was measured 
using Western blotting and flow cytometry (Section 5.3.1.4). Flow cytometry 
showed p38 phosphorylation was inhibited by SB203580 but only very low 
levels of inhibition were achieved. Western blotting showed SB203580 had no 
effect on p38 phosphorylation. The minimal effect of SB203580 on p38 
phosphorylation was as expected as SB203580 inhibits the catalytic activity of 
p38 and prevents the phosphorylation of downstream targets, rather than 
preventing the phosphorylation of p38 itself, by upstream targets (Sanjay 
Kumar et al., 1999). 
Therefore, further confirmation of p38 signalling inhibition in U937 cells, 
using SB203580, was required. The phosphorylation of MAPKAPK-2 was 
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selected for investigation as SB203580 has previously been shown to inhibit 
the activation of MAPKAPK-2 and subsequent phosphorylation of HSP27 
(Cuenda et al., 1995). The effect of SB203580 on the phosphorylation of 
MAPKAPK-2 was measured in this chapter by Western blotting but the 
Western blot was not clear; further optimisation of phospho-MAPKAPK-2 blot 
is needed. Without confirmation of the effect of SB203580 on MAPKAPK-2 
phosphorylation, there is limited evident to show SB203580 is effective at 
inhibiting p38 signalling in U937 cells. This therefore limits the conclusions 
which can be drawn in future sections, where SB203580 is used in 
combination with cell stressors.  
10 µM SB203580 has however been typically used in studies utilising 
U937 cells (Cuozzo, Raciti, Bertelli, Parente, & Di Renzo, 2012; Hisatsune et 
al., 2008; Hyun Soo Park et al., 2013; Tauchi et al., 2006; Wang, Zhou, He, & 
Chen, 2007;Zhang et al., 2012). As the results of this chapter show 10 and 25 
µM SB203580 has minimal effect of U937 cell death, and achieves low levels 
of p38 phosphorylation inhibition, 10 and 25 µM SB203580 were selected for 
use in combination with cell stressors.  
 
5.4.2 p38 inhibition and UV  
The effect of p38 inhibition and UV light on U937 cell death was initially 
investigated in combination with SB202190 and results showed pre-treatment 
with SB202190 increased the susceptibility of U937 cells to UV-induced cell 
death (Section 5.3.2.1). The effect of p38 signalling inhibition and UV on U937 
cell death was investigated further using the alternative p38 inhibitor, 
SB203580 (Section 5.3.2.2). Results showed that although SB203580 
increased the susceptibility of U937 cells to UV, the effect was minimal. The 
effects observed using SB203580 were not as great as those observed using 
SB202190, but this is likely to be due to different levels of p38 inhibition 
achieved by the different p38 inhibitors.    
Although it is widely believed UV light activates p38 signalling and 
subsequent apoptosis, p38 has also been implicated in providing protection 
against UV-induced apoptosis (Chouinard, Valerie, Rouabhia, & Huot, 2002; 
Gupta, Hoffman, & Liebermann, 2006; Ivanov & Ronai, 2000; Nemoto, Xiang, 
Huang, & Lin, 1998a). However, there is conflicting evidence for the role of 
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p38 signalling in UV-induced cell death specifically in U937 cells. Inhibition of 
p38 signalling, using SB203580, has been reported to have no effect on U937 
cell death induced by UV light (Franklin, Srikanth, Kraft, & Prescott, 1998). An 
alternative study has argued SB203580 increases the level of UV-induced 
apoptosis (Luchetti et al., 2009); the results presented in this chapter are in 
agreement with this study, but in addition, the results presented in the chapter 
confirm the effect using an additional p38 inhibitor, SB202190. In this thesis, 
cell death was measured by MTS assay and annexin V binding/ PI staining; 
Luchetti et al (2009) also used annexin V binding/PI staining to measure 
apoptosis, but in addition confirmed the effects on cell death by measuring 
total caspase activity and intracellular levels of Bcl-2. The study showed 
SB203580 and UV light treatment had no effect on the total number of 
apoptotic cells, compared to UV-only treated cells. SB203580 resulted in a 
lower percentage of cells in the early stages of apoptosis and a higher 
percentage of late apoptotic/secondary necrotic cells; the results presented in 
this chapter are in agreement with these findings. Franklin et al. (1998) used 
10 µM SB203580, as was used in this chapter, but cell death was assessed at 
a different time point (8 h following UV treatment) and using different methods 
(caspase-3 activity and DNA fragmentation) which could account for the 
inconsistency in the results. Luchetti et al (2009) also showed the effects of 
SB203580 and UV light on p38, and additionally ERK phosphorylation. In order 
to understand the mechanism underlying the observed findings, the effects of 
SB202190 and SB203580 on MAPK phosphorylation and other proteins needs 
to be investigated.  
 
5.4.3 p38 inhibition and chemotherapeutic agents  
The aim of this section was to investigate the role of p38 signalling in 
doxorubicin and vincristine-induced apoptosis is U937 cells in order to gain a 
greater understanding of the mechanisms of chemotherapy resistance in 
leukaemia.  
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5.4.3.1 Doxorubicin 
The effect of SB202190 and doxorubicin treatment on U937 cell death was 
assessed and results showed inhibition of p38 signalling, using SB202190 
increased the susceptibility of U937 cells to doxorubicin-induced reductions in 
metabolic activity (Section 5.3.3.1). Measurement of active caspase-3/7 levels 
however showed pre-treatment with SB202190 had no effect on doxorubicin-
induced apoptosis. Further work is required to confirm the effect of SB202190 
and doxorubicin on apoptosis.  
Cell death following treatment with an alternative p38 inhibitor, 
SB203580, and doxorubicin was investigated and it was shown SB203580 had 
no effect on doxorubicin-induced cell death in U97 cells (Section 5.3.3.2). 
SB203580. However, without confirmation of the effects of 10 µM SB203580 
on p38 signalling (as discussed in Section 5.4.1.2), it is not clear whether the 
lack of observed differences was due to the redundant role of p38 signalling in 
doxorubicin-induced cell death or due to the inhibitor not effectively inhibiting 
p38 signalling.  
p38 is activated in response to doxorubicin treatment in a range of cancer 
cell lines such as KB-3 cervical adenocarcinoma cells (Stone & Chambers, 
2000) and lung cancer cells  (Elsea, Roberts, Druker, & Wood, 2008) and p38 
signalling has been associated with resistance to doxorubicin (Chen et al., 
2012; Tan, Yu, & Luo, 2014). p38 activation is involved in the resistance of 
gastric cancer cells to doxorubicin as inhibition of p38 signalling, using 
SB203580, reduced the viability of doxorubicin-treated gastric cancer cells 
(Tan et al., 2014). SB203580 and doxorubicin caused an increase in intrinsic 
(mitochondrial) apoptosis, as evident by an increase in the expression of the 
pro-apoptotic protein Bax and a decrease in the expression of the anti-
apoptotic protein Bcl-2. SB203580 and doxorubicin treatment also suppressed 
tumour growth in vivo. In specific relation to leukaemia, a previous study has 
implicated the role of p38 signalling in doxorubicin resistance in an alternative 
leukemic cell line, K562 cells (Chen et al., 2012). Inhibition of p38 signalling, 
using SB202190, reduced doxorubicin-induced drug resistance in K562 cells 
which was associated with the decreased expression of P-glycoprotein (PGP) 
and multidrug resistance protein 1 (MDR1). The results presented in this 
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chapter using U937 cells, are in agreement with the study conducted by Chen 
et al. in K562 cells.  
 
5.4.3.2 Vincristine  
 Cell death following SB202190 and vincristine treatment was assessed, and it 
was shown that inhibition of p38 signalling, using SB202190, provides 
protection against vincristine-induced apoptosis in U937 cells. (Section 
5.3.3.3). In contrast, inhibition of p38 signalling, using SB203580 had minimal 
effects on vincristine-induced changes in cell death (Section 5.3.3.4). Given 
the striking differences observed using SB202190, it was expected that similar 
results would be observed using SB203580. However, without confirmation of 
p38 signalling inhibition by 10 µM SB203580, as discussed in Section 5.4.1.2, 
no firm conclusions can be drawn from the data for SB203580. It is possible, 
that greater differences in cell death might be observed if higher 
concentrations of SB203580 were used.  
Previous studies have implicated the role of p38 signalling in the 
resistance of cancer cells to vincristine treatment. Levels of phosphorylated 
p38 were higher in vincristine-resistant mouse lymphocytic leukaemia L1210 
cells, compared to vincristine-sensitive cells and inhibition of p38 signalling, 
using SB203580, resulted in an increased susceptibility of the mouse 
lymphocytic leukaemia cells to vincristine (Barančík et al., 2001). It is 
interesting to note that 30 µM SB203580 was utilised in this study, which is 
higher than the concentration used in this chapter. This could explain why no 
differences were observed for 10 µM SB203580 and vincristine treatment, 
although the different cell types may not be comparable. SB203580 also 
enhanced the vincristine-induced reductions in cell viabilities in two acute 
lymphocytic leukemic cell lines: REH and 697 cells (Alsadeq et al., 2015). 
Although the effect of p38 inhibition and vincristine has not previously been 
studied specifically in U937 cells, the results of this chapter contradict previous 
findings in other leukaemia cell lines (Alsadeq et al., 2015; Barančík et al., 
2001). However, there is convincing evidence presented in this chapter that 
p38 signalling inhibition, using SB202190, increases the susceptibility of U937 
cells to vincristine. Further work is now required to understand the 
mechanisms underlying this observation.  
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5.4.4 p38 inhibition and heat treatment 
The role of p38 signalling in the response of U937 cells to heat treatment was 
investigated using the p38 inhibitor SB202910, in combination with heat 
treatment (Section 5.3.4.1). It was shown that inhibition of p38 signalling, using 
SB202190 resulted in the U937 cells being more susceptible to heat treatment 
after 24 and 48 h. Inhibition of p38 signalling using SB203580 prior to heat 
treatment had minimal effects on heat treatment-induced cell death after 24 
and 48 h (Section 5.3.4.2).  
Heat treatment has previously been shown to activate p38 signalling in 
non-leukemic cells (Dorion, Bérubé, Huot, & Landry, 1999; Dorion, Lambert, 
& Landry, 2002; Rouse et al., 1994). Although the effect of heat treatment on 
p38 phosphorylation was not measured in this chapter, it has previously been 
shown that p38 is activated in U937 cells within 15 min of heat (42°C) 
treatment, and the heat treatment-induced activation of p38 is inhibited by pre-
treatment with 20 µM SB203580 for 30 min (Zhou, An, Xu, Liu, & Cao, 2005).  
 Heat shock proteins protect cells against stress induced by heat by 
mediating inhibition of apoptosis and therefore promoting cell survival (Beere, 
2004). However it is not established if the activation of p38 following heat 
treatment is essential for survival. The observation that inhibition of p38 
signalling, using SB202190 makes the cells susceptible to heat treatment, 
suggests a potential involvement of p38 in maintaining cell survival in U937 
cells in response to heat treatment. Inhibition of p38 signalling using 
SB203580 however had minimal effects on heat treatment-induced cell death. 
The different effects observed using SB20190 and SB203580 could be due to 
the different mechanisms of inhibition. SB202190 prevents the 
phosphorylation of p38 (Fox et al., 1998) whereas SB203580 inhibits the 
catalytic activity of p38 (Young et al., 1997) but does not inhibit the 
phosphorylation of p38 (Kumar, Jiang, Adams, & Lee, 1999). This suggests 
that perhaps the phosphorylation of p38 is essential for mediating survival in 
response to heat treatment. It is surprising SB203580 did not have an effect in 
the present  study as SB203580 inhibits the activation of MAPKAPK-2 and 
subsequent phosphorylation of heat shock protein 27 (HSP27/HSPB1) 
(Cuenda et al., 1995). It is possible HSP27 is activated by alternative pathways 
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or other heat shock proteins play a more prominent role in mediating survival 
in U937 cells.  
 
5.5 Summary 
The results presented in this chapter conclude that SB202190 is effective at 
inhibiting p38 signalling by preventing the phosphorylation of p38. Although 
there is some evidence that SB203580 inhibits p38 signalling, by causing 
minimal reductions in p38 phosphorylation, further work is needed to confirm 
the ability of SB203580 to inhibit p38 signalling, in particular the effect of 
SB203580 on MAPKAPK-2 phosphorylation. The lack of effects observed 
using SB203580 in combination with cell stressors, compared to the effects 
observed using SB202190 and cell stressors could be due the limited ability 
of SB203580 to inhibit p38 signalling.  
Whilst is has been established that p38 is essential for the survival of ALL 
and CLL cells (Bendall et al., 2005; Gaundar et al., 2009; Juarez et al., 2009; 
Ringshausen et al., 2004), there is limited evidence for the role of p38 
signalling in the survival of AML cells. The results presented in this chapter 
show that p38 signalling is important for mediating the survival of U937 cells, 
an AML cell line, in response to UV light, doxorubicin and heat treatment. 
Inhibition of p38 signalling, caused an increase in cell death induced by these 
cell stressors, compared to the stressors alone. In contrast, inhibition of p38 
prevented vincristine-induce cell death, suggesting p38 activation is essential 
for cell death induced by vincristine. The conflicting role of p38 in the survival 
of U937 cells to two different chemotherapeutic agents highlights the 
importance of understanding the role of p38 in response to specific 
chemotherapeutic agents, in order to provide effective therapeutic targeting of 
p38 signalling. 
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Chapter 6: Targeting ERK signalling in U937 cell line 
6.1 Introduction  
In the previous two chapters, the JNK and p38 signalling pathways have been 
targeted, which are both pathways activated by stress. In this chapter, ERK 
signalling is targeted, which in contrast to JNK and p38 signalling, does not 
have as prominent a role in inducing cell death in response to stress, but rather 
has an important role in cell growth and survival.  
The constitutive activation of ERK signalling has been reported in both 
leukemic cell lines and primary leukemic cells (Kim et al., 1999; Milella et al., 
2001; Morgan et al., 2001; Ricciardi et al., 2005; Towatri et al., 1997). 
Constitutive ERK activation enables survival of immature or abnormal 
leukemic cells. Numerous studies have shown inhibition of ERK signalling, 
using MEK inhibitors, reduces the survival and induces apoptosis in leukemic 
cells (Kerr et al., 2003; Lunghi et al., 2003; Milella et al., 2001; Morgan et al., 
2001). Targeting ERK signalling alone is therefore a promising therapeutic 
strategy for leukaemia.  
Targeting ERK signalling in combination with current chemotherapeutic 
agents could also potentially increase the efficacy of current leukaemia 
therapies. A limited number of studies have taken this approach; all-trans-
retinoic acid, cytarabine and ABT-737 cause cell death in AML cells and 
inhibition of ERK signalling makes the cells more susceptible to cell death 
induced by these chemotherapeutic agents (Konopleva et al., 2006; Milella et 
al., 2001). It is therefore possible that high levels of activated ERK may confer 
a level of resistance to therapies.  
It appears that there are a very limited number of such studies, targeting 
ERK signalling specifically in U937 cells. This could be due to previous studies 
stating that untreated U937 cells express very low levels or undetectable levels 
of phosphorylated ERK (Ajenjo et al., 2000; Milella et al., 2001; Vrana & Grant, 
2001). The results presented in Chapter 3 however showed high levels of 
phosphorylated ERK in U937 cells. Further investigations into the role of ERK 
signalling in U937 cells are therefore required. In particular to understand if the 
high levels of phosphorylated ERK observed in U937 cells mediates cell 
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survival in response to cell stressors, of which UV light and heat treatment will 
be the focus in this chapter.  
 
Aims 
The overall aim of this chapter is to gain a greater understanding of the role of 
ERK signalling in leukemic cell death using the model U937 cell. This will be 
achieved by:  
• targeting ERK signalling using the chemical inhibitors PD184352 and 
U0126;  
• determining the effects of ERK signalling inhibition on the susceptibility of 
U937 cells to UV light and heat treatment. 
 
Initially in this chapter, effective concentrations of the ERK inhibitors, 
PD184352 and U0126, will be established. The effect of the inhibitors on cell 
death will be investigated using MTS assays, PI assays and flow cytometry to 
measure annexin V binding and PI staining. The effect of PD184352 and 
U0126 on ERK phosphorylation will then be assessed by flow cytometry. Due 
to time restrictions, Western blotting will not be performed. In contrast to 
previous chapters, the inhibitor will not be used in combination of anisomycin, 
the effect of each ERK inhibitor alone will be tested. This is based on the 
results presented in chapter 3 showing ERK phosphorylation is high in 
untreated U937 cells and is inhibited by anisomycin. The inhibitors will be then 
used in combination with the cell stressors, which in this chapter will be 
restricted to UV light and heat treatment. The effect of ERK inhibition and cell 
stressors on U937 cells will be investigated by using several techniques to 
assess cell death.  
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6.2 Methods  
6.2.1 Cell culturing 
U937 cell line was cultured and maintained as described in Section 2.1.1. Prior 
to treatments, cells were prepared as described in Section 2.1.4.  
 
6.2.2 Treatment of U937 cells with ERK inhibitors 
The ERK inhibitors, PD184352 and U0126, prepared as described in Section 
2.2.1, were used in this chapter. U937 cells were treated with PD184352 and 
U0126 as described in Section 2.2.1. 
 
6.2.3 Measurement of the effects of ERK inhibition on U937 cell death 
The effect of ERK inhibition on U937 cell death was assessed using: 
• MTS assay to measure metabolic activity (Section 2.4.1.3) 
• PI assay to measure necrosis (Section 2.4.1.4) 
 
6.2.4 Measurement of the effects of ERK inhibition on MAPK activation 
The effect of ERK inhibition on the phosphorylation of ERK was measured by 
• Western blotting (Section 2.3.1) 
• flow cytometry (Section 2.3.2) 
 
6.2.5 Treatment of U937 cells with ERK inhibitors and cell stressors 
U937 cells were treated with the ERK inhibitors in combination with UV light 
and heat treatment, as described in Section 2.2. 
 
6.2.6 Measurement of the effects of ERK inhibition and cell stressors on 
U937 cell death  
The effect of ERK inhibition and cell stressors on U937 cell viability was 
assessed using: 
• MTS assay to measure metabolic activity (Section 2.4.1.3) 
• PI assay to measure necrosis (Section 2.4.1.4) 
• FITC Annexin V FITC Apoptosis Detection Kit I to measure cell viability 
(Section 2.4.2.1) 
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6.3 Results 
6.3.1 Inhibition of ERK signalling 
6.3.1.1 Effect of PD184352 on U937 cell death  
Initially the dose-dependent effect of PD184352 on U937 cell death was 
investigated. As the concentration of PD184352 increased, metabolic activity 
was reduced in a concentration-dependent manner (Figure 6.1A). Treatment 
with 0.78 to 6.25 µM PD184352 caused significant (P<0.05) decreases in 
metabolic activities compared to untreated cells; these differences were 
however minimal. More striking, significant (P<0.0001) reductions in metabolic 
activities were observed for 12.5 µM or higher of PD184352. To establish if 
the differences were due to cell death by necrosis, a PI assay was performed. 
Treatment with 0.2 to 6.25 µM PD184352 had no significant effect on necrosis 
in U937 cells compared to untreated cells (Figure 6.1B). Treatment with 12.5 
to 50 µM PD184352 caused significant (P<0.001) increases in the percentage 
of necrotic cells compared to untreated cells. Treatment with 50 µM 
PD184352, abolished metabolic activity but less than 10% of cells appeared 
necrotic (Figure 6.1B), which suggests PD184352 induces cell death by a 
mechanism other than necrosis.  
 The effect of PD184352 on U937 cell death was investigated further by 
measuring annexin V binding and PI staining on the flow cytometer. Treatment 
with 2.5 and 5 µM PD184352 caused a significant (P<0.01), but minimal 
reductions in U937 viabilities (Figure 6.1C). Treatment with 10 µM PD184352 
caused a significant (P<0.0001) decrease in cell viability (Figure 6.1C) which 
is consistent with the data for MTS assay (Figure 6.1A). Following treatment 
with 10 µM PD184352, there was a significant (P<0.0001) increase in the 
percentages of apoptotic (Figure 6.1D) and late apoptotic/secondary necrotic 
cells (Figure 6.1E). 10 µM PD184352 had no effect on necrosis (data not 
shown) which suggests the increase observed in the percentage of PI-positive 
cells (Figure 6.1B) was likely to be due to late apoptotic/secondary necrotic 
cells (Figure 6.1E). Collectively these results show that whilst concentrations 
of PD184352 up to 5 µM have minimal effect on cell death, higher 
concentrations cause cell death. 
 
Chapter 6: Targeting ERK signalling in U937 cell line 
 
192 
 
A B   
 
 
 
 
 
 
C       D 
 
 
 
 
 
 
 
E 
 
 
 
 
 
 
 
Figure 6.1: Effect of PD184352 on U937 cell death  
U937 cells were treated with various concentrations of PD184352 and then incubated at 37°C 
for 24 h before an (A) MTS assay, (B) PI assay or (C-E) BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical 
differences shown to untreated cells, calculated using one-way ANOVA with Dunnett’s post 
hoc test: * (P<0.05), ** (P<0.01), *** (P<0.001), **** (P<0.0001). 
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6.3.1.2 Effect of PD184352 on ERK phosphorylation   
The effect of PD184352 on ERK phosphorylation was measured by flow 
cytometry. Treatment with 5 and 12.5 µM PD184352 caused no significant 
changes in the percentage of cells expressing phosphorylated ERK compared 
to untreated cells (Figure 6.2A). The percentages of cells expressing 
phosphorylated ERK were significantly (P<0.001) reduced following treatment 
with 25 and 50 µM PD184352. Measurement of phospho-ERK mean 
fluorescence intensity (MFI) showed phospho-ERK MFI was significantly 
(P<0.0001) decreased by over 2-fold for cells treated with 5 to 50 µM 
PD184352 compared to untreated cells (Figure 6.2B). These results therefore 
show ERK signalling is inhibited by concentrations of PD184352 as low as 5 
µM. 
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Figure 6.2: Effect of PD184352 on ERK phosphorylation 
U937 cells were pre-treated with various concentrations of PD184352 at 37°C for 1 h. Cells 
were then prepared for flow cytometry to measure ERK phosphorylation. Cells were fixed with 
4% paraformaldehyde, permeabilised with 90% ice-cold methanol and stained with phospho-
p44/42 (ERK1/2) Alexa Fluor 647-conjugated antibody. (A) shows the percentage of cells 
expressing phospho-ERK1/2 and (B) shows phospho-ERK1/2 AlexaFluor 647 mean 
fluorescence intensity (MFI). Data presented as mean ± SD, n=3. Statistical differences shown 
to untreated cells, calculated using one-way ANOVA with Dunnett’s post hoc test: ** (P<0.01), 
**** (P<0.0001). 
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6.3.1.3 Effect of U0126 on U937 cell death  
The effect of an alternative inhibitor, U0126, on U937 cell death was 
investigated. Results showed metabolic activity was reduced in a 
concentration-dependent manner following treatment with U0126 (Figure 
6.3A).  For cells treated with 100 µM U0126, metabolic activity was reduced 
(P<0.0001) to 11%. The effect of U0126 on cell death was further tested by 
performing a PI assay. Treatment with 1.56 to 6.25 µM U0126 had no 
significant effect on the percentage of necrotic cells compared to untreated 
cells (Figure 6.3B). The percentages of necrotic cells were significantly 
(P<0.001) increased in a concentration-dependent manner following treatment 
with 12.5 to 100 µM U0126.  
 Flow cytometry analysis of cell viability showed treatment with 5 and 10 
µM U0126 did not cause a reduction in U937 cell viability (Figure 6.3C), and 
consequently had no effect on apoptosis (Figure 6.3D). Treatment with 25 µM 
U0126 caused a significant (P<0.001) decrease in cell viability compared to 
untreated cells but only by 3% (Figure 6.3C) which was due to an increase in 
the percentage of late apoptotic/secondary necrotic cells (Figure 6.3D). Taken 
together, these results show 25 µM or less PD184352 has minimal effects on 
U937 cell death.   
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Figure 6.3: Effect of U0126 on U937 cell death 
U937 cells were treated with various concentrations of U0126 and then incubated at 37°C for 
24 h before an (A) MTS assay, (B) PI assay or (C,D) BD PharmingenTM FITC Annexin V 
Apoptosis Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical 
differences shown to untreated cells, calculated using one-way ANOVA with Dunnett’s post 
hoc test: * (P<0.05), ** (P<0.01), *** (P<0.001), **** (P<0.0001). 
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6.3.1.4 Effect of U0126 on MAPK phosphorylation  
The effect of U0126 on ERK phosphorylation was measured by flow cytometry. 
Treatment with 5 and 12.5 µM U0126 had no significant effect on the 
percentages of cells expressing phosphorylated ERK compared to untreated 
cells (Figure 6.4A). The percentage of cells expressing phosphorylated ERK 
was significantly (P<0.001) reduced following treatment with 25 µM U0126. 
Measurement of phospho-ERK mean fluorescence intensity (MFI) showed 
treatment with 5 µM U0126 caused a significant (P<0.0001) decrease in 
phospho-ERK MFI compared to untreated cells, by around 2-fold (Figure 
6.4B). Phospho-ERK MFIs were decreased further following treatment with 
12.5 to 50 µM U0126. Collectively, these results suggest concentrations of 
U0126 as low as 5 µM can inhibit ERK signalling.  
 
 
A   B 
 
 
 
 
 
 
  
Figure 6.4: Effect of U0126 on ERK phosphorylation  
U937 cells were pre-treated with various concentrations of U0126 at 37°C for 1 h. Cells were 
then prepared for flow cytometry to measure ERK phosphorylation. Cells were fixed with 4% 
paraformaldehyde, permeabilised with 90% ice-cold methanol and stained with phospho-
p44/42 (ERK1/2) Alexa Fluor 647-conjugated antibody. (A) shows the percentage of cells 
expressing phospho-ERK1/2 and (B) shows phospho-ERK1/2 AlexaFluor 647 mean 
fluorescence intensity (MFI). Data presented as mean ± SD, n=3. Statistical differences shown 
to untreated cells, calculated using one-way ANOVA with Dunnett’s post hoc test: *** 
(P<0.001), **** (P<0.0001). 
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6.3.2 Effect of ERK inhibition and UV light 
6.3.2.1 Effect of PD184352 and UV light on U937 cell death  
The role of ERK signalling in UV-induced cell death was investigated by pre-
treating U937 cells with 5 µM PD184352 prior to UV light treatment.  For cells 
treated with 5 to 20s UV, metabolic activities were significantly (P<0.01) lower 
for cells pre-treated with 5 µM PD184352 compared to cells not treated with 
PD184352 (Figure 6.5A). However, similar differences were observed in the 
absence of UV. Results of the PI assay showed there were very minimal 
differences between UV-treated cells pre-treated with PD184352 and cells not 
pre-treated with PD184352 (Figure 6.5B). Treatment with 5 µM PD184352 
therefore has little effect on UV-induced cell death. 
 A higher concentration of PD184352 was tested. For all durations of UV 
light, metabolic activities were significantly (P<0.0001) lower for cells pre-
treated with 10 µM PD184352 compared to cells not treated with PD184352 
when treated with equivalent durations of UV light (Figure 6.5D). Similar 
differences were also observed in the absence of UV light, which is consistent 
with the data shown in Figure 6.1A. Results of the PI assay showed that for 
cells treated with 30 to 50 s UV, the percentages of PI-positive cells were 
significantly (P<0.05) higher for cells pre-treated with 10 µM PD184352 
compared to cells not treated with PD184352 however the differences were 
minimal. Taken together, these results show inhibition of ERK signalling using 
PD184352 has minimal effects on UV-induced U937 cell death.  
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A   B  
 
 
 
 
 
 
C     D  
 
 
 
 
 
 
 
 
Figure 6.5: Effect of PD184352 and UV light treatment on U937 cell death 
U937 cells were pre-treated with (A,B) 5 µM  or (C,D) 10 µM PD184352 at 37°C for 1 h to 
inhibit ERK signalling and then treated with various durations of UV light. After 24 h incubation 
at 37°C, an (A,C) MTS assay or (B,D) PI assay were performed. Data presented as mean ± 
SD; n=3. Statistical differences shown between PD184352 and no treatment at mean time 
points, calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), 
*** (P<0.001). 
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6.3.2.2 Effect of U0126 and UV light on U937 cell death  
To further investigate the role of ERK signalling in the response of U937 cells 
to UV, cells were pre-treated with U0126 prior to UV light treatment, and the 
effect on cell death was assessed. In the absence of UV, metabolic activity 
was significantly (P<0.05) lower for cells pre-treated with 5 µM U0126 
compared to cells not treated with U0126 (Figure 6.6A), which is consistent 
with Figure 6.3A. For cells treated with 5 to 50s UV, there were no significant 
differences in metabolic activities between cells treated with and without 5 µM 
U0126, when treated with equivalent durations of UV (Figure 6.6A). U0126 
had no effect on the percentage of PI-positive cells (Figure 6.6B), suggesting 
U0126 had no effect on necrosis induced by UV light treatment.   
 The effect of a higher concentration of U0126 was tested. For cells 
treated with 5 to 30 s UV, metabolic activities were significantly lower (P<0.05) 
for cells pre-treated with 10 µM U0126 compared to cells not treated with 
U0126 (Figure 6.6C). However, the differences observed were because of the 
effects of the inhibitor as a similar difference was observed for 0 s UV. 10 µM 
U0126 had no effect on necrosis in U937 cells induced by UV treatment 
(Figure 6.6D). Taken together, these results show inhibition of ERK signalling, 
using U0126, has no effect on UV-induced cell death in U937 cells.  
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A      B 
 
 
 
 
 
 
C    D 
  
 
 
 
 
 
 
Figure 6.6: Effect of U0126 and UV light treatment on U937cell death  
U937 cells were pre-treated with (A,B) 5 µM or (C,D) 10 µM U0126 at 37°C for 1 h to inhibit 
ERK signalling and then treated with various durations of UV light. After 24 h incubation at 
37ºC, an (A,C) MTS assay and (B,D) PI assay were performed. Data presented as mean ± 
SD; n=3. Statistical differences shown between U0126 and no treatment at mean time points, 
calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), **** (P<0.0001). 
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6.3.3 Effect of ERK inhibition and heat treatment 
6.3.3.1 Effect of PD184352 and heat treatment on U937 cell death  
The effect of ERK signalling in the response of U937 cells to heat treatment 
was investigated using PD184352. After 24 h, metabolic activities were 
significantly (P<0.0001) lower for heat treated cells in both the absence and 
presence of PD184352 (Figure 6.7A). PD184352 had no effect on heat-
induced changes in necrosis after 24 h (data not shown). Results from the 
measurement of cell viability after 24 h using flow cytometry (Figure 6.7B) were 
consistent with the results of the MTS assay (Figure 6.7A). For cells treated 
with 0 to 50 µM PD184352, cell viabilities were lower for heat treated cells 
compared to non-heat treated cells (Figure 6.7B).  After 24 h, no significant 
differences in the percentages of apoptotic cells were measured between heat 
treated and non-heat treated cells, pre-treated with and without PD184352 
(Figure 6.7C) and the significant (P<0.01) differences observed for the 
percentages of late apoptotic/secondary necrotic cells were minimal (Figure 
6.7D).  
After 48h, no significant differences in metabolic activities were 
measured between heat treated and non-heat treated cells treated with 
equivalent concentrations of PD184352 (Figure 6.7E). These results were 
confirmed by flow cytometry; after 48 h no differences in U937 viability (Figure 
6.7F), and hence no differences in the percentages of apoptotic (Figure 6.7G) 
and late apoptotic/secondary necrotic (Figure 6.7H) cells were measured. 
Collectively these results show that inhibition of ERK signalling, using 
PD184352 has no effect on heat-induced changes in cell death.  
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A                         24 h                  E                           48 h 
 
 
 
 
 
B            F  
 
 
 
 
C         G  
 
 
 
 
  
D           H  
 
 
 
 
 
 
 
Figure 6.7: Effect of PD184352 and heat treatment on U937 cell death  
U937 cells were pre-treated with PD184352 at 37ºC for 1 h to inhibit ERK signalling and then 
incubated at either 37°C or 42°C for 1 h. Cells were then incubated at 37°C for (A-D) 24 h or 
(E-H) before an (A,E) MTS assay or (B-D,F-H) BD PharmingenTM FITC Annexin V Apoptosis 
Detection Kit I were performed. Data presented as mean ± SD; n=3. Statistical differences 
shown between heat treatment and no treatment at mean PD184352 concentration points, 
calculated using two-way ANOVA with Sidak’s post hoc test: ** (P<0.01), **** (P<0.0001). 
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6.3.3.2 Effect of U0126 and heat treatment on U937 cell death  
The effect of U0126 an alternative ERK inhibitor and heat treatment on U937 
cell death was initially investigated by performing an MTS assay. After 24 h, 
metabolic activities were significantly (P<0.05) lower for heat treated cells, 
compared to non-heat treated cells, when treated with 1.56 to 50 µM U0126 
(Figure 6.8A). Similar differences were also observed in the absence of 
U0126. U0126 had no effect on heat-induced changes in necrosis (data not 
shown). 48 h after treatment, there were no significant differences in metabolic 
activities between heat treated and non-heat-treated cells, for all 
concentrations of U0126 (Figure 6.8B). Together, these results suggest 
inhibition of ERK signalling, using U0126, has no effect on heat-induced 
changes in U937 cell death and therefore this was not investigated further.  
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A                           24 h   B                          48 h  
 
 
 
 
 
 
 
 
Figure 6.8: Effect of U0126 and heat treatment on U937 cell death 
U937 cells were pre-treated with U0126 at 37°C for 1 h to inhibit ERK signalling and then 
incubated at either 37°C or 42°C for 1 h. Cells were then incubated at 37ºC for (A) 24 h or (B) 
24 h before an MTS assay was performed. Data presented as mean ± SD; n=3. Statistical 
differences shown between heat treatment and no treatment at mean U0126 concentration 
points, calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), 
**** (P<0.0001). 
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6.4 Discussion 
The overall aim of this chapter was to gain a greater understanding of the role 
of ERK signalling in leukemic cell death by studying the effects of ERK 
inhibition and cell stressors on cell death in the model U937 cell line.  
 
6.4.1 Inhibition of ERK signalling  
The ERK inhibitors, PD184352 and U0126, were used in this chapter to target 
ERK signalling. PD184352 and U0126 are non-competitive inhibitors with 
respect to ATP and ERK and both function to inhibit MEK1/2 and the 
subsequent activation of ERK1 and ERK2 (Favata et al., 1998; Sebolt-Leopold 
et al., 1999). The aim here was to confirm the inhibition of ERK signalling in 
U937 cells, using PD184352 and U0126, and to establish effective 
concentrations to use in combination with cell stressors.  
 
6.4.1.1. PD184352 
The effect of PD184352 on U937 cell death was assessed and results showed 
concentrations of PD184352 less than 5 µM, had minimal or no effects on 
U937 cell death whereas 10 µM or higher of PD184352 did cause low levels 
of cell death. (Section 6.3.1.1). A previous study utilising PD184352 in U937 
cells has shown treatment with up to 10 µM for 24 h has minimal effect on 
apoptosis (Rahmani et al., 2009). This study is in agreement with the results 
presented in this chapter and similarly to this chapter, used annexin V staining 
to assess apoptosis. Other studies have confirmed 10 µM or less PD184352 
has minimal effect on apoptosis in U937 cells, using alternative techniques to 
measure cell death: caspase assays and Wright-Giemsa staining (Dai, Dent, 
& Grant, 2003; Dai et al., 2001; Yu et al., 2002).  
The effect of PD184352 on ERK phosphorylation in U937 cells was 
measured using flow cytometry (Section 6.3.1.2). Result showed that low 
concentrations of PD184352 did not affect the percentages of cells expressing 
phosphorylated ERK, but rather caused the cells expressing phospho-ERK to 
express phospho-ERK at lower levels. These results therefore provide 
evidence that concentrations of PD184352 as low as 5 µM are able to partially 
inhibit ERK signalling.  
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Measurement of ERK phosphorylation by Western blotting would have 
provided further confirmation of the effect of PD184352 on the levels of 
phosphorylated ERK. It has previously been shown ERK phosphorylation, as 
measured by Western blotting, is inhibited in U937 cells by 10 µM PD184352 
after 6 h and remains inhibited after 16 h (Rahmani et al., 2009). Inhibition of 
ERK phosphorylation has also been observed 18 h after treatment with 10 µM 
PD184352 (Dai et al., 2001). In this chapter, cells were pre-treated with 
PD184352 for 1 h prior to treatment with cell stressors, therefore the levels of 
phosphorylated ERK were measured 1 h after treatment with PD184352, in 
order to confirm the levels of phosphorylated ERK prior to treatment. In 
experiments involving co-treatment with PD184352 and a cell stressor, 
PD184352 was not removed from the culture media; cells were therefore 
incubated with PD184352 for up to 48 h. It is likely that the lower 
concentrations of PD814352 would achieve greater inhibition of ERK 
phosphorylation after time periods longer than 1 h, however this was not 
tested. 
Although high concentrations of PD184352, such as 25 µM, achieved 
greater inhibition of ERK phosphorylation, these concentrations were not 
suitable for use due to the high levels of undesired cell death. 10 µM 
PD184352 has typically been used in previous studies to investigate the role 
of ERK signalling in U937 cells (Dai et al., 2003; Dai et al., 2001; Rahmani et 
al., 2009) but the results presented here showed 5 µM is also sufficient to 
inhibit ERK signalling. 5 µM was therefore selected as an initial concentration 
of PD184352 to use in combination with cell stressors. 
  
6.4.1.2 U0126  
The effect of an alternative ERK inhibitor, U0126, on U937 cell death was 
tested and results showed significant reductions in metabolic activity and 
increases in the percentages of necrotic cells following U0126, indicating 
U0126 has a significant impact on cell death. Flow cytometry, to measure 
annexin V binding and PI staining, however showed U0126 does not have an 
effect on apoptosis in U937 cells. The difference in these findings could be 
attributed to the ability of U0126 to affect cellular processes, other than 
apoptosis, which may alter metabolic activity such as cell growth and 
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proliferation. Given the important role of ERK signalling in cell growth and 
proliferation, this is a plausible explanation. However such effects were not 
observed for PD184352, which is surprising given that both U0126 and 
PD18435 inhibit ERK signalling via similar mechanisms. Alternative methods 
to assess cell growth and proliferation would provide a greater insight into the 
effect of U0126 on these cellular processes, in addition to further techniques, 
such as caspase-based assays to confirm the effect of U0126 on apoptosis. 
The results presented in this chapter however show that concentrations such 
as 5 and 10 µM U0126 do not have an effect on apoptosis, which is in 
agreement with a previous study showing treatment with 10 µM U0126 for 24 
h has minimal effect on U937 apoptosis (Rahmani et al., 2009).   
The effect of U0126 on ERK phosphorylation was measured using flow 
cytometry (Section 6.3.1.4). Similarly as for PD184352, these result indicate 
that low concentrations of U0126, such as 5 µM, inhibit ERK phosphorylation, 
by reducing the levels of phosphorylated ERK expressed by a cell, rather than 
affecting the number of cells expressing phosphorylated ERK.  
Given the minimal effect of U0126 on U937 apoptosis, and the ability of 
U0126 to inhibit ERK phosphorylation, 5 and 10 µM were selected as 
appropriate concentrations to use in combination with cell stressors in this 
chapter. 10 µM U0126 has previously been used to investigate ERK signalling 
in U937 cells  (Su et al., 2014). 
 
6.4.2 ERK inhibition and UV 
The effect of ERK inhibition and UV light treatment on U937 cell death was 
initially investigated by targeting ERK signalling using PD184352 (Section 
6.3.2.1). From the results presented, it is evident ERK signalling inhibition, 
using PD184352 does not have an effect on UV-induced apoptosis in U937 
cells. The effects of ERK inhibition and UV light on U937 cell death was 
investigated further using the alternative ERK inhibitor, U0126 (Section 
6.3.2.2). These results also showed U0126 had no effect on UV-induced 
apoptosis. As the two different ERK inhibitors tested both provide evidence 
that ERK signalling inhibition does not affect UV-induced cell death, it is 
evident that ERK signalling does not play a critical role in UV-induced 
apoptosis in U937 cells.  
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There is conflicting evidence for the role of ERK in providing cancer cells 
with protection against UV-induced apoptosis. In C8161 melanoma cells, the 
activation of ERK, induced by UV light, is inhibited by U0126 but ERK inhibition 
did not provide protection against UV-induced cell death, as measured by 
PARP fragmentation (Rieber & Rieber, 2006). ERK activation however has a 
protective role against UV-induced cell death in A431 epidermoid carcinoma 
cells (Kitagawa et al., 2002). In U937 cells, the phosphorylation of ERK was 
decreased following UV and was completely inhibited following PD98059 and 
UV treatment (Luchetti et al., 2009). However this did not have an effect on 
UV-induced apoptosis as the percentage of apoptotic cells and caspase 
activity was unaffected by PD98059 and UV compared to UV-only treated 
cells. The results in this chapter are in agreement the findings of Luchetti et al 
(2009).  
 
6.4.3 ERK inhibition and heat treatment 
To investigate the effects of ERK inhibition and heat shock on U937 cell death, 
cells were treated with PD184352 and heat treatment (Section 6.3.3.1). 
Results showed PD184352 had no effect on U937 cell death 24 or 48 h after 
heat treatment. The effect of ERK inhibition on heat treatment-induced cell 
death was investigated further using U0126 (Section 6.3.3.2). U0126 had no 
effect after 24 nor 48 h, on heat treatment-induced changes in metabolic 
activities. Collectively these results show ERK signalling is not involved in the 
response of U937 cells to heat-induced changes in cell death.  
ERK signalling has an important role in cell survival and has been 
implicated in preventing heat-induced cell death. Heat treatment (42°C, 60 
min) activated ERK1/2 phosphorylation in BaF3, murine pro-B cells (Ng & 
Bogoyevitch, 2000). Treatment of BaF3 cells with PD98059, an alternative 
ERK inhibitor, inhibited the heat treatment-induced activation of ERK and 
resulted in a greater reduction in viability. ERK signalling, in particular the 
activation of ERK1 is important for protection against heat-induced cell death 
in K562, chronic myeloid leukemic cells (Woessmann & Meng, 1999). 
Inhibition of ERK1 activity increased the sensitivity of K562 cells to heat shock-
induced reductions in cell viability, whereas the overexpression of ERK1 
resulted in resistance to cell death caused by heat treatment. ERK2 activation 
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was unaffected by heat treatment (43°C, 20 min) in a range of leukemic cell 
lines (K562, HL-60 and U937 cells).  
The effect of ERK signalling on heat-induced cell death, specifically in 
U937 cells has not previously been reported. The results of this chapter 
implicate ERK signalling is not involved in maintaining viability in U937 cells 
following heat treatment. The finding that ERK2 is not activated by heat  
treatment in U937 cells (Woessmann & Meng, 1999), provides support for the 
lack of involvement of ERK signalling observed in this chapter. However 
Woessmann et al. did not show the effect of heat treatment on ERK1 
phosphorylation. It has also been argued that heat treatment (42°C, 15 min or 
30 min) does in fact induce activation of ERK in U937 cells and the activation 
of ERK by heat treatment is inhibited by PD098059 (Zhou et al., 2005). 
Therefore, in order to fully understand the effects of ERK signalling in the 
response to heat treatment in U937 cells, the effects of heat treatment on ERK 
phosphorylation in U937 cells need to be investigated using this experimental 
system.  
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6.4 Summary 
Whilst it has previously been reported that U937 cells express low levels of 
phosphorylated ERK (Ajenjo et al., 2000; Milella et al., 2001; Vrana & Grant, 
2001), the results presented in this chapter, confirm untreated U937 cells have 
high levels of phosphorylated ERK, as observed in Chapter 3. PD184352 and 
U0126 are effective at inhibiting ERK signalling and inhibition of ERK signalling 
induces apoptosis in U937 cells, consistent with previous findings in other 
types of leukemic cells (Kerr et al., 2003; Lunghi et al., 2003; Milella et al., 
2001). There are limited studies available which demonstrate the role of ERK 
signalling in mediating U937 cell survival in response to cell stressors, such as 
UV light and heat treatment. The results presented in this chapter provide 
evidence that ERK signalling is not essential for the survival of U937 cells in 
response to UV light and heat treatment but further research is needed to 
investigate the role in response to other cell stressors, for example 
chemotherapeutic agents.  
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Chapter 7: Targeting MAPK signalling in PBMCs 
7.1 Introduction  
In previous chapters, the role of MAPK signalling pathways in leukemic cell 
death has been investigated using U937 cells, a human monocytic cell line. In 
this chapter, MAPK signalling pathways will be targeted in peripheral blood 
mononuclear cells (PBMCs) from healthy individuals.  
U937 cells are transformed cells which are a powerful in vitro research 
tool for studying leukaemia. Primary cells however are a more suitable model 
as they more closely mimic the physiology of cells in vivo and provide a greater 
insight into variation between individuals. In order to confirm the effects 
observed in U937 cells, future work is required to understand the role of MAPK 
signalling in leukemic death using primary blasts from AML patients. Prior to 
this, it is necessary to establish if the effects observed in U937 are specific to 
leukemic cells or whether there are effects on non-leukemic cells; it is 
important to ensure that unwanted cell death in non-leukemic cells is minimal. 
Peripheral blood mononuclear cells (PBMCs) are peripheral blood cells with a 
round nucleus and include lymphocytes and monocytes (Riedhammer, 
Halbirtter, & Weissert, 2014). PBMCs from healthy individuals are frequently 
used in leukemic studies; PBMCs from healthy individuals are used as a 
control to allow comparison between leukemic and non-leukemic cells 
(Admoni-Elisha et al., 2016; Le Dieu et al., 2009; Morsi et al., 2016).  
Constitutive activation of ERK has previously been reported in leukemic 
cells (Milella et al., 2001; Morgan, Dolp, & Reuter, 2001; Ricciardi et al., 2005) 
and high levels of active ERK were measured in U937 cells in Chapter 3 
(Section 3.3.5) but the levels of phosphorylated ERK need to be measured in 
PBMCs from healthy individuals to allow for comparisons to primary, non-
leukemic cells. The results presented in Chapter 6 showed inhibition of ERK 
signalling reduced the survival of U937 cells (Section 6.3.1) but ERK signalling 
was not essential for the survival of U937 cells in response to UV light and 
heat treatment (Sections 6.3.2 and 6.3.3). As the results presented in this 
chapter only show preliminary work in PBMCs, ERK signalling will not be 
targeted in PBMCs, instead JNK and p38 signalling will be the focus. In 
Chapters 4 and 5, it was shown that inhibition of JNK and p38 signalling, using 
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SP600125 and SB201290 respectively, sensitised U937 cells to UV-induced 
apoptosis (Sections 4.3.2.1 and 5.3.3.1). In contrast, inhibition of JNK and p38 
signalling provided protection against vincristine-induced apoptosis in U937 
cells (Sections 4.3.4.3 and 5.3.5.3). Investigations are required to determine if 
this effect is specific to leukemic cells or whether PBMCs from healthy 
individuals are affected in a similar manner.  
 
Aims 
The overall aim of this chapter is to gain a greater understanding of the role of 
MAPK signalling in leukemic cell death using PBMCs from healthy individuals. 
This will be achieved by: 
• Determining the effect of anisomycin and UV light on MAPK activation in 
PBMCs 
• determining the effects of cell stressors, to include anisomycin, UV light 
and vincristine on PBMC death; 
• determining the effects of JNK and p38 signalling inhibition on the 
susceptibility of PBMCs to UV and vincristine.  
 
Prior to investigating the effects of any treatments on PBMCS, it is necessary 
to establish if the process of PBMC isolation has any effect on MAPK 
activation, this will be achieved by measuring the activation of MAPKs using 
flow cytometry. Following this, the effect of the cell stressors on the activation 
of MAPKs in PBMCs and the effect on PBMC death will be investigated using 
flow cytometry. The effects of JNK and p38 inhibition on the susceptibility of 
PBMCs to UV and vincristine will be investigated using SP600125 and 
SB202190, respectively, as these inhibitors were shown to be the most 
effective in chapters 4 and 6. The effect of the inhibitors and cell stressors on 
PBMC death will only be assessed by flow cytometry to measure annexin V 
binding and PI staining.  
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7.2 Methods 
7.2.1 PBMC isolation  
Whole blood was collected from healthy individuals (Section 2.1.2.1) and 
PBMCs were isolated using Histopaque®-1077 as described in Section 
2.1.2.2.   
 
7.2.2 Preparation of PBMCs prior to experiments 
PBMCs, at a concentration of 5 x 105 cells/mL were plated into 96-well tissue 
culture plates under sterile conditions. PBMCs were treated immediately 
unless otherwise stated. Each experiment was performed on up to 3 individual 
participants, and in all cases experimental measurements were replicated 3 
times.  
 
7.2.3 Treatment of PBMCs with cell stressors 
PBMCs were treated with the following cell stressors:  
• anisomycin (Section 2.2.5) 
• UV light (Section 2.2.2) 
• vincristine (Section 2.2.3)  
 
7.2.4 Treatment of PBMCs with MAPK inhibitors and cells stressors  
JNK signalling was inhibited in this chapter using SP600125 and p38 signalling 
was inhibited using SB202190, which were prepared as described in Section 
2.2.1. PBMCs were treated with JNK or p38 inhibitors prior to treatment with 
cell stressors as described in Section 2.2.  
 
7.2.5 Measurement of MAPK phosphorylation  
The effects of PBMC isolation, anisomycin treatment and UV light treatment 
on MAPK phosphorylation in PBMCs were measured by flow cytometry as 
described in Section 2.3.2. 
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7.2.6 Measurement of the effects of treatments on PBMC death 
The effects of cell stressors alone, or the effects of JNK or p38 inhibition in 
combination with cell stressors on PBMC viability was assessed using FITC 
Annexin V FITC Apoptosis Detection Kit I as described in Section 2.4.2.1.   
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7.3 Results 
7.3.1 Effect of PBMC isolation on MAPK phosphorylation 
To determine if the process of isolating PBMCs affects MAPK phosphorylation, 
phosphorylated-JNK, c-Jun, p38 and ERK levels were measured 0, 2 and 24 
h after isolation. PBMC isolation had no effect on the percentage of cells 
expressing phosphorylated JNK after 2 h and although there was a significant 
(P<0.05) increase after 24 h, the difference was minimal (Figure 7.1A). After 2 
and 24 h, there were no significant changes in the percentages of PBMCs 
expressing phosphorylated c-Jun compared to 0 h (Figure 7.1B). Whilst there 
was no difference in the percentage of cells expressing phosphorylated p38 
after 2 h compared to 0 h, there was a significant (P<0.05) decrease in the 
percentage of cells expressing phosphorylated p38 after 24 h, however this 
difference was minimal (Figure 7.1C). PBMC isolation had no effect on 
phosphorylated ERK expression 2 h after isolation; there was a significant 
(P<0.0001) increase in phosphorylated ERK 24 h post isolation (Figure 7.1D). 
Collectively, these results show PBMC isolation does not affect the 
phosphorylation of JNK, c-Jun or p38. ERK phosphorylation is however 
affected; ERK signalling was not investigated further in this chapter. 
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Figure 7.1: Effect of PBMC isolation on MAPK phosphorylation  
PBMCs were isolated from healthy human blood using Histopaque-1077 and then incubated 
at 37°C for 0, 2 or 24 h. PBMCs were then prepared for flow cytometry to measure (A) JNK, 
(B) c-Jun, (C) p38 and (D) ERK phosphorylation. PBMCs were fixed with 4% 
paraformaldehyde, permeabilised using 90% ice-cold methanol, and then stained with (A) 
phospho-SAPK/JNK (Thr183/Thr185) Alexa Fluor 647-conjugated antibody, (B) phospho c-
Jun (Ser73) Alexa Fluor 488 conjugated antibody, (C) phospho-p38 (Thr180/Tyr182) Alexa 
Fluor 647-conjugated antibody or (D) phospho-p44/42 (Thr202/Tyr204) Alexa Fluor 647-
conjugated antibody. Data presented as mean ± SD, n=3 experimental replicates for a single 
participant. Statistical differences shown to 0 h, calculated using one-way ANOVA with 
Dunnett’s post hoc test: * (P<0.05), **** (P<0.0001). 
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7.3.2 Effect of anisomycin on MAPK signalling components in PBMCs 
In chapters 3-6 anisomycin was used as a signalling agonist to test the ability 
of the MAPK inhibitors to inhibit the MAPK signalling pathways. To test if 
anisomycin could also be used as a signalling agonist in PBMCs, the effect of 
anisomycin on JNK, c-Jun and p38 phosphorylation was measured by flow 
cytometry. The percentage of PBMCs expressing phosphorylated JNK was 
significantly (P<0.05) increased 30 min after treatment with 1 µM anisomycin 
compared to untreated PBMCs; but the difference was less than 3% (Figure 
7.2A). The percentages of PBMCs expressing phosphorylated c-Jun and p38 
were unaffected by treatment with 1 µM anisomycin for 30 min (Figures 7.2B 
and 7.2C). 
As 1 µM anisomycin had little effect on MAPK phosphorylation in PBMCs, 
higher concentrations of anisomycin (0 to 50 µM) were tested to ensure that 
the lack of MAPK activation was not due to insufficient concentration of 
anisomycin. These investigations were focused on the activation of JNK 
following anisomycin treatment. There were no significant differences in the 
percentages of anisomycin-treated PBMCs expressing phosphorylated JNK 
compared to untreated PBMCs (Figure 7.3).  
Longer incubations with a high concentration of anisomycin were also 
tested. Incubation with 50 µM anisomycin for 30 min had no significant effect 
on the percentage of PBMCs expressing phosphorylated JNK compared to 
untreated PBMCs (Figure 7.4A). Treatment with 50 µM anisomycin for 1 h 
caused a significant (P<0.01) increase in the percentage of PBMCs 
expressing phosphorylated JNK compared to untreated PBMCs but the 
difference was minimal (Figure 7.4B). Taken together these results suggest 
anisomycin is unable to activate MAPKs under the conditions tested.  
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Figure 7.2: Effect of anisomycin on MAPK phosphorylation in PBMCs  
PBMCs were incubated with 1 µM anisomycin at 37°C for 30 min and then (A) phospho-JNK, 
(B) phospho-c-Jun, (C) phospho-p38 levels were then measured using flow cytometry. 
PBMCs were fixed with 4% paraformaldehyde, permeabilised using 90% ice-cold methanol, 
and then stained with (A) phoshpo-SAPK/JNK (Thr183/Thr185) Alexa Fluor 647-conjugated 
antibody, (B) phospho c-Jun (ser73) Alexa Fluor 488 conjugated antibody or (C) phospho-p38 
(Thr180/Tyr182) Alexa Fluor 647-conjugated antibody. Data presented as mean ± SD, n=3 
experimental measurements for a single participant.  Statistical differences shown to untreated 
PBMCs, calculated using an unpaired t-test: * (P<0.05). 
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Figure 7.3: Effect of high concentrations of anisomycin on JNK 
phosphorylation in PBMCs  
PBMCs were incubated with 0 to 50µM of anisomycin at 37°C for 30 min and then phospho-
JNK, levels were measured using flow cytometry. PBMCs were fixed with 4% 
paraformaldehyde, permeabilised using 90% ice-cold methanol, and then stained with 
phospho-SAPK/JNK (Thr183/Thr185) Alexa Fluor 647-conjugated antibody. Data presented 
as mean ± SD, n=3 experimental measurements for a single participant.  
 
A B 
 
 
 
 
 
 
Figure 7.4: Effect of longer incubations with anisomycin on JNK 
phosphorylation in PBMCs  
PBMCs were incubated with 50 µM anisomycin at 37°C for (A) 30 min or (B) 60 min and then 
phospho-JNK levels were measured using flow cytometry. PBMCs were fixed with 4% 
paraformaldehyde, permeabilised using 90% ice cold methanol, and then stained with 
phospho-SAPK/JNK (Thr183/Thr185) Alexa Fluor 647-conjugated antibody. Data presented 
as mean ± SD, n=3 experimental measurements for a single participant. Statistical differences 
shown to untreated PBMCs, calculated using an unpaired t-test: ** (P<0.01). 
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7.3.3 Effect of UV light on PBMC death 
To determine the effect of UV light on PBMC death, PBMCs were treated with 
various durations of UV light and the effect on PBMC cell death was assessed 
using flow cytometry to measure annexin V binding and PI staining. UV light 
caused a significant (P<0.0001) decrease in PBMC viability (Figure 7.5A). The 
percentages of necrotic PBMCs were unaffected by UV treatment (data not 
shown). The decreased viabilities observed in PBMCs following UV treatment 
were due to increases in both the percentages of apoptotic and late 
apoptotic/secondary necrotic PBMCs (Figures 7.5B and 7.5C).   
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Figure 7.5: Effect of UV light on PBMC viability 
PBMCs were treated with various durations of UV light treatment and then incubated at 37°C 
for 24 h. (A) viability (B) necrosis, (C) apoptosis and (D) late apoptosis/secondary necrosis 
were measured using BD PharmingenTM FITC Annexin V Apoptosis Detection Kit I. Data 
presented as mean ± SD, n=3 experimental replicates for a single participant. Statistical 
differences shown to untreated PBMCs, calculated using one-way ANOVA with Dunnett’s post 
hoc test: **** (P<0.0001). 
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7.3.4 Effect of UV light on JNK activation in PBMCs 
To determine if JNK was activated in PBMCs following UV light treatment, 
levels of phosphorylated JNK were measured by flow cytometry up to 60 min 
after UV treatment. Three different UV treatment times were tested: 0, 6 and 
18 s. For each duration of UV light, there were no significant changes in the 
percentages of PBMCs expressing phosphorylated JNK over 60 min, 
compared to 0 min (Figure 7.6A and Table 7.1). Therefore, the activation of 
JNK over a longer period of 4 h was studied. There were no significant 
changes in the percentages of PBMCs expressing phosphorylated JNK after 
1, 2, 3, or 4 h compared to 0 h (Figure 7.6B and Table 7.1). These results 
indicate that JNK signalling is not activated in PBMCs following UV light 
treatment.  
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Figure 7.6: Effect of UV light on JNK activation  
U937 cells were treated with 0, 6 and 18 s UV, incubated at 37°C for 0 to 60 min and then 
phospho-JNK levels were then measured using flow cytometry. PBMCs were fixed with 4% 
paraformaldehyde, permeabilised using 90% ice cold methanol, and then stained with 
phospho-SAPK/JNK (Thr183/Thr185) Alexa Fluor 647-conjugated antibody. Data presented 
as mean ± SD, n=3 experimental measurements for a single participant.  
 
Table 7.1: Statistical analysis to show the effect of UV light on JNK activation  
Data presented as mean ± SD; n=3 experimental measurements for a single participant. 
Statistical differences shown between mean incubation times for each UV treatment time, 
calculated using two-way ANOVA with Tukey’s post hoc test. 
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7.3.5. Effect of MAPK inhibition and UV light on PBMC death 
7.3.5.1 Effect of JNK inhibition and UV light on PBMC death 
The results presented in Section 7.3.4 suggested JNK is not activated in 
PBMCs following UV light treatment. To provide further evidence to establish 
the involvement of JNK activation in the response of PBMCs to UV light 
treatment, PBMCs were treated with SP600125 prior to UV light treatment. 
There were no differences in PBMC viabilities between PBMCs treated with 
and without SP600125 for all durations of UV light (Figure 7.7A). Whilst the 
percentages of apoptotic PBMCs were significantly (P<0.05) lower for cells 
pre-treated with SP600125 compared to PBMCs not treated with SP600125 
(Figure 7.7B), the percentages of late apoptotic/secondary necrotic were 
significantly (P<0.05) higher for PBMCs pre-treated with SP600125 (Figure 
7.7C). The results suggest SP600125 has minimal effects on UV-induced 
changes in PBMC viability, providing further support that JNK signalling is not 
involved in the response of PBMCs to UV light treatment.  
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Figure 7.7: Effect of SP600125 and UV on PBMC viability 
PBMCs were pre-treated with 0 or 10 µM SP600125 at 37°C for 1 h to inhibit JNK signalling 
and then treated with various durations of UV light. After 24 h, (A) viability, (B) apoptosis and 
(C) late apoptosis/secondary necrosis were measured using BD PharmingenTM FITC Annexin 
V Apoptosis Detection Kit I. Data presented as mean ± SD, n=3 participants. Experimental 
measurements were replicated 3 times for each of the participants and the data was 
combined. Statistical differences shown between SP600125 and no inhibitor at UV time points, 
calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01). 
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7.3.4.1 Effect of p38 inhibition and UV light on PBMC death 
To determine if p38 signalling is involved in UV-induced cell death in PBMCs, 
PBMCs were pre-treated with SB202190 prior to UV light treatment. There 
were no significant differences in PBMC viabilities between PBMCs treated 
with and without SB202190 for all durations of UV light tested (Figure 7.8A). 
For PBMCs treated with 3 to 18 s UV, the percentages of apoptotic PBMCs 
were lower for PBMCs pre-treated with SB202190 compared to PBMCs not 
treated with SB202190 (Figure 7.8B) whereas the percentages of late 
apoptotic/ secondary necrotic PBMCs were higher for PBMCs treated with 
SB202190 (Figure 7.8C). SB202190 therefore causes minimal changes in the 
different stages of apoptosis but has little effect on the overall viability of the 
UV-treated PBMCs. 
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Figure 7.8: Effect of SB202190 and UV on PBMC viability 
PBMCS were pre-treated with 0 or 10 µM SB202190 at 37°C for 1 h to inhibit p38 signalling 
and then treated with various durations of UV light. After 24 h, (A) viability, (B) apoptosis and 
(C) late apoptosis/secondary necrosis were measured using BD PharmingenTM FITC Annexin 
V Apoptosis Detection Kit I. Data presented as mean ± SD, n=3 participants. Experimental 
measurements were replicated 3 times for each of the participants and the data was 
combined. Statistical differences shown between SB202190 and no inhibitor at UV time points, 
calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), *** 
(P<0.001). 
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7.3.6 Effect of vincristine on PBMC death 
To determine the effect of vincristine on PBMC death, PBMCs were treated 
with various concentrations of vincristine and the effect on PBMC viability was 
assessed using flow cytometry to measure annexin V binding and PI staining. 
Vincristine treatment had minimal effects on PBMC viability (Figure 7.9A). 
Although 10 to 40 nM vincristine caused a significant (P<0.01) decrease in 
PBMC viability, viability was only reduced by 5%. The differences observed 
were due to changes in the percentage of apoptotic cells (Figure 7.9B); the 
percentages of necrotic and late apoptotic/secondary necrotic cells were 
unaffected by vincristine treatment (data not shown).  
The effects of vincristine on PBMC death was further investigated using 
higher concentrations of vincristine, 0 to 100 µM. Treatment with 0 to 12.5 µM 
vincristine had no significant effect on PBMC viability compared to untreated 
PBMCs (Figure 7.9C). Treatment with 100 µM vincristine caused a significant 
(P<0.01) decrease in PBMC viability compared to untreated PBMCs but only 
by around 10%. Vincristine treatment had no effect on the percentage of 
necrotic or late apoptotic/secondary necrotic PBMCs (data not shown), the 
small but significant difference in PBMC viability following treatment with 100 
µM vincristine was due to a significant (P<0.01) increase in the percentage of 
apoptotic PBMCs (Figure 7.9D). Collectively, these results show vincristine 
does not induce significant levels of cell death in PBMCs, even at high 
concentrations of vincristine.  
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Figure 7.9: Effect of vincristine on PBMC viability  
PBMCs were treated (A,B) 0 to 40 nM or (C-D) 0 to 100 nM vincristine and then incubated at 
37°C for 24 h. (A,C) viability or (B,D) apoptosis were measured using BD PharmingenTM FITC 
Annexin V Apoptosis Detection Kit I. Data presented as mean ± SD, n=3 experimental 
measurements for a single participant.  Statistical differences shown to untreated PBMCs, 
calculated using one-way ANOVA with Dunnett’s post hoc test: * (P<0.05), ** (P<0.01), *** 
(P<0.001). 
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7.3.6 Effect of MAPK inhibition and vincristine on PBMC death 
7.3.6.1 Effect of JNK inhibition and vincristine on PBMC death 
The effect of vincristine treatment on the activation of MAPKs in PBMCs was 
not investigated. However due to the limited ability of vincristine to induce cell 
death in PBMCs observed in Section 7.3.5, PBMCs were treated with 
SP600125 prior to vincristine treatment to assess if JNK inhibition altered the 
susceptibility of PBMCs to vincristine-induced cell death. Whilst significant 
(P<0.0001) differences in PBMC viabilities were observed between PBMCs 
treated with and without SP600125 and equivalent concentrations of 
vincristine, the differences were minimal (Figure 7.10A). The differences were 
due to small alterations in the percentage of apoptotic PBMCs (Figure 7.10B). 
SP6002125 therefore did not alter the sensitivity of PBMCs to vincristine-
induced cell death.  
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Figure 7.10: Effect of SP600125 and vincristine on PBMC viability 
PBMCs were pre-treated with 0 or 10 µM SP600125 at 37°C for 1 h to inhibit JNK signalling 
and then treated with various concentrations of vincristine. After 24 h, (A) PBMC viability or 
(B) apoptosis were measured using BD PharmingenTM FITC Annexin V Apoptosis Detection 
Kit I. Data presented as mean ± SD, n=3 participants. Experimental measurements were 
replicated 3 times for each of the participants and the data was combined. Statistical 
differences shown between SP600125 and no inhibitor at vincristine concentration points, 
calculated using two-way ANOVA with Sidak’s post hoc test: * (P<0.05), ** (P<0.01), *** 
(P<0.001), **** (P<0.0001). 
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7.3.6.2 Effect of p38 inhibition and vincristine on PBMC death 
Further investigations were performed to investigate if inhibition of another 
MAPK pathway, the p38 pathway, altered the sensitivity of PBMCs to cell 
death induced by vincristine. The small reductions observed in PBMC viability 
following vincristine treatment were prevented by inhibition of p38 signalling 
using SB202190 (Figure 7.11A). The differences were not due to changes in 
the percentages of necrotic or late apoptotic/secondary necrotic PBMCs (data 
not shown). The percentages of apoptotic PBMCs were lower for vincristine-
treated PBMCs pre-treated with SB202190 compared to those not pre-treated 
with SB202190 (Figure 7.11B). Although the effects are minimal, it appears 
that inhibition of p38 signalling, using SB202190 does prevent vincristine-
induced changes in PBMC viability.  
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Figure 7.11: Effect of SB202190 and vincristine on PBMC viability 
PBMCs were pre-treated with 0 or 10 µM SB202190 at 37°C for 1 h to inhibit p38 signalling 
and then treated with various concentrations of vincristine. After 24 h, (A) PBMC viability or 
(B) apoptosis were measured using BD PharmingenTM FITC Annexin V Apoptosis Detection 
Kit I. Data presented as mean ± SD, n=3 participants. Experimental measurements were 
replicated 3 times for each of the participants and the data was combined. Statistical 
differences shown between SB202190 and no inhibitor at vincristine concentration points, 
calculated using two-way ANOVA with Sidak’s post hoc test: **** (P<0.0001). 
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7.4 Discussion 
The overall aim of this chapter was to gain a greater understanding of the role 
of MAPK signalling in leukemic cell death by comparing the effects observed 
in previous chapters using the U937 human monocytic cell line, to PBMCs 
from healthy individuals.  
 
7.4.1 Levels of active MAPKs in PBMCs 
The JNK and p38 signalling pathway are typically activated by stress and 
therefore prior to performing experiments using PBMCs, it was necessary to 
establish whether or not the process of PBMC isolation had an effect on MAPK 
activation (Section 7.3.1). PBMC isolation had minimal effects on the activation 
of JNK, c-Jun and p38 and therefore PBMCs were treated immediately 
following isolation in the remaining experiments in this chapter.  
Low levels of phosphorylated JNK, c-Jun and p38 were measured in 
untreated PBMCs which is consistent with the observations in U937 cells 
(Section 3.3.5). Previous studies have demonstrated leukemic cells have high 
levels of active ERK compared to non-leukemic cells (Milella et al., 2001; 
Morgan, Dolp, & Reuter, 2001; Ricciardi et al., 2005). The work presented in 
this thesis is consistent with these previous findings. In chapter 3, it was shown 
that 95% of untreated U937 cells expressed phosphorylated ERK (Section 
3.3.5) whereas only 32% of untreated healthy PBMCs expressed 
phosphorylated ERK (Section 7.3.1). It is not surprising that a higher 
percentage of untreated PBMCs express phosphorylated ERK compared to 
phosphorylated JNK and p38, as ERK signalling is involved in cell survival 
(Shaul & Seger, 2007; Yoon & Seger, 2006). 
 
7.4.2 Activation of MAPKs in PBMCs 
Prior to targeting MAPK signalling in combination with cell stressors in PBMCs, 
it was necessary to confirm that the concentrations of MAPK inhibitors used in 
U937 cells were able to achieve MAPK inhibition in PBMCs. This was achieved 
in Chapter 3 by using the MAPK signalling inhibitors in combination with a 
signalling agonist, anisomycin (Section 3.3.5). Initially the effects of 
anisomycin on MAPK activation was tested and results showed treatment with 
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1 µM anisomycin for 30 min had minimal effects on the activation of JNK, c-
Jun, p38 and ERK (Section 7.3.2).  
The effect of anisomycin on MAPK activation was investigated further by 
focusing on the activation of JNK. Initially higher concentrations of anisomycin 
were investigated but results showed higher concentrations of anisomycin had 
no effect on the activation of JNK. A 30 min incubation with anisomycin was 
selected based on the results in U937 cells (Section 3.3.5) but as no effects 
were observed in PBMCs after this period of incubation, a longer incubation 
(1 h) with anisomycin was tested but showed no effect on JNK activation. It 
was believed the lack of JNK activation following anisomycin treatment was 
unlikely to be due to the methods used to measure phosphorylated MAPKs as 
phosphorylated ERK was detected in untreated PBMCs (Section 7.3.2). In 
addition, alternative methods to prepare PBMCs for flow cytometry were 
tested, such as the as the permeabilisation of PBMCs using BD PhosflowTM 
Perm Buffer II, but similar results were observed as those presented in this 
chapter (data not shown). 
The results presented in this chapter therefore suggest anisomycin is 
unable to activate MAPKs, in particular JNK, in PBMCs (Section 7.3.2). This 
is in contrast to the effects of anisomycin in U937 cells, in which anisomycin 
treatment readily causes the activation of JNK, c-Jun and p38 (Section 3.3.5). 
In order to make a direct comparison to U937 cells, the effect of anisomycin 
specifically on MAPK activation in monocytes needs to be investigated, which 
could be achieved by enriching the monocytes from the PBMCs.  
There appears to be no previous published studies regarding the effects 
of anisomycin specifically in healthy PBMCs. It was expected anisomycin 
would be effective in PBMCs as anisomycin is a protein synthesis inhibitor 
which functions by inhibiting peptidyl transferase during translation in 
eukaryotic ribosomes (Hori et al., 2008). Cancer cells have a high demand for 
protein synthesis due to high rates of proliferation and increased rates of 
survival (Bhat et al., 2015). The difference in the sensitivities of U937 cells and 
healthy PBMCs to anisomycin could be attributed to different protein synthesis 
rates between cancer and non-cancer cells. For example, various cancer cell 
lines were 2-4 times more susceptible to cell death induced by amicoumacin 
A, an alternative protein synthesis inhibitor, compared to non-cancer cell lines 
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(Prokhorova et al., 2016). Therefore, alternative compounds to protein 
synthesis inhibitors, might be more suitable as MAPK signalling agonists in 
healthy PBMCs. Lipopolysaccharide is a potential compound which has 
previously been shown to activate MAPKs in PBMCs (van den Blink et al., 
2001; Wu, Alexis, Bromberg, Jaspers, & Peden, 2009) 
  
7.4.3 UV light treatment 
The effect of UV light on PBMC death was investigated and results showed 
PBMC viability decreased in a dose-dependent manner (Section 7.3.3) which 
was similar to that observed in U937 cells (Section 3.3.1). It is well established 
that UV light is able to activate JNK signalling; UV light was used as an 
alternative stimulus to induce JNK activation in PBMCs. JNK was activated 
within 15 min following anisomycin treatment in U937 cells (Section 3.3.5), 
suggesting JNK is rapidly activated in response to cell stressors. Therefore, 
the activation of JNK signalling following UV treatment in PBMCs was 
measured up to 60 min following UV treatment but results showed JNK was 
not activated during this time (Section 7.3.4). A longer incubation time (up to 
4 h) was studied but also showed no activation of JNK. The ability of UV light 
to induce JNK activation in PBMCs from healthy individuals has however been 
shown in a previous study; both JNK1 and JNK2 were activated in PBMCs 
following treatment with 60 J/m2 UV for 30 and 60 min (Wang et al., 2011). 
The ability of UV to stimulate JNK activation in PBMCs as observed in the 
study by Wang et al. (2011) could be due to the longer durations of UV 
treatment used compared to the short durations used in this thesis. Another 
possible explanation for the inconsistencies in results could be due to the 
methods used to measure JNK activation in PBMCs; Wang et al. (20011) used 
Western blotting whereas flow cytometry was used in this chapter. It was 
originally believed that the lack of JNK activation was not due to the flow 
cytometry method used to detect phosphorylated JNK in PBMCs, however 
additional measurement of JNK phosphorylation by Western blotting in 
PBMCs following both anisomycin and UV light treatment would have provided 
clarification of this matter.   
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As neither anisomycin nor UV light were able to activate MAPK signalling in 
PBMCs, it was not possible to confirm the effect of MAPK inhibitors on MAPK 
phosphorylation in PBMC. Therefore, the same concentration of inhibitors, as 
were used for U937 cells were tested, but without confirmation of signalling 
inhibition, the conclusions which can be drawn from the following data are 
limited.  
 
7.4.4 MAPK inhibition and UV light 
In Chapter 4, it was shown that inhibition of JNK signalling using SP600125, 
made U937 cells more susceptible to UV-induced apoptosis (Section 4.3.2.1). 
In this chapter, PBMCs were treated with SP600125 to determine if JNK 
inhibition altered the susceptibility of PBMCs to UV-induced cell death (Section 
7.3.5.1). The data shown is data combined for 3 individual participants, yet 
interestingly similar effects were observed in each of the 3 individuals 
(individual data not shown). SP600125 had little effect on the sensitivity of 
PBMCs to cell death induced by UV light, suggesting JNK signalling is not 
involved in the response of PBMCs to UV light. Similar effects on UV light-
induced death in PBMCs were observed when p38 signalling was inhibited 
using SB202190.  The effects observed are not as striking as in U937 cells, 
but without confirmation of the ability of 10 µM SP600125 or 10 µM SB202190 
to inhibit JNK and p38 phosphorylation PBMCs respectively, limited valid 
conclusions can be drawn from the data.   
   
7.4.5 Vincristine treatment 
The effect of vincristine on PBMC death was investigated and results showed 
concentrations of vincristine up to 40 nM, which were effective at inducing cell 
death in U937 cells (Section 3.3.3.2), had minimal effects on cell death in  
PBMCs (Section 7.3.6). Higher concentrations of vincristine, up to 100 µM, 
were tested but these concentrations also had minimal effect on PBMC cell 
death. These results suggest U937 cells are more susceptible to vincristine-
induced cell death than healthy PBMCs. These results are in agreement with 
a previous study which reported the IC50 value for vincristine in U937 cells as 
0.09 ng/mL, whereas the IC50 value for PBMCs was greater than 100 ng/mL 
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(Chadarat Ampasavate et al., 2010). As vincristine binds to tubulin and 
prevents subsequent cell division, the differences in susceptibility of U937 cells 
and PBMCs to vincristine are likely to be due to differences in proliferation 
rates; U937 cells have a high proliferation rate whereas ex vivo PBMCs in 
culture have low proliferation rates.  
 
7.4.6 MAPK inhibition and vincristine 
Treatment with SP600125 protected U937 cells from vincristine-induced cell 
death suggesting the importance of JNK activation in the induction of U937 
cell death in response vincristine (Section 4.3.4.3). PBMCs were treated with 
SP600125 in combination with vincristine, to determine if JNK signalling 
inhibition, altered the susceptibility of PBMCs to cell death (Section 7.3.6.1). 
Inhibition of JNK signalling, using SP600125 however had minimal effects on 
vincristine-induced cell death in PBMCs, suggesting JNK signalling is not 
involved in the protection against PBMC cell death in response to vincristine.  
Inhibition of p38 signalling, using SB202190, also protected U937 cells 
from vincristine-induced cell death (Section 5.3.5). Although the effect of 
vincristine treatment alone was minimal, inhibition of p38 signalling in PBMCs 
using SB202190, also protected the PBMCs from vincristine- induced cell 
death (Section 7.3.6.2). Therefore it appears that the activation of p38 
signalling is important for providing protection from vincristine-induced cell 
death in both U937 cells and PBMCs from healthy individuals. This suggests 
that potential methods to promote the activation of p38 in leukemic cells in 
response to vincristine may also increases the levels of p38 and subsequent 
cell death in non-leukemic cells.  
 
7.5 Summary 
In this chapter, the activation of JNK following anisomycin or UV light treatment 
was not detected. Further work is needed to confirm the reasons for this and 
to confirm the ability of MAPK inhibitors to inhibit MAPKs in PBMCs. UV light 
decreased PBMC viability in a similar manner to U937 cells, but the ability of 
JNK and p38 inhibition to alter the susceptibility of PBMCs to UV light was 
minimal. PBMCs are less sensitive to vincristine-induced cell death compared 
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to U937 cells. JNK inhibition had little effect on PBMC death yet p38 inhibition 
prevented vincristine-induced death.  
It is difficult to draw valid conclusions from the work presented in this 
chapter, as each experiment was conducted on PBMCs from a very limited 
number of healthy individuals, up to 3, but in some cases, only a single 
individual. Further work involving a larger number of individuals is required; 
studying a larger number of individuals will also provide an insight into variation 
between individuals.    
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Chapter 8: General Discussion 
The overall aim of this thesis was to investigate the role of MAPK signalling 
pathways in leukemic cell death. This was achieved by targeting the JNK, p38 
and ERK pathways in combination with various cell stressors in the U937 cell 
line. In addition, preliminary work was performed to investigate the role of 
MAPK pathways in PBMCs from healthy individuals. The aim of this chapter 
is to discuss potential models for the involvement of MAPK signalling pathways 
in leukemic cell death in response to the stimuli tested in this thesis, and to 
consider the implications of these findings. The approaches taken to target 
MAPK signalling will be discussed, and areas for potential further work will be 
identified.  
 
8.1 Role of MAPKs in leukemic cell death  
The constitutive activation of ERK1/2 has previously been reported in AML 
cells (Kim et al., 1999; Milella et al., 2001; Ricciardi et al., 2005), consistent 
with this, the results presented in this thesis show high levels of 
phosphorylated ERK1/2 in U937 cells. High levels of active ERK1/2 mediate 
leukemic cell survival (Kerr et al., 2003; Milella et al., 2001; Morgan et al., 
2001), confirmed in this study, where inhibition of ERK1/2 signalling in U937 
cells reduced cell survival. As the role of ERK1/2 signalling in leukemogenesis 
appears to be well-established and less is known about the roles of the JNK 
and p38 pathways, the JNK and p38 pathways will remain the focus for the 
following discussion.    
JNK signalling has distinct and opposing functions in cancer (Bubici & 
Papa, 2014; Tournier, 2013) and whilst the role of JNK signalling appears to 
be well established in solid tumours, the role in leukemic cell death is poorly 
understood. There is conflicting evidence for the role of JNK signalling in the 
response of leukemic cells to chemotherapy (Cripe et al., 2002; Lagadinou et 
al., 2008; Liou et al., 2017; Mc Gee et al., 2002; Nica et al., 2008). p38 
signalling has been implicated primarily in lymphocytic leukaemias (Bendall et 
al., 2005; Gaundar et al., 2009; Ringshausen et al., 2004), whilst the role in 
myeloid leukaemias, in particular AML, is poorly understood. As for JNK 
signalling, the role of p38 in the response of leukemic cells to chemotherapy, 
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is controversial  (Dumka et al., 2009; Giafis et al., 2006; Parmar et al., 2004; 
Pedersen et al., 2002). The role of MAPKs in leukemic cell death therefore 
appears to be specific to the type of leukaemia, the cell type and the 
chemotherapy used. This thesis utilised U937 cells, as a model cell line for 
AML. The role of MAPK pathways in U937 cell death was investigated in this 
thesis in response to various cell stressors: UV light, heat treatment and the 
chemotherapeutic agents doxorubicin and vincristine.  
One of the most important conclusions from the work presented in thesis 
is that the role of MAPKs in U937 cell death is stimuli-specific. UV treatment 
and heat treatment provided a good model for investigating the role of MAPK 
signalling pathways in leukemic cell death. However the findings that the role 
of MAPKs in leukemic cell death is stimuli-specific, highlights that future work 
should focus on investigating the role of MAPKs in response to specific 
chemotherapeutic agents, as this will have the most important clinical 
implications. The role of MAPK signalling pathways in the response to UV, 
heat treatment and doxorubicin in leukemic cells will briefly be discussed here. 
The most important findings in this thesis are related to vincristine, hence the 
role of MAPKs in vincristine-induced cell death in leukemic cells will be 
discussed in more depth.  
 
8.1.1 Role of MAPKs in leukemic cell death induced by UV  
Radiation is a type of cancer treatment which induces cell death by causing 
direct DNA damage and protein damage (Reisz, Bansal, Qian, Zhao, & Furdui, 
2014). UV light was used as an apoptotic stimulus in this thesis in order to 
investigate the role of MAPK signalling pathways in leukemic cell death 
induced by DNA and protein damage (Figure 8.1). Results of this study 
showed ERK signalling was not involved in the response of U937 cells to UV-
induced cell death, which is in agreement with previous findings in U937 cells 
(Luchetti et al., 2009). In this thesis, increased UV-induced cell death was 
observed in U937 cells following inhibition of JNK and p38 signalling. This 
suggests that the activation of JNK and p38 signalling mediates cell survival 
in response to DNA and protein damage induced by UV light (Figure 8.1).  
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Although typically the main function of p38 signalling is to promote cell 
death, p38 is able to mediate cell survival in certain cellular contexts 
(Cappellini et al., 2005; Kurosu et al., 2005), including the response to DNA 
damage. Two cell cycle checkpoints which allow for DNA repair are the G1/S 
checkpoint and the G2/M checkpoint (Bartek & Lukas, 2007). p38 activation is 
involved in the activation of both checkpoints, enabling cell survival (Thornton 
& Rincon, 2009). Activation of p38 is required for the initiation  of the G2/M 
checkpoint following UV treatment (Bulavin et al., 2001). Given the role of p38 
activation in the induction of cell cycle checkpoints, it is likely that the p38-
mediated survival of U937 cells in response to UV treatment observed in this 
thesis is due to the role of p38 in facilitating DNA repair mechanisms prior to 
mitosis. This idea is further supported by the evidence that the activation of 
MAPKAPK-2, a downstream target of p38, is also required for mediating U937 
cell survival in response to UV (Figure 8.1). MAPKAPK-2 has been shown to 
be critical for the G2/M and G1/S checkpoints following UV-induced DNA 
damage (Manke et al., 2005). In order to confirm that p38 activation mediates 
cell survival in U937 cells following UV treatment by activating cell cycle 
checkpoints, the effect of p38 inhibition and UV light treatment on the 
activation of checkpoint kinases, such as checkpoint kinase 1 (Chk1) and 
checkpoint kinase 2 (Chk2) could be measured. The p53 tumour suppressor 
protein and p21 protein are also likely to be involved; it would therefore be 
useful to also measure the effects of p38 inhibition and UV light treatment on 
the activation of p53 and p21. 
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Figure 8.1: Model for the involvement of MAPK signalling pathways in the response of U937 cells to various cell stressors 
The JNK and p38 signalling pathways are involved in mediating either cell survival or apoptosis in response to UV light, heat treatment, doxorubicin and 
vincristine. The activation of JNK and p38 is essential for mediating cell survival in response to UV light. Cell survival in response to heat treatment is mediated 
by p38 activation and activation of c-Jun by a pathway which does not require JNK activation. p38 activation mediates cell survival in response to doxorubicin 
treatment, whereas JNK activation is required for induction of apoptosis. The activation of JNK and p38 is required for vincristine-induced apoptosis. 
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The role of JNK signalling in the response to UV treatment is however 
somewhat surprising. The work presented in this thesis suggests that the 
activation of JNK, but not c-Jun is important for mediating U937 cell survival in 
response to UV treatment. These findings contradict a vast amount of previous 
research which implicates the apoptotic role of JNK signalling, particularly in 
the response to UV treatment. There are two possible explanations which 
could explain these observations. Firstly, the conclusion that the activation of 
JNK mediates cell survival is based on data using the JNK inhibitor, 
SP600125. The effects of JNK inhibition and UV light treatment on the 
activation of JNK and c-Jun were not directly measured. It is possible the 
results observed cannot be attributed to direct alterations in JNK activation. 
SP600125 was initially believed to be a highly specific inhibitor of JNK 
signalling (Bennett et al., 2001), others have argued that although SP600125 
shows greater inhibition of JNK phosphorylation compared to other kinases, 
SP600125 is able to inhibit other kinases such as p38 to an extent (Bain, 
Plater, et al., 2007; Bain, Mclauchlan, Elliott, & Cohen, 2003). Therefore it is 
possible that the effects observed are due to the effects of SP600125 on p38 
signalling and hence the findings are similar to those previously discussed or 
an alternative pathway may be affected.  
The alternative explanation is that SP600125 does inhibit JNK 
phosphorylation but the inhibition of the JNK signalling pathway has effects on 
other signalling pathways. Signalling pathways do not act in isolation, but 
rather function as part of a complex signalling network with interactions 
between signalling pathways, termed cross-talk. Cross-talk between signalling 
pathways ensures that the correct cellular response is triggered in response 
to a stimulus. One such example is the cross-talk between the p38 and JNK 
signalling pathways; cross talk between p38 and JNK, mediated by MAPK 
phosphatase-1 (DUSP1/MKP-1), is important for determining the fate of the 
cell following exposure to UV light (Staples, Owens, Maier, Cato, & Keyse, 
2010). Cross-talk however does not just occur between two pathways, multiple 
pathways are involved. If JNK is unable to be activated following UV-induced 
DNA damage, cross-talk may enable alternative pathways to be activated, 
which induce cell death. Surprisingly, a highly specific inhibitor of c-Jun 
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phosphorylation was utilised and showed c-Jun has no effect on UV-induced 
cell death in U937 cells. If JNK signalling is involved in UV-mediated cell 
survival, it is possible other downstream targets of JNK phosphorylation are 
activated when c-Jun activation is inhibited; a single kinase is capable of 
activating multiple downstream targets. To investigate these two theories, the 
effects of JNK inhibition and UV light treatment on the components of the JNK 
signalling pathway and alternative pathways need to be measured.  
Results also showed that PBMCs from healthy individuals were as 
susceptible to UV treatment as the U937 cells. This has important clinical 
implications as it confirms radiation is not a suitable treatment for leukaemia, 
as both leukemic and non-leukemic cells would be susceptible to the radiation. 
As leukemic cells do not form a solid tumour, it would be difficult to selectively 
target the leukemic cells with radiation. This, however, is a general 
phenomenon for the treatment of cancer with radiation; hence chemotherapies 
which specifically target cancer cells are a more desirable treatment option. 
The JNK and p38 signalling pathways provided protection from UV-induced 
cell death in PBMCs, as observed for U937 cells. This suggests that the 
involvement of JNK and p38 signalling in providing protection against UV-
induced cell death is a general response and is not specific to leukemic cells.  
 
8.1.2 Role of MAPKs in leukemic cell survival in response to heat 
treatment  
Sub-lethal heat treatments, which alone are insufficient to cause cell death, 
are able to sensitise cancer cells to radiation therapy and chemotherapy (Falk 
& Issels, 2001; Hildebrandt et al., 2002; Jolly & Morimoto, 2000). Heat 
treatment causes protein damage (Figure 8.1) as small increases in 
temperature cause protein unfolding and protein aggregation. Protein damage 
as a result of heat treatment initiates a cellular response, termed the heat 
shock response. The heat shock response involves the upregulation of a 
family of proteins, the heat shock proteins (HSPs) which function as molecular 
chaperones and facilitate the refolding of damaged proteins. The HSPB1 
(HSP27), HSPA (HSP70) and HSPC (HSP90) subfamilies have a protective 
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role, preventing apoptosis induced by various stimuli, including heat treatment 
(Beere, 2005). 
Although ERK signalling plays an important role in cell survival, results 
showed that ERK activation was not involved in mediating cell survival in U937 
cells in response to heat treatment. It was however shown that the activation 
of p38 is required for the survival of U937 cells following heat treatment (Figure 
8.1). This is not surprising as HSPB1 is phosphorylated by MAPKAPK-2, a 
downstream target of p38 (Cuenda et al., 1995). Although the results of this 
study do not suggest an involvement of MAPKAPK-2 in the response of U937 
cells to heat treatment, this is more likely to be due to lack of inhibition of 
MAPKAPK-2 by SB203580 as previously discussed. It is likely that protein 
damage, as a result of heat treatment causes the activation of p38, the 
subsequent activation of MAPKAPK-2 and the phosphorylation of HSPB1. 
HSPB1 is a signalling molecule which has multiple downstream targets. One 
mechanism by which HSPB1 could promote cell survival is by interacting with 
protein kinase B (Akt). The interaction between Akt and HSPB1 stabilises Akt 
which is a kinase that promotes cells survival (Rane et al., 2003). This 
interaction may be mediated by HSPC proteins (Sato, Fujita, & Tsuruo, 2000). 
HSPB1 could also prevent apoptosis by preventing the release of cytochrome 
c (Paul et al., 2002). These are just two possible mechanisms by which p38-
mediated activity of HSPB1 could promote cell survival in U937 cells following 
heat treatment. The anti-apoptotic role of HSPs is too extensive to discuss 
further here. It is however evident that the interactions between HSPs and 
MAPK signalling pathways in leukemic cells needs confirming.  
The work presented in this thesis suggests the activation of JNK is not 
involved in the response of U937 cells to heat treatment. HSPA proteins are 
anti-apoptotic proteins which are able to inhibit the phosphorylation and 
activation of JNK (Li et al., 2010; Mosser et al., 2000; Park, Lee, Huh, Seo, & 
Choi, 2001). It is possible that in U937 cells, HSPA proteins are induced 
following heat treatment, which inhibit the activation of JNK, and hence no 
further effects are observed when the cells are treated with SP600125. The 
activation of c-Jun is however important for U937 cell survival following heat 
treatment (Figure 8.1). c-Jun is typically activated by JNK signalling, but as 
results suggest JNK is not activated following heat treatment, it is possible c-
Chapter 8: General Discussion  
 
250 
 
Jun is activated by an alternative pathway. The mechanism by which c-Jun is 
activated following heat treatment requires further investigation.  
 
8.1.3 Role of MAPKs in leukemic cell death induced by doxorubicin 
Doxorubicin, an anthracycline antibiotic, is a chemotherapy used in the 
treatment of leukaemia. Doxorubicin exerts its intracellular effects on cell death 
through two mechanisms: inhibition of DNA synthesis and DNA damage 
(Figure 8.1). Doxorubicin directly intercalates with DNA and it is the interaction 
between doxorubicin and DNA which inhibits DNA topoisomerase II and 
prevents the synthesis of DNA (Yang et al., 2014). Alternatively, upon entering 
a cell doxorubicin can become oxidised by proteins in the cytoplasm to form a 
doxorubicin semiquinone. The doxorubicin semiquinone is an unstable 
metabolite which is readily reduced back to doxorubicin by a process which 
generates reactive oxygen species (ROS), such as free radicals. Generation 
of ROS results primarily in DNA damage, but also protein damage and lipid 
peroxidation, all of which trigger apoptosis.  
The activation of stress-activated protein kinases following doxorubicin 
treatment is well established in cancer cells (Kim & Freeman, 2003; Krilleke et 
al., 2003; Lagadinou et al., 2008; Panaretakis et al., 2005). The results 
presented in this thesis show that the activation of JNK is required for 
doxorubicin-induced apoptosis in U937 cells (Figure 8.1), which is consistent 
with previous findings (Lagadinou et al., 2008). The pro-apoptotic role of c-
Jun, a downstream target of JNK has previously been implicated in the 
response to doxorubicin; Lagadinou et al. (2008) however did not investigate 
the involvement of c-Jun in U937 cells. In this thesis it was shown that the 
activation of c-Jun is also important for the apoptotic effects of doxorubicin in 
U937 cells (Figure 8.1). It is widely believed that JNK signalling is involved in 
the induction of the intrinsic (mitochondrial) apoptotic pathway. In U937 cells, 
the activation of JNK and c-Jun following DNA damage and inhibition of DNA 
synthesis is likely to activate pro-apoptotic proteins (Bak, Bax and BH3-only 
proteins). This results in the release of cytochrome c from the mitochondria, 
activation of effector caspases and subsequent activation of apoptosis. 
Although the downstream effects of JNK signalling activation on apoptosis 
Chapter 8: General Discussion  
 
251 
 
appear to be well-characterised, the mechanisms by which doxorubicin leads 
to JNK activation requires further investigations.  
Both doxorubicin and UV light cause DNA damage yet the involvement 
of JNK signalling in response to the two stressors is different and opposing. 
This could be related to the mechanisms by which DNA damage occurs. UV 
light has a direct effect on DNA, whereas DNA damage induced by doxorubicin 
is an indirect effect as a result of the generation of ROS. Alternatively, 
doxorubicin exerts its apoptotic effects by two mechanisms, inhibition of DNA 
synthesis and causing DNA damage. It is possible that JNK activation plays a 
more prominent role in the induction of apoptosis following inhibition of DNA 
synthesis, whereas p38 is involved in apoptosis induced by DNA damage, or 
vice versa.  
In contrast to JNK signalling, p38 is activated in U937 cells following 
doxorubicin treatment and the activation of p38 is important for promoting cell 
survival in response to doxorubicin (Figure 8.1). This observation could be 
related to the involvement of p38 in cell cycle checkpoints, as discussed for 
UV light (Section 8.1.1).  
 
8.1.4 Role of MAPKs in vincristine-induced cell death  
Microtubule-targeting agents, such as the vinca alkaloids (vincristine, 
vinblastine) are commonly used in the treatment of various types of leukaemia. 
Microtubules are intracellular filaments which have an important function in 
chromosomal segregation during mitosis (cell division), which makes them an 
ideal target for chemotherapy (Dumontet & Jordan, 2010; Jordan & Wilson, 
2004). Vincristine inhibits microtubule formation by binding to the β-tubulin 
subunit of the α-β heterodimer and preventing the addition of tubulin dimers to 
the assembly end (+ end) of the microtubule (Figure 8.2). Inhibition of 
microtubule assembly prevents mitotic spindle formation, disables the 
movement and alignment of chromosomes and hence blocks progression from 
G2 to M phase of the cell cycle. A vast amount of previous research has 
implicated MAPK signalling pathways in the response of cancer cells to 
microtubule inhibitors (Fan & Chambers, 2001), and in particular in the 
response of leukemic cells to vincristine (Alsadeq et al., 2015; Barančík et al., 
2001; Bates et al., 2015a; Shiah et al., 2001; Yoshida et al., 2011). Studies 
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regarding the role of MAPK signalling pathways in response to microtubule 
inhibitors are however limited in AML cells. Vinblastine, an alternative 
microtubule inhibitor to that used in this thesis, induces apoptosis in ML-1 cells 
(AML cell line) and causes the activation of JNK and p38 in ML-1 cells 
(Stadheim, Xiao, & Eastman, 2001). However it was not shown if the activation 
of JNK and p38 was essential for cell death. The results presented in this 
thesis suggest that the activation of the JNK and p38 signalling pathways are 
required for vincristine-induced cell death in U937 cells (Figure 8.2). This is 
likely to occur via a mechanism which does not require the activation of c-Jun 
and MAPKAPK-2, which are downstream targets of JNK and p38 
phosphorylation, respectively. This appears to be the first evidence to link the 
JNK and p38 signalling pathways to vincristine-induced cell death specifically 
in AML cells. Further work is however required to confirm that the effects 
observed are due to changes in the levels of active JNK and p38; signalling 
inhibitors were used to target the JNK and p38 signalling pathways but the 
effect of JNK and p38 inhibition and vincristine treatment on the activation of 
JNK and p38, respectively was not directly measured.  
Activation of JNK following vincristine treatment could be due to the 
accumulation of cells in the G2/M phase of the cell cycle. In normal cells, JNK 
is temporarily activated during the late G2/M phase of the cell cycle (Fan & 
Chambers, 2001). Microtubule inhibitors cause accumulation of cells in the 
G2/M phase, and hence an accumulation of cells expressing JNK; the 
transient expression of active JNK therefore becomes sustained. The duration 
of JNK activation depends on the pro- or anti-apoptotic function of JNK (Liu & 
Lin, 2005) and therefore the sustained activation of JNK as a result of mitotic 
arrest could result in apoptosis (Chen, Wang, Templeton, Davis, & Tan, 1996). 
This provides one possible explanation for the involvement of JNK in the 
response of U937 cells to vincristine. However as p38 signalling was also 
found to be activated following vincristine treatment, it is more likely that JNK 
and p38 are activated as part of a stress response induced by the disruption 
of microtubule formation. JNK and p38 signalling have previously been 
implicated in the stress response to microtubule disarray (Wang et al., 1998). 
In order to fully understand the importance of JNK and p38 activation in 
vincristine-induced cell death in leukemic cell death, it is necessary to 
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understand how the pathways are affected in non-leukemic cells. This was 
investigated in this study using PBMCs from healthy individuals. U937 cells 
were shown to be more sensitive to vincristine-induced cell death than healthy 
PBMCs. This is consistent with previous findings in a study also utilising U937 
cells and PBMCs from healthy individuals (Ampasavate et al., 2010). This is a 
very important finding as it indicates vincristine is an ideal therapy as it affects 
leukemic cell death, whilst having minimal effects on non-leukemic cells. 
However, in order to draw such conclusions, further work is required to gain a 
more thorough understanding of the mechanisms which account for the 
resistance of healthy PBMCs to vincristine. 
A possible explanation for the lack of vincristine-induced cell death in 
healthy PBMCs could be attributed to the differences between transformed 
and primary cells. Transformed cells are able to rapidly proliferate in vitro; as 
vincristine targets microtubule formation and prevents subsequent cell 
division, transformed cells such as U937 cells are highly sensitive to 
vincristine. Healthy PBMCs however are likely to have a much slower rate of 
proliferation in vitro; PBMCs are terminally differentiated cells which have very 
limited division potential and mitogenic stimuli required for proliferation are 
likely to be lacking. If the PBMCs are not proliferating there will be a limited 
requirement for the production of new microtubules and hence there is a lack 
of target for vincristine (Figure 8.2). In order to establish if the differences 
observed are due to differences between transformed and primary cells, 
PBMCs from AML patients need to be compared to PBMCs from healthy 
individuals. A previous in vitro study compared primary leukemic and non-
leukemic cells; lymphocytes from healthy individuals were more resistant to 
vincristine than lymphocytes from children with ALL (Kaspers et al., 1991). 
However it cannot be assumed that AML cells would behave in a similar 
manner to ALL cells.  
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Figure 8.2: Model for the role of JNK and p38 signalling in vincristine-induced apoptosis in leukemic and non-leukemic cells 
Microtubules have an important function in chromosomal segregation during mitosis which is critical for the survival of leukemic cells. Microtubules are formed 
by the addition of tubulin heterodimers to the + end of microtubules. Vincristine inhibits microtubule formation by binding the β-tubulin subunit of the heterodimer, 
preventing the formation of microtubules. Leukemic cells such as U937 cells have high proliferation rates and inhibition of microtubule formation by vincristine 
causes mitotic arrest. This causes the activation of JNK and p38, which ultimately leads to apoptosis, through a mechanism which could involve the inhibition 
of anti-apoptotic proteins. Non-leukemic cells, such as PBMCs do not rapidly proliferate in vitro so there is no requirement for new microtubule formation and 
hence there is no target for vincristine allowing the cells to survive. 
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In this study, U937 cells, a monocytic cell line was compared to PBMCs, 
which is a population of cells consisting mainly of monocytes (10-30%) and 
lymphocytes (70-90%). In addition to different cell types, different populations 
of cells are likely to present in terms of other factors such as age of the cell. 
Different populations of cells might have different proliferation rates and be 
differentially affected by vincristine. In order to allow for a more direct 
comparison between U937 cells and non-leukemic cells, further investigation 
should be performed on monocytes isolated from PBMCs.  
Although cell lines provide a good model, they do not allow for 
consideration to variation between individuals. Previous work in a University of 
Chester laboratory has highlighted the variation in the response of CLL 
patients to various chemotherapeutics, which has been associated with altered 
activation of signalling pathways (Dempsey, unpublished data). An alternative 
study has highlighted variation in the levels of JNK activation following 
vincristine treatment between patients with CLL (Bates, Lewis, Eastman, & 
Danilov, 2015). Therefore primary leukemic cells ultimately need to be 
compared to non-leukemic cells from healthy individuals. Bates et al. (2015) 
also showed that the activation of JNK in CLL lymphocytes following vincristine 
treatment was higher for lymphocytes treated ex vivo compared to JNK 
activation in lymphocytes treated in vivo. This is important to take into account 
when considering the clinical implications of this research.  
 
8.2 Targeting MAPK signalling in leukemic cells  
One of the main limitations of this study is that the JNK, p38 and ERK pathways 
were targeted individually and were mainly considered as separate, unrelated 
pathways. Signalling pathways form complex signalling networks with cross-
talk between pathways; future research in this area should take a more 
integrated approach to targeting the MAPK pathways. Due to the complexity 
of cell signalling, this would be challenging but there are two possible 
approaches which could be taken to address signalling cross-talk. As 
previously mentioned, the effects of MAPK inhibition and cell stressors on 
MAPK activation need to be assessed in future work. To account for cross-talk 
between pathways, it is important to not only measure the effects on the 
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signalling molecule being targeted, but also to simultaneously assess the 
effects on other signalling molecules following treatment. There are a number 
of commercial signalling arrays available which can achieve this; these arrays 
provide a better overview of a signalling response following treatment by 
showing phosphorylation changes in multiple interrelated pathways. Another 
approach which could be taken is to use multiple signalling inhibitors 
simultaneously to target a small number of pathways. The results from a 
signalling array would direct which pathways would be most appropriate to 
target. It might be necessary to use multiple inhibitors at different times. It is 
possible that the inhibition of one pathway may lead to the activation of 
another, which could then be targeted with an inhibitor following the initial 
inhibitor. Leukaemia therapy which targets multiple signalling pathways is 
more likely to be effective than therapy targeting a single pathway.  
In this thesis, the JNK, p38 and ERK signalling pathways were targeted 
using small molecule inhibitors. One of the main strengths of the work 
presented is that each MAPK signalling pathway was investigated using two 
alternative inhibitors, which provides a more thorough understanding of the 
role of each pathway, and in particular the involvement of particular 
components of the pathway. For example, JNK signalling was targeted using 
both SP600125 which prevents the phosphorylation of JNK and JNK-IN-8 
which prevents the phosphorylation of the downstream target c-Jun.  
Targeting MAPK signalling pathways using small molecule inhibitors 
however presents many problems including poor efficacy and specificity, 
reversibility and poor selectivity for different MAPK isoforms. With the 
exception of JNK-IN-8, the MAPK inhibitors used in this thesis were ATP-
competitive inhibitors. The efficacy of ATP-competitive inhibitors is reduced by 
high levels of intracellular ATP (Bogoyevitch, 2005; Bubici & Papa, 2014). In 
addition, ATP-competitive inhibitors display poor specificity as they target the 
ATP-binding site which is highly conserved in protein kinases. Although ATP-
competitive MAPK inhibitors have been used extensively in research to target 
MAPK signalling pathways, novel MAPK inhibitors which show greater 
specificity have been developed and should be utilised in future research. 
Further research should also focus on the development of MAPK inhibitors 
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which can be used clinically, and also on methods to deliver these inhibitors 
specifically to cancer cells.  
Not only is specificity a problem with MAPK inhibitors, reversibility of the 
MAPK inhibitors also limits their use. SP00125 for example is reversible 
however JNK-IN-8 which is a novel irreversible inhibitor was also tested in this 
thesis. Where possible, irreversible inhibitors should be used in the future to 
provide more effective signalling inhibition. Consideration must also be paid to 
the order in which cells are treated with MAPK inhibitors and cell stressors. 
Cells were pre-treated with a MAPK inhibitor prior to treatment with a cell 
stressor. This approach was selected based on previous research and the 
assumption that addition of the inhibitors prior to treatment would prevent the 
MAPKs from being activated by the treatments. However in order to gain a 
more thorough understanding, addition of the inhibitors after treatment should 
also be tested. This is particularly important for reversible inhibitors, where the 
treatment with cell stressors has the potential to reverse the effects of the 
inhibitors.  
Given the differential role of MAPK isoforms in cancer, it is important to 
selectively target individual MAPK isoforms in leukemic cells. It is difficult to 
achieve this with small molecule inhibitors; the small molecule inhibitors used 
in this thesis target multiple MAPK isoforms. Isoform-specific targeting of 
MAPKs can be achieved by knocking down individual MAPK genes using 
methods to silence genes such as small interfering RNAs (siRNAs). 
Knockdown of individual MAPK isoforms is an important research tool to 
identify the importance of a particular isoform. However this approach cannot 
be taken to target MAPK signalling pathways therapeutically due to the long 
term and unwanted side effects of the complete loss of a particular MAPK 
isoform. Not only should individual MAPK isoforms be targeted, but the effects 
of treatment on individual MAPK isoforms should be measured using isoform-
specific antibodies.   
 
8.3 Implications of the research 
Collectively, the evidence presented in this thesis suggests that targeting 
MAPK signalling pathways in combination with chemotherapy has the potential 
to be an effective therapeutic approach for leukaemia. Some 
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chemotherapeutic agents require the activation of MAPKs for the induction of 
cell death, and if a cancer cell has mutations that impair MAPK activation, it 
will be chemoresistant. Understanding the mechanisms leading to the failure 
of MAPK activation will be of great therapeutic value, and approaches to 
enhance the activation of the MAPK required, might prove to be effective. In 
contrast, where MAPK activation mediates cell survival in response to a 
chemotherapeutic agent, inhibition of the pathway in combination with 
standard chemotherapy might be beneficial.  
The importance of MAPKs in the development of leukaemia suggests that 
they might be a useful prognostic marker. High levels of phosphorylated ERK2 
has been associated with a poor prognosis in AML patients (Kornblau et al., 
2006). Measurement of active MAPK levels in a leukaemia patient prior to 
commencing treatment might also be beneficial in predicting if a patient will 
respond to a particular treatment. For example, vincristine-induced cell death 
requires the activation of JNK. If an individual already has high levels of active 
JNK prior to starting vincristine treatment, then it is likely they will not respond 
well to the treatment. Measurement of MAPK levels could therefore be useful 
in determining which treatment is best to use for a patient. Measurement of 
MAPK levels could also be useful for monitoring the response of a patient to a 
treatment. For example, if neither JNK nor p38 are activated following 
vincristine treatment, this might suggest the patient will not respond to this 
treatment and an alternative therapy should be started. 
The development of the hallmarks of cancer concept has been successful 
in leading to many generalised therapeutic approaches. However, more recent 
research, including that previously discussed, suggest inclusion of a 
personalised elements into the ‘hallmarks’ would be beneficial. In oncology, 
personalised medicine is the tailoring of medical treatment to the individual 
characteristics of each patient. This approach relies on the understanding of 
an individual’s molecular and genetic profile. Here, it has been suggested how 
an understanding of the MAPK signalling pathways in leukemic cell death 
could be used to deliver personalised medicine in leukaemia patients. The 
MAPK signalling pathways however represent a small number of pathways 
which function as part of a complex signalling network. Gaining a greater 
understanding of which pathways are deregulated in relation to each of the 
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hallmarks of cancer will enable a personalised approach to treatment. If a 
patient presents with certain characteristic, then treatments which target 
specific signalling pathways related to these characteristics, can be utilised.  
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